Investigations of cellular and molecular mechanisms of endothelial dysfunction in the kidney by Gordon, Adele R.
INVESTIGATION OF CELLULAR AND
MOLECULAR MECHANISMS OF ENDOTHELIAL
DYSFUNCTION IN THE KIDNEY
ADELE R. GORDON




This thesis and the data presented in it are entirely the result ofmy own efforts. This
work contains no material which has been accepted for the award of any other degree
or diploma in any university or tertiary institution and, to the best ofmy knowledge
contains no material previously published or written by another person, except where
stated in the text.




Many cardiovascular diseases are associated with abnormal function of the
endothelium, a condition commonly referred to as endothelial dysfunction (ED). ED
is well characterised as the diminished capacity of the endothelium to mediate
vasorelaxation that results from a decrease in the availability of nitric oxide (NO).
However, additional physiological roles ofNO may also be altered. For example, NO
plays a vital role in promoting natriuresis/diuresis within the kidney and thus
contributes to the maintenance of normal blood pressure. This prompted the
hypothesis that diminished availability ofNO as a result of ED in the kidney could
result in sodium retention and may provide an explanation for the sustained elevation
of blood pressure in hypertension. There are several reasons for why NO availability
may be decreased during ED. One proposed explanation is altered activity of
endothelial nitric oxide synthase (eNOS), the enzyme responsible for generating NO.
However, little is known of the mechanisms involved in regulating eNOS activity
within the kidney. This thesis describes experiments which aim to further elucidate
the cellular and molecular mechanisms involved in the regulation and activation of
renal eNOS and discusses how these may be affected during ED.
Subcellular localisation to caveolae and interactions with proteins which reside there
(e.g. caveolin-1, bradykinin receptor and endothelin type B receptor) are important
features of eNOS regulation. The first approach was to determine if interactions
between eNOS and regulatory proteins within the kidney were altered in an animal
model of ED, the spontaneously hypertensive rat (SHR). Western blot analysis of
isolated caveolae revealed no alterations in eNOS or caveolin expression in SHR
compared to normotensive WKY rats. Likewise, no change in caveolin expression
was observed in whole kidney homogenates, whereas eNOS expression was slightly
increased. Although interactions between caveolin-1 and eNOS in isolated
endothelial cells were observed, it was not possible to replicate this within tissue, and
raises questions concerning the extent to which these proteins interact in vivo. These
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data imply that alterations in renal caveolin expression are not altered during ED
whereas eNOS may be upregulated.
Experiments then focused on activation of eNOS by endothelin-1. Within the renal
medulla this is mediated by the endothelin type B receptor (ETB) and leads to
inhibition of sodium reabsorption. However, the cellular mechanisms remain
unknown due to the lack of precise localisation of medullary ETB. Therefore,
localisation of ETB was investigated by introducing a LacZ reporter gene into the
endothelin type B receptor locus (EDNRB) by homologous recombination in ES
cells, thereby generating EDNRB-LacZ mice which expressed LacZ wherever ETB
was expressed. These mice, together with another strain of EDNRB-Ea.cZ mice
(supplied by Dr. M. Shin), were used to determine renal ETB localisation. Analysis of
LacZ expression in homozygote mice revealed intense staining within the medulla,
particularly within endothelial cells of the medullary capillaries. In contrast, renal
tubules were negative for transgene expression. Since the vasa recta is also a major
site of eNOS expression within the medulla, these results suggest that ET-1 activates
eNOS by binding to ETB located on vasa recta. These observations enhance the
understanding of the basic cellular and molecular mechanisms involved in
ETB/eNOS mediated sodium transport and provide a platform for ongoing
physiological experiments and investigations into potential pathways which may be
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Chapter 1 - Introduction
1.1 THE ENDOTHELIUM AND ENDOTHELIAL DYSFUNCTION — AN
OVERVIEW
The historical view of the endothelium as merely an inert single layer of cells lining
the blood vessels has radically changed in the last 20 years. It is now clear that the
vascular endothelium controls many important physiological functions including
control of vascular tone through the production of vasodilator (e.g. nitric oxide,
prostacyclin, endothelium-derived hyperpolarizing factor (EDHF)) and
vasoconstrictor (e.g. endothelin, angiotensin II, thromboxane A2, prostaglandin H2)
substances. Therefore, it is of no surprise that the endothelium is a major target for
cardiovascular risk factors such as hypertension. Indeed, hypertension is associated
with an imbalance in relaxing and contracting factors resulting in abnormal function
of the endothelium, a condition commonly referred to as endothelial dysfunction
(ED).
In addition to altered vascular tone, other roles of the endothelium may be affected
during ED. These include inhibition of platelet aggregation and smooth muscle cell
proliferation and prevention of leukocyte adhesion to the vessel wall. As depicted in
figure 1-1 alterations in these actions may result in pro-atherogenic consequences.
ED is therefore thought to be a key initial event in the development of hypertension,
atherosclerosis and other cardiovascular diseases.
Although associated with alterations in several endothelial factors (e.g. decreased
EDHF and increased thromboxane A2 or prostaglandin H2), ED is most commonly
characterised as the diminished bioavailability of endothelium-derived nitric oxide
(NO). This free radical gas mediates the actions described above as well as many
other physiological processes throughout the cardiovascular system and other regions
of the body. However, the molecular mechanisms associated with decreased NO
bioavailability remain largely unknown. Elucidation of such mechanisms may prove
extremely important in the understanding of the pathologic processes involved in ED
and hypertension. One conclusion that can be drawn from the vast array of studies on
2
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ENDOTHELIAL
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vasoconstriction vascular smooth muscle
cell proliferation




Figure 1-1. Endothelial dysfunction is associated with the development and progression of
hypertension and atherosclerosis.
ED is that the mechanisms involved vary in different models of hypertension and in
different vascular beds. Furthermore, given the importance of the kidney in the
control of long term blood pressure and development of hypertension and the
recently described role of NO as a regulator of natriuresis and diuresis, it is
surprising that little is known ofwhether this is affected by ED.
Endothelium-derived NO production is tightly regulated on several levels, any of
which may be affected during ED. One proposed explanation to account for the
reduction ofNO bioavailability is altered activity of endothelial nitric oxide synthase
(eNOS), the enzyme responsible for generating NO within the endothelium. Recent
data imply that alterations in interactions with regulatory proteins, such as caveolin-
1, may be involved.
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Moreover, with regard to the kidney, regulatory information for eNOS is almost
absent despite the crucial role of eNOS in normal renal physiology. Several recent
studies suggest that the endothelin system may be involved and that endothelin-1
(ET-1) may be a major physiological activator of eNOS and NO production within
the kidney. However, the mechanisms involved are only beginning to be unravelled.
Therefore, the subject of this thesis is to explore regulation of eNOS within the
kidney by investigating whether eNOS activity is altered during ED and by
examining interactions with the ET-1 system. In particular, it focuses on interactions
of eNOS with receptors (e.g. endothelin type B receptor (ETB)) and regulatory
proteins (e.g. caveolin-1) that are known to play a role in activation and control of
this enzyme.
1.2 PHYSIOLOGICAL ROLES OF NO
In 1980, Furchgott and Zawadzki (Furchgott & Zawadzki, 1980) demonstrated that
vascular relaxation in response to acetylcholine (ACh) was dependent on the
presence of the endothelium and named the factor responsible as endothelium-
derived relaxing factor (EDRF). Several years later, the actions of EDRF were
attributed to that of the free radical gas, NO (Ignarro et al., 1986; Furchgott et al.,
1987; Ignarro et al., 1987; Palmer et al., 1987). Now, 20 years on, NO is considered
a major, widespread effector molecule in cardiovascular, renal and brain physiology
as well a key regulator in the immune response (Moncada et al., 1991). Although the
roles and regulation of NO in the kidney are the focus of this thesis, many of the
pathways and mechanisms involved in NO synthesis and regulation were first
established within the vasculature. Therefore, vascular derived NO will also be
reviewed.
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1.2.1 NO in the vasculature
Within the vasculature, NO is produced by endothelial cells and induces relaxation of
vascular smooth muscle cells. In addition, NO has a regulatory effect on platelets and
circulating monocytes. The pathways involved in physiological stimulation and
production ofNO and the effects NO has within the vasculature have been the source
ofmuch interest within the cardiovascular field.
1.2.1.1 NO release by blood vessels
Physiologically, shear stress appears to be the main stimulus for the tonic release of
NO. However, endothelial cells may also be stimulated to produce NO by
circulating, autocrine and paracrine substances.
Shear stress is caused by the friction of rapid blood flow on the endothelium.
Rubanyi et al were first to observe that the NO concentration released from
endothelial cells and subsequent vasorelaxation of smooth muscle cells of a perfused
artery increased with perfusion rate (Rubanyi et al., 1986) suggesting that NO is a
mediator of flow-dependent vasodilatation. Shear stress is now known to be one of
the most important physiological regulators of NO production (Pohl et al., 1986;
Cooke et al., 1990; Joannides et al., 1995).
However, NO synthesis and release is also stimulated by a variety of agonists (e.g.
bradykinin (BK), endothelin-1 (ET-1), adenosine diphosphate (ADP) and thrombin)
which elicit their effects by causing an increase in intracellular calcium ([Ca2+];) upon
binding to specific membrane bound G-protein coupled receptors (GPCRs). In vitro
and in vivo studies show that specific inhibitors of NO synthesis can abolish the
effects of these agonists on relaxation of smooth muscle cells (Rees et al., 1989;
Vallance et al., 1989; Whittle et al., 1989; Rees et al., 1990). Some exogenous
pharmacological agents act in similar ways (e.g. ACh acting via muscarinic receptors
and the calcium ionophore, A23187). These activators of NO synthesis have been
extensively reviewed elsewhere (Busse et al., 1985; Furchgott & Vanhoutte, 1989).
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The intracellular regulatory mechanisms controlling NO-stimulated relaxation of
vascular smooth muscle cells are summarised in figure 1-2 producing a simplified
picture ofNO production. In the endothelium, NO is formed when the amino acid, L-
arginine is converted to L-citrulline (Palmer et al., 1988a; Palmer et al., 1988b). This
reaction is catalysed by one of three nitric oxide synthases (NOS), eNOS, which is
activated in response to increases in [Ca2+]i and requires the presence of several
cofactors. This enzyme and the other NOS isoforms, neuronal NOS (nNOS) and
inducible NOS (iNOS), will be discussed in more detail in section 1.3. Downstream,
NO diffuses abluminally and induces relaxation of the smooth muscle by increasing
cyclic guanosine monophosphate (cGMP) formation via stimulation of the enzyme
soluble guanylate cyclase (sGC) (Rapoport et al., 1983). This culminates in
activation of cGMP-dependent protein kinases (protein kinase G, PKG),
dephosphorylation of myosin light chains, leading to vasodilatation (Draznin et al.,









L-arg ► L-citrulline + NO-
platelets
endothelium
Figure 1-2. Production of NO in vasculature. Abbreviations: ACh, acetylcholine; BK,
bradykinin; ET-1, endothelin-1; ADP, adenosine diphosphate; R, receptor; L-arg, L-arginine;
NOS, nitric oxide synthase; sGC, soluble guanylate cyclase; cGMP, cyclic guanosine
monophosphate; PKG, protein kinase G.
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1.2.1.2 Regulation ofbloodpressure
NO is continuously produced by endothelial cells and acts on underlying vascular
smooth muscle cells to maintain a constant state of vasodilatation and thus
contributes to maintenance of vascular tone. This effect is unmasked by infusion of
isolated arteries with L-NMMA, a specific inhibitor ofNO biosynthesis, resulting in
abolition of endothelium-dependent relaxation and induction of endothelium-
dependent contractions (Palmer et al., 1988b; Rees et al., 1990). In vivo studies
produced similar results. Acute intravenous infusion of L-NMMA in anaesthetised
rabbits induced an increase in blood pressure (Rees et al., 1989), a study which has
since been replicated in other species (Aisaka et al., 1989; Whittle et al., 1989;
Gardiner et al., 1990; Rees et al., 1990). Furthermore, administration of L-NMMA
into the brachial arteries of the human forearm caused a 50% reduction in basal
blood flow (Vallance et al., 1989) and an increase in blood pressure (Haynes et al.,
1993). Thus, under normal conditions, basal release ofNO plays an important role in
regulating blood flow and blood pressure. A deficiency in NO would therefore have
an adverse effect and may result in the development and maintenance of
hypertension.
1.2.1.3 Regulation ofsmooth muscle cell proliferation
As well as regulating relaxation of vascular smooth muscle cells, the endothelium
also plays a role in maintaining vascular structure. In the presence of a healthy, intact
endothelium, vascular smooth muscle cells remain in a relatively quiescent state due
to the presence ofNO and other regulatory factors (Garg & Hassid, 1989). However,
removal of the endothelium and hence a deficiency in NO release, results in smooth
muscle cell proliferation (Clowes et al., 1983), a common feature in the development
of atherosclerotic lesions.
1.2.1.4 Regulation ofplatelet aggregation and adhesion
NO has an inhibitory effect on platelet aggregation and adhesion to the vessel wall
(Furlong et al., 1987; Radomski et al., 1987b; Radomski et al., 1987a). Aside from
the stimulated endothelial generation of NO described above, platelets themselves
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can induce production ofNO from the endothelium by releasing ADP (see figure 1-
2). In addition, platelets also possess their own L-arginine/NO pathway similar to
that described above and synthesise NO when activated by ADP, collagen and
thrombin (Radomski et al., 1987b). This autocrine and paracrine generation of NO
may represent a negative feedback mechanism of anti-aggregation. However, during
ED this mechanism may be altered and favour platelet aggregation and adhesion to
the vessel wall.
1.2.1.5 Regulation ofleukocyte adhesion
NO also inhibits leukocyte adhesion to the vessel wall by altering expression of cell
surface adhesion molecules (Kubes et al., 1991; Niu et al., 1994). Alteration of
physiological NO release can lead to infiltration ofmonocytes to the endothelium, a
key initial step in the development of foam cells and progression of atherosclerosis.
Therefore, endothelium-derived NO has multiple effects within the vasculature. By
controlling blood pressure and protecting the vessel wall from platelet adhesion and
infiltration ofmonocytes and smooth muscle cells, NO plays a key role in prevention
of hypertension and atherosclerosis.
1.2.2 NO in the kidney
It is well known that the kidney plays a major role in the long-term regulation of
blood pressure. This is largely controlled through changes in extracellular fluid
volume by pressure natriuresis/diuresis where an increase in blood pressure is
compensated by an increase in renal excretion of salt and water (Guyton et al., 1990).
It is also widely recognised that the kidney may be the key to understanding
hypertension. This is highlighted by the observation that all genetic disorders
currently identified as contributing to or causing hypertension involve mutations in
genes which control renal sodium handling (Lifton, 1996). One of the major
regulators of blood pressure and salt/water homeostasis is the renin-angiotensin
system which plays an important role in the process of pressure natriuresis (reviewed
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in (Guyton & Hall, 2000a)). More recently, the NO system has also been shown to
contribute to the control of pressure natriuresis/diuresis.
1.2.2.1 Control ofnatriuresis/diuresis
The diuretic and natriuretic effects of NO were first described by Lahera et al who
studied the contribution ofNO to renal function in the absence of changes in blood
pressure. Intrarenal infusion of rats with ACh and BK significantly increased renal
blood flow, urinary volume and sodium excretion without changes in blood pressure
(Lahera et al., 1990; Lahera et al., 1991a). Intravenous infusions of low doses (0.1-
1.0|Ug/kg/min) of L-NAME, an inhibitor ofNO release, to rats resulted in decreased
urine volume and sodium excretion again without affecting systemic blood pressure
and glomerular filtration rate. In contrast, infusion of higher doses (10-50[ig/kg/min)
resulted in significantly increased blood pressure and after an initial fall in urinary
volume and sodium excretion, these parameters were normalised through pressure
natriuresis (Lahera et al., 1991b). The primary determinant of glomerular filtration
and the amount of sodium excreted is renal perfusion pressure. By inducing increases
in renal perfusion pressure in anaesthetised dogs, Salom et al, described the
involvement of NO in pressure natriuresis. Intrarenal infusion of L-NAME
(1.0|ig/kg/min) abolished the increase in urinary sodium excretion and diuresis
produced by increasing renal perfusion pressure from 100 to 150mmHg. Again,
blood pressure and glomerular filtration rate did not change (Salom et al., 1992).
Therefore, together these studies indicate that NO plays a role in sodium and water
excretion in response to changes in renal perfusion pressure by mechanisms which
are independent of vascular and glomerular events.
Enzymatic studies have shown that the kidney medulla, in particular the inner
medulla, has a greater capacity to produce NO than the renal cortex (Mattson & Wu,
2000a). Furthermore western blotting revealed the highest levels ofNOS expression
are found in the medulla (Mattson & Higgins, 1996b) suggesting that medullary
produced NO may be responsible for the effects described above. Indeed, NO
increases medullary blood flow, which is known to promote sodium and water
9
Chapter 1 - Introduction
excretion (reviewed in (Mattson & Wu, 2000a)). Another potential mechanism may
involve inhibition of renin secretion although there is much controversy on this
subject (Kurtz & Wagner, 1998).
More recent studies indicate that NO may induce natriuresis by inhibiting sodium
reabsorption within the medulla directly. Using isolated cortical collecting ducts,
Stoos et al reported the inhibition of sodium transport following addition of ACh and
NO donors. (Stoos et al., 1995). Likewise a similar study using isolated thick
ascending loops ofHenle reported a decrease in chloride transport following addition
of a NO donor. Endogenous NO was also investigated. Upon addition of L-arginine,
a similar decrease in chloride flux was observed via an L-NAME sensitive pathway
(Plato et al., 1999). L-arginine was subsequently shown, through the use of NOS
knockout mice, to function through the activation of eNOS as opposed to nNOS and
iNOS (Plato et al., 2000b). Furthermore, eNOS -/- mice are hypertensive (Huang et
al., 1995; Shesely et al., 1996; Stauss et al., 2000) whereas nNOS -/- animals have
slightly lower blood pressure than wild types (Plato et al., 2000b). However, at
present there are no data correlating changes in blood pressure with salt sensitivity in
eNOS -/- mice.
It should be clear from the information above that the role of NO as a
diuretic/natriuretic agent has been well described for some time. However the
mechanisms involved, particularly those which regulate renal NO release, are only
beginning to be unravelled. As described above, eNOS appears to be the major
isoform involved in regulating sodium transport. However, although shear stress is
the major physiological activator of eNOS within the vasculature (see section
1.2.1.1), it is not known if the same applies to the kidney. Recent data have
suggested that renal NO release may be mediated by receptor activation. In particular
the endothelin system may be involved and ET-1, acting via the endothelin type B
receptor (ETB), may be a major physiological activator ofNO production within the
kidney.
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1.2.2.2 The renal endothelin system
The endothelin system is well known to play an important role in regulation of
vascular tone and control of blood pressure (reviewed in (Rubanyi & Polokoff, 1994;
Haynes & Webb, 1998)). The endothelin system within the kidney regulates a wide
range of effects, including regulation of renal blood flow, control of glomerular
filtration rate and, as alluded to above, control of sodium and water reabsorption.
1.2.2.3 Endothelin synthesis
The endothelin family is made up of three 21 amino acid peptides (ET-1, -2 and -3)
with ET-1 being the major renal isoform (reviewed in (Kohan, 1997)). ET-1 was
originally identified as a substance released from endothelial cells that caused potent,
sustained vasoconstriction in isolated coronary vessels (Yanagisawa et al., 1988).
ET-1 is synthesised from inactive precursors by successive rounds of proteolysis.
PreproET-1 is cleaved by a furin-like endopeptidase to form big ET-1. Big ET-1 is
then cleaved to form ET-1. This step is catalysed by endothelin converting enzymes
(ECE) (see figure 1-3).
endothelium






Figure 1-3. The autocrine and paracrine mechanisms of the endothelin system in the
vasculature. Abbreviations: ETB, endothelin type B receptor; ETA, endothelin type A receptor;
ECE, endothelin converting enzyme; ET-1, endothelin-1.
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1.2.2.4 Endothelin receptors
Endothelin elicits vasoconstriction of blood vessels via increased [Ca2+]; resulting
from binding to two subtypes of endothelin receptors, termed endothelin type A
(ETa) and endothelin type B (ETB), located on smooth muscle cells (Sakamoto et al.,
1991; Hosoda et al., 1992). ETA and ETB are encoded by EDNRA and EDNRB genes
respectively. Both receptors are 7 transmembrane GPCRs and activate an
overlapping set of G proteins. ETA binds endothelins with different affinities (ET-
1>2>3) whereas ETB binds all endothelins with equal affinity. ET-1 can also induce
vasodilatation of smooth muscle cells via activation of ETB located on endothelial
cells resulting in prostaglandin and NO production (de Nucci et al., 1988; Filep et
al., 1991).
1.2.2.5 Renal expression ofET-1 and endothelin receptors
The renal vasculature is one of the most sensitive vascular beds to ET-1-induced
vasoconstriction probably due to the high abundance of endothelin receptors found
on vascular smooth muscle cells in renal resistance vessels. ET-1 is produced within
the renal vasculature and contributes to control of renal blood flow through
constriction of glomerular afferent and efferent arterioles and control of glomerular
filtration rate.
However, the highest concentrations of immunoreactive ET-1 are in fact found
within the inner medulla (Kitamura et al., 1989a; Kitamura et al., 1989b),
interestingly corresponding to the highest levels of eNOS expression and NO
production (see section 1.2.2.1). This has been confirmed by in vitro autoradiography
and [125I]-ET-1 binding (Dean et al., 1994; Yukimura et al., 1996; Zhuo et al., 1998).
These studies also showed, using ETB and ETA specific antagonists, high expression
of the receptors within the medulla. In particular cultured inner medullary collecting
duct cells (IMCD) release high amounts of ET-1 (Kohan & Fiedorek, 1991; Kohan &
Padilla, 1992) and express ETA and ETB (Kohan et al., 1992). However, this
observation remains to be confirmed in vivo (refer to section 1.2.2.8).
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The main stimulus for ET-1 production from epithelial cells appears to be increased
osmolality, in particular increases in sodium (Yang et al., 1993; Migas et al., 1995).
Renal ET-1 expression is increased during salt loading. Both ET-1 mRNA and
protein expression were reported to be upregulated in mice fed an 8% NaCl diet
compared with mice on a normal or sodium deficient diet (Melo et al., 1998; Ohuchi
et al., 1999b). These observations, together with high expression of the endothelin
system in the medulla, suggest a role in sodium handling and homeostasis.
1.2.2.6 Endothelin system and control ofNa+ transport
There is now considerable evidence supporting the role of ET-1 as a
diuretic/natriuretic hormone. Intravenous infusion of low doses of ET-1 in the rat
caused natriuresis due to reduced sodium transport in the proximal and distal tubules,
whereas higher doses resulted in sodium retention due to glomerular vasoconstriction
(Harris et al., 1991). ETA and ETB specific antagonists revealed that ETBwas mainly
responsible for the diuretic/natriuretic effect whilst ETA mediated vasoconstriction
(Clavell et al., 1995; Hoffman et al., 2000).
The role of the endothelin system in natriuresis has been confirmed using transgenic
animal models. Although ET-1.-/- homozygous mice die from respiratory failure,
ET-1 +/- heterozygous mice develop elevated blood pressure despite ET-1 being a
potent vasoconstrictor (Kurihara et al., 1994; Morita et al., 1998). Furthermore,
collecting duct specific knockouts of ET-1 are hypertensive, have reduced urine
volume and excrete less sodium (Ahn et al., 2002).
Similar results were reported using animals deficient in ETB. Spotting lethal (si) rats
carry a naturally occurring 301 base pair deletion in the EDNRB gene which die soon
after birth from aganglionic megacolon (Gariepy et al., 1996). Genetic "rescue" of
these rats with an EDNRB transgene under the control of a dopamine-(3-hydroxylase
promoter results in viable animals which express ETB only in ganglionic cells of the
intenstine but are deficient in ETB elsewhere (Gariepy et al., 1998). When
administered a high salt diet (8% NaCl), these animals developed severe
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hypertension which was reversed by amiloride, the specific epithelial sodium channel
(ENaC) blocker (Gariepy et al., 2000). These results implicate a role of ETB in
inhibition of sodium reabsorption via ENaC. This has been supported by in vitro
studies using cultured IMCD cells to demonstrate that ET-1, acting via ETB,
downregulates ENaC activity (Gallego & Ling, 1996). However, the rats above also
exhibited significantly increased plasma ET-1 levels, which may have caused an
increase in vascular resistance and therefore complicates the interpretation of these
results. Mouse models of ETB deficiency also exist. Since homozygous ETB
knockout mice also die from aganglionic megacolon (Hosoda et al., 1994), a similar
"rescue" strategy to that described above was adopted by Ohuchi et al (Ohuchi et al.,
1999b). These mice also develop salt-sensitive hypertension. However, no data on
plasma ET-1 levels were reported. In addition another ETB mouse mutant was
developed by the same group by breeding ETB +/- heterozygotes to piebald (s)
mutants which harbour a naturally occurring mutant EDNRB allele (Ohuchi et al.,
1999a). The offspring (s/-) had ETB levels 1/8 of normal expression and had
significantly higher blood pressure than s/+ or wild type animals, without elevated
plasma ET-1 levels. Taken together the findings from these transgenic studies
consolidate the physiological role of the endothelin system in sodium transport.
1.2.2.7 Interaction ofrenalNO and endothelin system in Na+ transport
The same group that demonstrated a decrease in chloride transport in isolated
ascending loops of Henle following addition of NO donors and L-arginine (see
section 1.2.2.1), also showed a similar effect following addition of ET-1 (Plato et al.,
2000a). Furthermore L-NAME inhibited the ET-1-induced decrease in chloride
transport. Removal of L-arginine resulted in a similar effect. These findings suggest
that ET-1 exerts its natriuretic effect through an NOS-dependent pathway. Again this
was shown to be mediated by ETB. Hoffman et al also reported an equivalent effect
in vivo in anaesthetised rats. Following big ET-1 infusion, urinary flow rate and
sodium excretion were significantly increased with no change in blood pressure,
glomerular filtration rate or renal blood flow (Hoffman et al., 2000). However, pre-
treatment with L-NAME abolished the natriuretic effect of ET-1.
14
Chapter 1 - Introduction
Downstream, NO is thought to inhibit sodium reabsorption through a cGMP-kinase
dependent mechanism which phosphorylate and block sodium channels (Light et al.,
1990; Lahera et al., 1993). The observation that ET-1/ ETB increased cGMP
production in cultured rat IMCD cells provides indirect evidence further supporting a
link between NO, the ET system and sodium transport (Wong et al., 2000). As
described in section 1.2.2.6, ET-1 may inhibit sodium reabsorption by
downregulating ENaC activity. There is also evidence that ET-1 can inhibit Na -K -
ATPase activity (Zeidel et al., 1989). In addition, it was reported that ET-1 inhibited
reabsorption of sodium and water in isolated cortical collecting ducts and IMCD by
blocking the action of anti-diuretic hormone (also known as vasopressin) (Tomita et
al., 1990; Nadler et al., 1992). A similar finding was reported for NO (Stoos et al.,
1995).
This array of studies provides evidence that renal ET-1, acting via the ETB, is a major
activator of eNOS and NO production and together they regulate sodium transport
resulting in diuresis/natriuresis (Plato & Garvin, 1999; Kotelevtsev & Webb, 2001).
However, from these studies it is not possible to identify the precise cellular and
molecular mechanisms involved. Localisation data may provide some answers.
1.2.2.8 Localisation ofeNOS and ET system in the kidney
To help describe the localisation of eNOS and the ET system within the renal
medulla, a schematic diagram of a juxtamedullary nephron is shown in figure 1 -4.
Much of the evidence to date would suggest that renal ET-1 acts in an autocrine
fashion where ET-1 is produced by IMCD cells and binds to ETB on the same cell
resulting in eNOS stimulation and NO production (figure l-5a). However, despite
the presence of ETB on cultured IMCD cells (Kohan & Padilla, 1992), in vitro and in
vivo radioligand ([125I]-ET-1) electron microscopy revealed either low or no
expression in cells of the renal tubules (Dean et al., 1994; Yukimura et al., 1996;
Zhuo et al., 1998).
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Instead the majority ofbinding was localised to glomerular capillaries and vasa recta,
the peritubular capillaries found deep within the medulla. However, it is difficult to
distinguish between cells using this method and binding sites may be inaccessible to
intravascularly administered [125I]-ET-1 (Dean et al., 1994; Zhuo et al., 1998).
Furthermore, no indication is given regarding receptor subtypes. Therefore, it is clear
that further precise localisation is required.
As for eNOS, the highest levels of calmodulin-dependent NOS activity were found
in micro-dissected vasa recta compared to other renal vessels (Mattson & Wu,
2000b). This was confirmed by precise staining using a nuclear localised reporter
gene (LacZ) under the control of the eNOS promoter (Teichert et al., 2000). Teichert
et al reported strong staining within the endothelial cells of the vasa recta but no
expression within renal tubules. Likewise, no eNOS expression was detected in renal
tubules by immunohistochemical analysis using an anti-eNOS antibody compared to
strong staining within renal vessels (Bachmann et al., 1995). Nevertheless, Wu et al
reported high NOS activity within micro-dissected IMCD segments compared to
moderate activity within isolated glomeruli and vasa recta and low activity in other
regions of the nephron (Wu et al., 1999). The same study used RT-PCR to reveal that
nNOS was the major isoform in IMCD cells whilst eNOS was the predominant
isoform in isolated vasa recta. In contrast, RT-PCR performed by Terada et al
reported high expression in isolated IMCD segments compared to a small signal
obtained from vasa recta, glomeruli and other renal tubules (Terada et al., 1992b).
These discrepancies may be a consequence of cross-contamination resulting from the
microdissection procedure. Therefore, histological analysis appears to yield more
accurate results.
Morphological analysis suggests that the main site of ETB and eNOS expression is
the endothelium of the vasa recta. Given that these cells lie in close proximity to
IMCD cells, separated only by a basal membrane and together with the physiological
experiments described earlier, it is hypothesised that ET-1, released from IMCD
cells, acts in a paracrine fashion by binding to ETB on the vasa recta where eNOS is
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activated and NO produced (figure 1 -5b). In turn, NO acts on IMCD cells to reduce
sodium transport thereby promoting natriuresis/diuresis. This hypothesis assumes
that the vasa recta is the major site of ETB expression. However, as described above
this remains to be confirmed.
1.2.3 Endothelial dysfunction in the kidney
ED was first characterised as impaired endothelium-dependent vasorelaxation by
Konishi and Su by measuring aortic responses to ACh in spontaneously hypertensive
rats (SHR) compared to normotensive Wistar-Kyoto rats (WKY) (Konishi & Su,
1983). Since then impaired endothelium-dependent vasorelaxation has been reported
in several other models ofED and in other vascular beds.
Given the importance of the endothelium in kidney physiology, it is of little surprise
that the renal vascular bed is also a target for ED and may contribute to the
development and/or maintenance of hypertension. In fact, patients with hypertension
have impaired endothelium-dependent vasorelaxation in renal arteries manifested as
decreased renal blood flow and abnormal renal vascular resistance in response to L-
arginine infusion (Higashi et al., 1995; Higashi et al., 1996). Impaired renal NO
release and decreased renal perfusion pressure were also observed in stroke-prone
SHR (SHRSP) animals in response to ACh infusion (Hirata et al., 1996). Similar
attenuation of ACh-induced vasorelaxation has also been reported in
deoxycorticosterone acetate (DOCA) salt-hypertensive rats and Dahl salt-sensitive
rats (Hayakawa et al., 1993).
However, it should be clear from the physiological roles of NO described in the
previous section that vasorelaxation is not the only parameter that may be affected
during ED. In particular, NO-induced inhibition of sodium reabsorption may be a
target. Dahl salt-sensitive rats and SHR have blunted pressure-natriuresis curves
compared to their normotensive counterparts. Administration of L-arginine to these
rats is associated with increased urinary sodium excretion and normalisation of
pressure-natriuresis (Ikenaga et al., 1993; Patel et al., 1993; Hu & Manning Jr, 1995;
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Larson & Lockhart, 1995). Furthermore, urinary excretion of NO metabolites (N02
and NO,) were significantly lower in hypertensive patients (Sierra et al., 1998).
Therefore, it is hypothesised that the diminished ability of NO to inhibit sodium
reabsorption within the renal medulla may result in sodium retention and
subsequently lead to sustained elevation of blood pressure through the resetting of
pressure natriuresis.
As described above, locally produced medullary ET-1 can be major activator ofNO.
Therefore, it is of interest that in hypertensive patients daily urinary excretion of ET-
1 was significantly decreased compared to normotensive subjects (Hoffman et al.,
1994). This ET-1 was of renal origin and implies that these patients had impaired
ET-1 production in the kidney, particularly in the renal medulla. Urinary ET-1
excretion was also lower in SHR, reflected by reduced levels of ET-1 mRNA
(Hughes et al., 1992) and decreased immunoreactive ET-1 in the inner medulla
(Kitamura et al., 1989b). Moreover, cultured IMCD cells isolated from SHR had
lower ET-1 mRNA and released less ET-1 compared to the normotensive, WKY
(Hughes et al., 1992). It should also not be overlooked that in some animal models of
salt sensitive hypertension the renal endothelin system appears to be activated.
PreproET-1 mRNA levels were increased in kidneys from Dahl salt-sensitive rats
(Ikeda et al., 1999) and renal ET-1 mRNA expression was enhanced in DOCA-salt
hypertensive rats (Deng et al., 1996). Whereas Ikeda et al did not specify intrarenal
sites of increased expression, the latter report documented the increase in ET-1 only
within the renal vasculature and glomeruli implying that ETA-mediated
vasoconstriction may be activated and be the cause of increased systemic blood
pressure. Therefore, this should be regarded independently of ETB -mediated effects
of ET-1 within the medulla.
ETb expression is also altered in animals models of hypertension. Hirata et al
reported that the DOCA-salt sensitive rat expressed less ETB mRNA and produced
less NO in response to ET-1 perfusion compared to controls (Hirata et al., 1995b).
Likewise, expression of ETB was decreased in Dahl salt-sensitive rats, although this
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was reported in large renal arteries. No data were described for IMCD or vasa recta
(Kakoki et al., 1999).
Taken together, these observations imply that impairment of the renal medullary ET
system is associated with hypertension. Decreased ET-1 induced NO production via
eNOS may lead to an inability to block sodium reabsorption resulting in diminished
salt and water excretion. Thus, renal ED may play an important role in the
maintenance and development of hypertension. In order to address this, the
molecular mechanisms underlying the pathways involved need to be unravelled.
Several explanations have been given for why NO bioavailability is altered during
ED. One of these, as alluded to above, may be impairment ofNO production by the
ET system. However, most likely it is a complex, multi-factorial process. Due to the
pivotal role of eNOS in both the vasculature and within the kidney, as described
above, it is hypothesised that eNOS activity may be altered during ED. Since eNOS
is a tightly regulated enzyme, its activity can potentially be altered on a number of
different levels. The following section describes some of the factors involved in
eNOS regulation and how these may be altered during ED. eNOS regulation within
the kidney will also be reviewed although data on this area are limited.
The other isoforms ofNOS, nNOS and iNOS may also play a role in ED. However,
since these isoforms are not thought to regulate ET-1 induced NO production within
the kidney, they have not been considered further.
1.3 REGULATION OF eNOS AND ALTERATIONS DURING ED
eNOS was first described in vascular endothelial cells by Palmer and Moncada in
1989 (Palmer & Moncada, 1989), a finding which sparked an entire new era in NO
research. The enzyme was soon purified (Pollock et al., 1991) and cloned (Janssens
et al., 1992; Lamas et al., 1992; Sessa et al., 1992) and since then an enormous
amount of research has been dedicated to this enzyme. It rapidly became obvious that
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eNOS-mediated NO generation is a highly regulated cellular event involving tight
control of eNOS activity. Regulatory mechanisms include transcriptional regulation,
post-translational modifications (e.g. phosphorylation and acylation), cellular
localisation and interactions with regulatory proteins. This complex regulation of
eNOS activity will be discussed below.
1.3.1 Synthesis of NO - an overview
NO is synthesised from the oxidation of amino acid, L-arginine (Palmer et al.,
1988a; Palmer et al., 1988b) (see figure 1-6). The enzymes responsible for catalysing
this reaction are the NO synthases (NOS), of which three isoforms have been
described (reviewed in (Stuehr, 1999)). These isoforms are expressed in different
tissues and carry out distinct biological roles. Two of the NOS, endothelial NOS
(eNOS) and neuronal NOS (nNOS), are constitutively expressed in cells and
generally synthesise NO in response to calcium-releasing agonists and fluid shear
stress. However, Ca2+- independent pathways also exist. eNOS and nNOS are named
after the cell types in which they were originally identified (i.e. endothelial cells and
neurons) although they are now known to be expressed in a variety of cell types. The
third NOS, inducible NOS (iNOS), was originally identified as being inducible by
cytokines in macrophages and synthesises NO via Ca2+ - independent mechanisms.
nNOS, iNOS and eNOS are also commonly referred to as NOS I, II and III
respectively.
h hnh2 nh2
L-arginine L-citrulline nitric oxide
Figure 1-6. NOS-catalysed NO synthesis from L-arginine.
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1.3.2 Structure of eNOS
The reaction described in figure 1-6 is a greatly simplified account ofNOS-catalysed
NO synthesis. Instead the reaction relies on a number of cofactors which are essential
for eNOS activity (reviewed in (Fleming & Busse, 1999; Stuehr, 1999)). eNOS is a
140kDa protein comprised of an N-terminal oxygenase domain (1-491 amino acids)
and a C-terminal reductase domain (492-1205 amino acids) (see figure 1-7). Within
the oxygenase domain are binding sites for heme, cofactor tetrahydrobiopterin (BH4)
and the substrate L-arginine thus forming the active site for NO synthesis. The
reductase domain contains sites for cofactors flavin mononucleotide (FMN) and
flavin adenine dinucleotide (FAD) and the co-substrate nicotinamide adenine
dinucleotide phosphate (NADPH). There is also a binding site for the Ca2+- binding
protein, calmodulin (CaM). Upon binding of calcium-loaded CaM, electrons pass
from NADPH, through the CaM-binding domain and towards the heme located in
the oxygenase domain which allows the heme to bind oxygen and catalyse NO
synthesis. The functional eNOS is formed only when two subunits dimerize to form a
homodimer and it is thought that electrons transfer from the reductase domain of one
subunit to the oxygenase domain of the other (domain swapping). In addition to
containing binding sites for substrates and cofactors, the oxygenase domain is also
electron flow
N - OXYGENASE (1-491 aa) CAM REDUCTASE (492-1205 aa)
u u u v ; u
Arg Zn BH4 heme a





Gly-2 Cys-15 (Gly-Leu)5 Cys-26
acylation
Figure 1-7. Diagram of eNOS structure. Abbreviations: Arg, L-arginine; Zn, zinc; BH4,
tetrahydrobiopterin; FMN, flavin mononucleotide; FAD, flavin adenine dinucleotide; NADPH,
nicotinamide adenine dinucleotide phosphate; Gly, glycine; Cys, cysteine; Leu, leucine.
23
Chapter 1 - Introduction
subject to acylation. Co-translational N-myristoylation and post-translational
cysteine palmitoylation of the N-terminus are required for correct subcellular
targeting of eNOS (refer to section 1.3.5).
1.3.3 Transcriptional regulation of eNOS expression
Despite being designated a constitutively expressed enzyme, basal eNOS expression
is also regulated by a number of factors (refer to table 1-1). However, the
mechanisms involved and the physiological significance of the effects of these
factors are not yet fully established (reviewed in (Forstermann et al., 1998)). These
factors may modulate transcription directly via binding of transcription factors (e.g.
Spl (SV40 virus promoter specific transcription protein 1), AP-1, -2 (activator
protein-1, -2), NF-1 (nuclear factor-1) and GATA). The eNOS promoter also
contains consensus sequences for regulatory cis elements (e.g. shear stress response
elements and estrogen response elements (Venema et al., 1994)). However, the
functional relevance of these potential regulatory binding sites has not been proven.
mRNA stability (i.e. the balance between gene transcription and mRNA degradation)
may also be a potential mechanism for altered transcript levels. VEGF (vascular
endothelial growth factor), hydrogen peroxide and proliferation have all been shown
to stabilise eNOS mRNA, whereas TNF-a (tumor necrosis factor-a), hypoxia, high
concentrations of oxidised low density lipoprotein (oxLDL) and lipopolysaccharide
decrease mRNA stability (Yoshizumi et al., 1993; Arnal et al., 1994; McQuillan et
al., 1994; Liao et al., 1995; Lu et al., 1996; Bouloumie et al., 1999; Drummond et
al., 2000). Physiologically, shear stress is one of the major regulators of NO
production and therefore it is appropriate that induction of eNOS transcription is
controlled by this factor (Nishida et al., 1992). The significance of the other factors
described here remain to be elucidated. Atherogenic substances (e.g.
lysophosphatidylcholine and oxLDL) which increase eNOS expression may be
involved in a pathological defence mechanism against atherosclerotic lesion
formation (Hirata et al., 1995a; Cieslik et al., 1999). On the other hand, TNF-a
which is commonly found in atherogenic vessels, downregulates eNOS expression
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and may provide an explanation as to why NO availability is diminished in
atherosclerosis (Yoshizumi et al., 1993; Alonso et al., 1997).
Table 1-1. Factors which modulate eNOS expression
Upregulates eNOS expression Downregulates eNOS expression
exercise (Sessa et al., 1994)
shear stress (Nishida et al., 1992)
estrogen (via Spl) (Kleinert et al.,
1998)*
proliferation (Arnal et al., 1994)*
H202 (Drummond et al., 2000)
VEGF (Bouloumie et al., 1999)
TGF-(3 (Inoue et al,, 1995)
low oxLDL (Flirata et al., 1995a)
lysoPC (via Spl) (Cieslik et al., 1999)
TNF-a (Yoshizumi et al., 1993; Alonso
et al., 1997)
erythropoietin (Wang & Vaziri, 1999)
hypoxia (McQuillan et al., 1994)*
high oxLDL (Liao et al., 1995)
lipopolysaccharide (Lu et al., 1996)
NO (negative feedback via cGMP
mediated processes) (Vaziri & Wang,
1999)
Abbreviations: H202, hydrogen peroxide; VEGF, vascular endothelial growth factor; TGF-P,
transforming growth factor-(3; oxLDL, oxidised low density lipoprotein; lysoPC,
lysophosphatidylcholine; TNF-a, tumor necrosis factor-a.
* contradictory findings by some groups. Refer to (Flowers et al., 1995; Arnal et al., 1996; Arnet et
al., 1996)
1.3.4 Regulation of eNOS by phosphorylation
Phosphorylation may also be an important regulator of eNOS activity (reviewed by
(Fleming & Busse, 2003)). eNOS is primarily phosphorylated on serine residues and
to a lesser extent on threonine and tyrosine residues (Michel et al., 1993; Corson et
al., 1996; Garcia-Cardena et al., 1996a). Although tyrosine phosphorylation has been
reported, little is known of the residues and kinases involved. On the other hand,
serine-1177 (Ser-1177) phosphorylation occurs in response to shear stress
(Dimmeler et al., 1999; Gallis et al., 1999) and a variety of calcium mobilizing
agents (e.g. VEGF, estrogen, insulin and BK (Fulton et al., 1999; Michell et al.,
1999; Fleming et al., 2001; Kim et al., 2001)) mediated by different kinases
depending on the stimulus. For example, shear stress and VEGF induce
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phosphorylation via protein kinase B (PKB), whereas insulin appears to activate both
PKB and AMP-activated protein kinase (AMPK). Phosphorylation is also thought to
be dependent on intracellular localisation of eNOS (Gonzalez et al., 2002).
Phosphorylation of Ser-1177 increases eNOS activity by increased electron flow
through the reductase domain (McCabe et al., 2000). On the contrary, threonine-495
(Thr-495) is a negative phosphorylation site and is constitutively phosphorylated by
protein kinase C (PKC) thus decreasing eNOS activity (Fleming et al., 2001). This is
thought to inhibit eNOS by sterically preventing binding of calmodulin.
Dephosphorylation of Thr-495 by protein phosphatase 1, in response to BK and other
agonists that increase [Ca2+](, significantly increases eNOS activity (Fleming et al.,
2001). Therefore, changes in phosphorylation state play a crucial role in regulating
eNOS activity.
1.3.5 Intracellular localisation of eNOS
It is now known that eNOS subcellular localisation plays a vital role in eNOS
regulation. Incorrect localisation negatively affects enzyme activity (see below).
Within the cell, eNOS is found predominantly within the Golgi apparatus and also at
the plasma membrane, in particular caveolae (Hecker et al., 1994). Acylation of the
enzyme has been shown to be an important determinant of eNOS localisation (Liu et
al., 1997).
1.3.5.1 Myristoylation
The glycine residue (Gly-2) at the N-terminus of eNOS is myristoylated, an
irreversible co-translational modification (see figure 1-7). Site-directed mutagenesis
of this residue to produce non-myristoylated eNOS (myr ) resulted in an abnormal
localisation profile. Wild type eNOS was associated primarily with the particulate or
membrane cellular fraction whereas mutation ofGly-2 resulted in complete cytosolic
localisation and decreased enzyme activity (Busconi & Michel, 1993; Sessa et al.,
1993; Sakoda et al., 1995). More precise localisation revealed that myristoylation
was required for targeting to the Golgi apparatus. Cells transfected with mutant
eNOS did not colocalise with the Golgi marker, mannosidase. Moreover, despite
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retaining the catalytic properties of the enzyme, these cells produced markedly less
stimulated production of NO than cells transfected with wild type eNOS (Sessa et
al., 1995). It has also been reported that myristoylation is required for palmitoylation
(see below) (Sessa et al., 1993; Liu et al., 1996) and lack ofmyristoylation affects
localisation of eNOS to caveolae on the plasma membrane by attenuating
palmitoylation. Thus myristoylation is required for optimal eNOS activity through
correct intracellular targeting to the membrane, Golgi apparatus and caveolae (via
palmitoylation).
1.3.5.2 Palmitoylation
The N-terminal of eNOS is also subject to palmitoylation on cysteine residues 15 and
26 (Cys-15 and Cys-26, see figure 1-7). Mutation of these residues or the unique
(Gly-Leu)5 repeat lying between these residues results in attenuated palmitoylation
(palm ). Transfection of these mutants revealed altered cellular distribution with
markedly reduced membrane association however myristoylation was not affected
(Robinson & Michel, 1995; Liu et al., 1997). Compared to the cytosolic distribution
of eNOS myr", eNOS palm" had a more diffuse perinuclear localisation pattern
indicating that palmitoylation may be involved in stabilising the membrane
interaction conferred by myristoylation alone. This is supported by Shaul et al who
reported that the decrease in eNOS activity of palm" mutant cells in membrane
fractions was not as great as in myr" mutant cells (Shaul et al., 1996).
The same group of researchers used biochemical subfractionation methods to show
that eNOS also resides in specialised domains of the plasma membrane termed
caveolae. By measuring eNOS activity in caveolae isolated from cells transfected
with palm" mutants they report that palmitoylation is important for caveolar targeting
(Shaul et al., 1996). Compared to wild type eNOS, the palm" mutant eNOS did not
colocalise with the main component of caveolae, caveolin-1 (Garcia-Cardena et al.,
1996b). However, more recent studies imply that palmitoylation alone is not
sufficient to target eNOS to caveolae. Instead, eNOS requires additional signals,
found within eNOS itself, to enhance caveolar localisation. At present the nature of
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these sequences are unknown (Prabhakar et al., 2000). Targeting of eNOS to
caveolae also involves additional post-translational modifications (e.g.
phosphorylation, and protein-protein interactions, refer to section 1.3.6). As with
myr" mutant cells, palm" produced significantly reduced NO upon stimulation with
ionomycin confirming that mislocalisation of eNOS results in suboptimal NO release
(Liu et al., 1996).
1.3.5.3 Two distinct intracellularpools ofeNOS
The majority of reports agree that eNOS is compartmentalised into two distinct
intracellular pools. These pools may be differentially regulated and respond to
different stimuli as implicated by Govers et al (Govers et al., 2002). O'Brien et al
and Sessa et al were first to show by electron and immunofluoresence microscopy
respectively, that the majority of cellular eNOS is found within the Golgi apparatus
(O'Brien et al., 1995; Sessa et al., 1995). However, several years on, the function of
Golgi-localised eNOS remains a mystery. Much of the data suggest that this pool
contains potentially active eNOS. Resting levels of [Ca2+]f, one of the main stimuli
for eNOS, are high in the perinuclear and Golgi regions of the cell which rise further
upon activation of surface receptors and shear stress (Geiger et al., 1992; Burnier et
al., 1994). Furthermore, disruption of the Golgi apparatus with brefeldin A inhibited
eNOS activity (Stanboli & Morin, 1994). However, this has not been supported
elsewhere (Bauersachs et al., 1997). Until recently there was no evidence of direct
activation of Golgi-localised eNOS. Using an NO sensitive dye, DAF-2 DA (4,5-
diaminofluorescein diacetate), Fulton et al reported that basal and VEGF-stimulated
NO synthesis were present in the perinuclear area (Fulton et al., 2002) thus
concluding that the Golgi apparatus contains a pool of active eNOS. This is in
agreement with the early palmitoylation mutagenesis studies. Even though the palm"
mutants produced less NO, it was not abolished altogether suggesting that Golgi-
localised eNOS was capable of NO synthesis. However, the question of
physiological stimulation and the relative amounts of NO produced in this
subcellular compartment remain unanswered.
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In recent years, the focus has turned from Golgi to caveolar localised eNOS.
Biochemical subfractionation methods used to isolate caveolae revealed highest
eNOS protein content and activity in caveolar fractions compared to non-caveolar
fractions (Shaul et al., 1996). However, these findings have not been confirmed by
immunostaining. Although several studies show intracellular colocalisation of eNOS
with caveolin-1, a caveolar marker protein, the extent of this localisation is
inconsistent with the biochemical data (Garcia-Cardena et al., 1996b). Whereas the
biochemical data implies that most cellular eNOS resides in caveolae,
immunostaining clearly shows only a small fraction of eNOS co-localised with
caveolin-1, with the majority being localised to the Golgi apparatus described above
(Liu et al., 1997). Despite these inconsistencies, caveolar-localised eNOS has
received much attention and it is generally accepted that this form of regulation is
necessary for optimal, stimulated NO release.
The localisation of eNOS to these two distinct pools is by no means static. eNOS -
green fluorescent protein (GFP) fusion proteins have been used to visualise
intracellular movement of eNOS and report dynamic movement of eNOS cycling
between the two compartments (Sowa et al., 1999). By photobleaching sections of
the Golgi apparatus and the plasma membrane and measuring fluorescence recovery,
Sowa et al reported that eNOS-GFP translocates to and from the Golgi apparatus at
high speed and suggest a role in eNOS activation and de-activation.
Taken together, the data imply that during translation eNOS is myristoylated and is
targeted to the Golgi apparatus where it is consequently palmitoylated and
translocates to caveolae. Upon stimulation, eNOS can recycle back to the Golgi
apparatus by mechanisms involving depalmitoylation or changes in protein-protein
interactions (see below).
1.3.6 eNOS - caveolin interactions
Much of the recent research in the eNOS regulatory field has focused on its
localisation to caveolae and interaction with the resident caveolar protein, caveolin-1.
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Until recently most of the studies described were performed in vitro and the role of
caveolin-1 with regard to eNOS regulation in vivo was unknown. In vivo
immunohistochemical studies have shown that eNOS and caveolin-1 are
codistributed to the endothelium of the carotid artery, aorta, vena cava and femoral
artery of the hamster (Segal et al., 1999) and in the rat myocardial capillary
endothelium as shown by immunogold labelling and electron microscopy (Reiner et
al., 2001). However, only with the recent generation of caveolin-1 knockout mice
has the physiological regulatory role of caveolin-1 started to be unravelled.
1.3.6.1 Localisation ofeNOS to caveolae
As described above, several studies have localised eNOS to specialised
microdomains of the plasma membranes known as caveolae (Garcia-Cardena et al.,
1996b; Shaul et al., 1996). Caveolae were first described by electron microscopists in
the 1950s when they were given the name plasmalemmal vesicles by Palade (Palade,
1953). Two years later Yamada proposed the name caveolae intracellularis or "little
caves" to describe these flask-shaped invaginations (Yamada, 1955).
Originally studied for their involvement in transcytosis, caveolae are now thought to
play an important role in signal transduction (reviewed in (Anderson, 1998)). In
addition to eNOS, they contain a variety of signal transduction molecules. These
include GPCRs (e.g. ETA (Chun et al., 1994), m2 ACh (Raposo et al., 1987) and BK
receptors (de Weerd & Leeb-Lundberg, 1997)), G-proteins (Ga and G[3) (Lisanti et
al., 1994), CaM (Shaul et al., 1996), adenyl cyclases (Toya et al., 1998), cationic
amino acid transporter (CAT-1) which transports L-arginine into the cell (McDonald
et al., 1997) and the calcium pump (Fujimoto, 1993) suggesting that many of the
components required for optimal eNOS function are concentrated within caveolae
and therefore may function as signal transduction centres.
Caveolae are present in most cells and are extremely abundant in certain cell types
such as capillary endothelial cells (Simionescu et al., 1972), fibroblasts (Bretscher &
Whytock, 1977) and smooth muscle cells (Forbes et al., 1979). Structurally, they
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consist predominantly of cholesterol and glycosphingolipids which form the lipid
core and accounts for the detergent insolubility of caveolae at low temperature, a
characteristic property which is exploited during purification procedures (reviewed in
(Anderson, 1998)). In addition to the lipid core, caveolae contain the characteristic
protein, caveolin.
1.3.6.2 Caveolin
Caveolin-1 was first identified as a 22-kDa protein which is tyrosine phosphorylated
upon transformation with the Rous sarcoma viral oncogene (Glenney, 1989). A few
years later caveolin was shown to be a major component of caveolae (Rothberg et
al., 1992) and was soon cloned by two independent groups (Glenney & Soppet,
1992; Kurzchalia et al., 1992). Glenney and Soppet's study revealed an unusually
large (33 amino acids) hydrophobic domain suggesting that caveolin is an integral
membrane protein (see figure 1-8). It is thought that this domain forms a hairpin
structure within the membrane with both the N-terminal (residues 1-101) and C-
terminal (residues 135-178) remaining in the cytoplasm (Dupree et al., 1993). This
protein is now more accurately referred to as caveolin-la, as a shorter isoform,
caveolin-1 [3, also exists which lacks the N-terminal sequence (1-32 amino acid
residues) as a result of two translation start sites (Scherer et al., 1995). In addition to
caveolin-1, are caveolin-2 (2a, 2(3 and 2y) and caveolin-3 (Way & Parton, 1995;
plasma membrane
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Scherer et al., 1996; Tang et al., 1996) which show similar protein structures. Whilst
caveolin-1 and -2 have similar tissue distributions, caveolin-3 is strongly associated
with expression in muscle. Initial reports suggested that caveolins played a structural
role in caveolae formation as transfection of 2B2318 lymphocytes, which lack
caveolae, with caveolin-1 resulted in the de novo formation of caveolae (Fra et al.,
1995). However, other groups report that caveolae-like structures can exist in the
absence of caveolin-1 (Anderson, 1998). More recently the focus has turned to the
ability of caveolin-1 to interact with many other caveolar proteins, in particular
eNOS, thus suggesting a role in signal transduction.
Like eNOS, caveolin-1 is palmitoylated on three cysteine residues (Cys-133, Cys-
143, Cys-156, see figure 1-8) (Dietzen et al., 1995). However, unlike eNOS,
palmitoylation is not required for caveolar localisation. Instead, a region in the N-
terminus of caveolin-1, residues 82-101 appears important for membrane localisation
due to the high content of basic and aromatic residues in this region (Schlegel et al.,
1999; Schlegel & Lisanti, 2000). This region is known as the caveolin-scaffolding
domain (CSD) as it is also involved in mediating interactions with other caveolar-
localised proteins (Li et al., 1996) and caveolin itself (Sargiacomo et al., 1995).
Amongst these proteins are adenylyl cyclase (Toya et al., 1998), heterotrimeric G
proteins (Gs, G0, G;) (Li et al., 1995) and, of course, eNOS (see below). In addition,
each of these molecules contains a caveolin-binding motif characterised as (j)x(|)xxxx(t>
and (()xxxx<])xx(|), where ([) is aromatic amino acid Trp, Tyr or Phe and x is any
residue) (Couet et al., 1997).
1.3.6.3 eNOS interacts with caveolin-1
The localisation of eNOS to caveolae renders the enzyme inactive. This has been
attributed to the dynamic interaction between eNOS and caveolin-1 in which
caveolin negatively regulates eNOS activity (Michel et al., 1997a). This interaction,
first identified by co-immunoprecipitation using antibodies against caveolin, revealed
that the majority of eNOS is found in association with caveolin-1 in cultured
endothelial cells (Feron et al., 1996; Garcia-Cardena et al., 1996a). Conversely, co-
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immunoprecipitations performed using antibodies against eNOS, did not
significantly affect the total pool of caveolin suggesting that only a small fraction of
the caveolin pool is associated with eNOS. However, the extent to which eNOS and
caveolin are complexed is controversial considering that immunostaining clearly
shows that not all eNOS co-localises with caveolin at an intracellular level (refer to
section 1.3.5.3).
The eNOS-caveolin interaction was subsequently shown to be regulated by Ca2+-
CaM (Michel et al., 1997a). In the presence of Ca2+, eNOS-caveolin complexes from
endothelial cell lysates were disrupted. In contrast, eNOS-CaM complexes were
observed which did not form in the absence of Ca2+. Co-transfection of COS-7 cells
with eNOS and caveolin led to marked inhibition of eNOS activity demonstrating for
the first time the negative regulatory properties of caveolin on eNOS activity. Upon
addition of Ca2+-CaM, the interaction was disrupted and eNOS activity restored.
In 1998, the same group examined the intracellular localisation of eNOS-caveolin
complexes in endothelial cells following treatment with the Ca2+ ionophore A23187
and provided evidence for the eNOS-caveolin regulatory cycle (Feron et al., 1998b).
In the absence of A23187, the majority of eNOS in association with caveolin, was
detected in the particulate (i.e. membrane) fraction. Upon treatment with the Ca2+
ionophore caveolin-eNOS complexes were disrupted and eNOS was found in both
the particulate and soluble (i.e. cytosolic) fractions. This suggests that during
activation eNOS is translocated to the cytosol. When performed in the presence of
EGTA, a Ca2+ chelator, eNOS relocated back to the membrane fraction bound to
caveolin. They also reported that eNOS dissociation from caveolin was agonist
induced using COS cells transfected with eNOS and the muscarinic ACh receptor.
Addition of the agonist, carbachol, resulted in rapid disruption of eNOS-caveolin
complexes, quickly followed by reassociation of the proteins. Agonist induced
translocation of eNOS has been reported elsewhere (Michel et al., 1993; Fukuda et
al., 1995; Prabhakar et al., 1998). In addition, this pattern of recycling of eNOS-
caveolin complexes was shown to be palmitoylation dependent, probably as a result
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of targeting of eNOS back to caveolae (Feron et al., 1998b). Palmitoylation and de-
palmitoylation of eNOS is also regulated by agonists (Robinson et al., 1995).
Since agonist induced activation of eNOS is not a particularly physiological regulator
ofNO production, attention turned to the potential association of caveolar regulation
of eNOS and shear stress. Acute changes in shear stress or pressure induce rapid
release of NO from the vascular endothelium resulting in vasodilatation. Recently
Rizzo et al proposed that these haemodynamic forces may transmit through caveolae
(Rizzo et al., 1998). Using isolated caveolae from lung exposed to different vascular
flow in situ, they reported that increased flow enhanced caveolar eNOS activity
compared to other cellular membrane fractions. In parallel, increased flow induced
eNOS-caveolin dissociation as shown by co-immunoprecipitation. Conversely a
greater amount of eNOS-CaM complexes appeared after enhanced flow. Thus shear
stress induced activation of eNOS is associated with release of eNOS from its
inhibitory association with caveolin.
In summary, in resting cells eNOS is tonically inhibited by caveolin-1 (figure 1-9).
Activation is initiated by increases in [Ca2+]j in response to agonist binding to cell
surface receptors or increased shear stress. The rise in [Ca2+]j causes CaM to displace
caveolin resulting in translocation of eNOS to the cytosol where it is free to generate
NO. As the levels of [Ca2']jdrop below a threshold level, CaM dissociates and the
inhibitory eNOS-caveolin complex reforms.
As described in section 1.3.6.3 eNOS and caveolin interact directly. Using
glutathione S-transferase (GST)-caveolin-l fusion proteins and the yeast two-hybrid
system, Ju et al mapped the regions of interaction to the oxygenase domain of eNOS
(see figure 1-7) and the CSD of caveolin (see figure 1-8). Incubation of purified
eNOS with synthetic peptides corresponding to 82-101 amino acids of caveolin-1
(cav82-101) inhibited binding of eNOS to CaM-sepharose and resulted in
significantly attenuated eNOS activity. This inhibition could be competitively
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of endothelial cell lysates with cav82-101 abolished co-immunoprecipitation of the
eNOS-caveolin complexes. In comparison, a scrambled peptide bearing 60%
homology to cav82-101 had no effect on eNOS-caveolin co- immunoprecipitation
(Michel et al., 1997b). Caveolin also directly interacts with eNOS, albeit to a lesser
extent, via its C-terminal cytoplasmic tail (Garcia-Cardena et al., 1997; Ju et al.,
1997). However, present data suggest that the CSD is alone sufficient to interact with
eNOS and inhibit its activity.
Garcia-Cardena et al further characterised the interaction using site-directed
mutagenesis to mutate the putative caveolin-binding motif of eNOS
(F350SAAPFSGW to A350SAAPASGA). Cells transfected with both mutant eNOS
and caveolin released the equivalent amount of NO as cells transfected with eNOS
alone. In contrast co-transfection ofwild type eNOS and caveolin resulted in marked
inhibition ofNO release (Garcia-Cardena et al., 1997).
Although Ju et al reported no interaction between caveolin-1 and the reductase
domain of eNOS by the yeast two-hybrid system (Ju et al., 1997), Ghosh et al clearly
showed the presence of such an interaction. They demonstrated interactions between
the purified reductase domain of eNOS and GST-caveolin-1 as well as interaction
within the oxygenase domain. Furthermore, by measuring cytochrome c activity, an
artificial acceptor of electrons transferred from the reductase domain, they
demonstrated the inhibition of eNOS reductase domain-specific activity by caveolin
82-101 amino acid peptides, again reversed by addition of excess CaM. They
concluded that caveolin inhibition of eNOS is the result of diminished electron
transfer between reductase and oxygenase domains (Ghosh et al., 1998).
1.3.6.4 Physiological consequences ofeNOS-caveolin interactions
The physiological importance of eNOS-caveolin interactions has only become clear
within the last couple of years. Two independent reports provided strong in vivo
evidence supporting the role of caveolin as a negative regulator of eNOS. These
studies report the generation of caveolin-1 null mice by gene targeting which lack
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caveolae and have similar phenotypes (Drab et al., 2001; Razani et al., 2001). Aortic
rings from these mice were used to assess vascular tone. Compared to wild-type, the
knockout mice exhibited an impaired vasoconstrictor response to phenylephrine and
an enhanced relaxation response to ACh. NOS inhibitor, L-NAME, restored the
proper vasoconstrictor response and it was concluded that the changes in vascular
responses in caveolin-1 knockout mice were a consequence of increased eNOS
activity. In addition, NO production was measured in aortic vascular smooth muscle
cells isolated from caveolin -/-. Basal NO release was significantly higher in
knockouts complemented by an increase in cGMP content (Drab et al., 2001).
Another in vivo study has been described which also illustrates the physiological
importance of eNOS-caveolin interactions. In the study by Bucci et al, a chimeric
peptide comprised of the caveolin scaffolding domain (amino acids 82-101) fused to
a cellular internalisation sequence was incubated with mouse aortic rings (Bucci et
al., 2000). The peptide blocked ACh-induced vasorelaxations suggesting that the
peptide is a potent inhibitor of eNOS. A scrambled version of the peptide had no
effect. Together these studies have confirmed the in vitro data and established that
caveolin-1 is a negative regulator of eNOS activity in vivo.
1.3.7 Additional protein interactions
As well as interacting with CaM and caveolin-1, eNOS interacts with a variety of
other proteins, including heat shock protein 90 (hsp90), kinases, eNOS interacting
protein (NOSIP) and, of particular interest, GPCRs (reviewed in (Fulton et al., 2001;
Fleming & Busse, 2003)). As described above (refer to section 1.3.6.1), caveolae
contain a variety of signal transduction molecules, many of which are needed to
make up the eNOS "signalling complex" (see figure 1-10). This colocalisation of
molecules may facilitate enzyme activity and subsequently NO production by
bringing all the necessary components for eNOS activation (e.g. GPCRs and CaM)
and downstream NO production (e.g. G proteins and adenyl cyclases) into close
proximity. At present there is no direct evidence localising ETB to caveolae.
However, it is likely to follow the pattern of expression of other GPCRs. For
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Figure 1-10. eNOS signalling complex. Abbreviations: CaM, calmodulin; GPCR, G protein coupled
receptor (e.g. receptors for acetylcholine, bradykinin and endothelin); E, eNOS; C, caveolin-1, L-arg,
L-arginine, CAT-1, cationic amino acid transporter.
example, the presence of bradykinin B2 receptors within caveolae has been reported
(de Weerd & Leeb-Lundberg, 1997) and have been shown to physically interact with
eNOS via the intracellular domain 4 (ID4) by in vitro binding assays (Ju et al.,
1998). Likewise ID4 of the angiotensin II ATI receptor and the ETb physically
interact with eNOS in vitro (Marrero et al., 1999). Although no in vivo studies have
been published to support this observation, ETa was localised to caveolae by
immunofluoresence and was found to co-immunoprecipitate with caveolin-1 (Chun
et al., 1994) implying that ETb may also reside there. Interaction of eNOS with
bradykinin B2 receptors is reported to inhibit eNOS activity (Ju et al., 1998).
Furthermore, eNOS and GPCRs are reported to be associated in unstimulated cells.
Upon stimulation with BK, the proteins dissociate.
1.3.8 Regulation of renal eNOS
NO has several effects within the kidney including control ofmedullary blood flow,
regulation of acid-base balance and inhibition of sodium reabsorption (see section
1.2.2.1). However, despite the well-defined roles ofNO within the kidney, little is
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known of the mechanisms involved. Much of the evidence suggests that eNOS is the
main isoform controlling these processes and although the published data on eNOS
regulation is extensive, much of this has been performed in vitro and has not yet been
reproduced in vivo. Furthermore, it is quite plausible that eNOS is differentially
regulated depending on the type of tissue or vascular bed (Andries et al., 1998; Piech
et al., 2003). Therefore mechanisms involved in regulation of eNOS in the heart
cannot simply be extrapolated to the kidney. In fact, with regard to the kidney, eNOS
regulatory information is almost absent and requires further investigation.
Since eNOS is thought to have a crucial role in promoting natriuresis, it is interesting
that eNOS proteins levels were dramatically increased in the inner medulla of rats
fed on high salt compared to those on low salt (Mattson & Higgins, 1996). However,
hyperosmolality has been reported to decrease eNOS mRNA and protein levels in
cultured IMCD (Chen et al., 2002).
As described in section 1.3.6.1, subcellular localisation to caveolae is an important
regulatory feature of eNOS. However, it is not known if this occurs within the
vascular and epithelial structures of the kidney. Evidence regarding caveolin-1
localisation may provide some clues. Although protein analysis show that the kidney
expresses very low amounts of caveolin compared to the lung (Lisanti et al., 1994),
precise immunohistochemical analysis revealed expression within the glomerulus,
mesangial cells, collecting duct and endothelial cells of the efferent and afferent
arterioles (Breton et al., 1998; Tamai et al., 2001). Of particular interest was the high
expression within the descending vasa recta corresponding to large numbers of
caveolae as shown by immunogold labelling and electron microscopy (Breton et al.,
1998). This vascular bed is also a major site of renal eNOS and ETB expression as
described in section 1.2.2.8. Therefore, this circumstantial evidence suggests that
caveolin may be a potential regulatory mechanism controlling renal eNOS
production.
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1.3.9 Alterations in eNOS regulation during ED
It should be clear from the complexity of eNOS regulation described above that there
are many possible ways in which eNOS activity could be potentially altered during
ED. Like ED itself, it probably involves a combination of different factors. Some of
these factors are described below. Of particular interest is the emerging evidence
indirectly suggesting that the pathogenic mechanism underlying ED may involve
alterations in eNOS-caveolin interactions within caveolae.
1.3.9.1 Alterations in substrate and cofactor availability
Despite the fact that intracellular levels of L-arginine can be between 100 and
1000|iM and that the Km for NOS is only ~ 5|iM, several studies have demonstrated
the beneficial effects of L-arginine in conditions such as hypertension,
hypercholesterolemia and diabetes and in experimental animal models of these
disorders (Chen & Sanders, 1991; Creager et al., 1992; Pieper & Peltier, 1995).
However, the mechanisms involved are unclear. Some suggestions include
antagonism of NOS by endogenous asymmetric dimethyl arginine (ADMA) or
breakdown of L-arginine by arginase expressed within the endothelium (Vallance et
al., 1992; Buga et al., 1996). Furthermore, it is not known if the concentrations of L-
arginine within caveolae reflect that within the rest of the cell (McDonald et al.,
1997). Indeed caveolar concentrations may be significantly lower due to reduced
transport of L-arginine into these regions and may be a rate-limiting factor.
Deficient levels of the cofactor BH4, will trigger eNOS to produce superoxide (02~)
instead of NO (see section 1.3.9.4) (Pou et al., 1992). Recent studies suggest that
BH4 levels may be decreased in conditions such as diabetes and
hypercholesterolemia (Pieper, 1997; Stroes et al., 1997).
1.3.9.2 Alterations in NOS expression
As described in section 1.3.3 eNOS transcription is modulated by a number of
factors, including several substances associated with atherosclerotic lesion formation.
In animal models of hypertension, alterations in NOS protein expression are also
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detected. In the SHR, increased calcium-dependent NOS activity is reflected by
increased eNOS protein expression and higher levels of cGMP, despite these animals
exhibiting impaired endothelium-dependent relaxations (Mourlon-Le Grand et al.,
1992; Nava et al., 1996; Bauersachs et al., 1998; Nava et al., 1998; Vaziri et al.,
1998). This probably signifies an upregulation in the NO pathway to compensate for
increased blood pressure. However, these observations have not always been
confirmed elsewhere (Ruetten et al., 1999). Increased aortic eNOS expression is also
observed in a model of ED induced by aortic banding (Bouloumie et al., 1997) but is
decreased in the kidneys of the two-kidney, one clip model of hypertension
(Wickman et al., 2001). Polymorphisms of the eNOS gene linked to hypertension
have been reported in a number of separate Japanese studies (Nakayama et al., 1997;
Miyamoto et al., 1998; Uwabo et al., 1998). In particular, a variable number of
tandem repeats in intron 4 and an exon 7 variant that leads to an amino acid change
(Glu298Asp) have been identified. However, these polymorphisms have not been
observed in other populations (Bonnardeaux et al., 1995; Benjafield & Morris,
2000).
1.3.9.3 Uncoupling ofGPCR and Gproteins
Activation of eNOS may be altered in ED. Some reports describe defects in
activation of GPCRs or the signalling pathways activated by these receptors, for
example uncoupling of GPCRs and G proteins. In several models of ED,
endothelium-dependent vasorelaxation in response to a calcium ionophore is less
altered than responses to receptor mediated agonists (Bossaller et al., 1987). Indeed,
the endothelin system within the kidney medulla is impaired in hypertensive patients
and in several animal models of hypertension (refer to section 1.2.3) and may result
in diminished eNOS activation and NO production. However, Panza et al reported
that abnormalities in signal transduction did not relate to impaired agonist-induced
vasorelaxation responses in hypertensive patients (Panza et al., 1995).
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1.3.9.4 Destruction ofNO by superoxide
Although not affecting eNOS activity directly, inactivation of NO by increased
concentrations of 02" is probably one of the major factors accounting for reduced
NO bioavailability in ED. Treatment of rabbits, that had been maintained on a
cholesterol rich diet, with superoxide dismutase (SOD) increased endothelium-
dependent vasorelaxation and infusion of ascorbic acid in hypertensive patients
improved vascular responses to ACh (Mugge et al., 1991; Solzbach et al., 1997).
Augmented 02" was also observed in SHR and aortic-banding induced hypertension
(Bouloumie et al., 1997; Bauersachs et al., 1998).
1.3.9.5 Alterations in eNOS-caveolin interactions
The first report to investigate eNOS-caveolin interactions in a pathogenic situation
was by Feron et al (Feron et al., 1999). They demonstrated that incubation of bovine
aortic endothelial cells with hypercholesterolemic human serum was associated with
upregulation of caveolin-1 levels and impairment of basal NO release. This was
paralleled by an increase in the formation of inhibitory eNOS-caveolin complexes,
despite no increase in eNOS levels. Higher Ca2+-CaM levels were required to disrupt
the increased number of complexes. However, it is puzzling as to why a small
increase in caveolin protein levels should result in the formation ofmore complexes
since the same group previously published that the majority of eNOS is already
found in association with caveolin (Feron et al., 1996).
A similar study, using oxLDL-treated porcine pulmonary artery endothelial cells,
revealed that eNOS and caveolin were displaced from caveolae to the cytosol.
Incubation with oxLDL also significantly reduced eNOS activity in response to ACh.
Removal of oxLDL was followed by redistribution of eNOS and caveolin to caveolar
membrane fractions (Blair et al., 1999).
Only one study to date has investigated alterations in eNOS-caveolin interactions
during hypertension. Following confirmation of decreased NO production from
pulmonary arteries isolated from pulmonary hypertensive rats, Murata et al measured
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protein-protein interactions of eNOS with caveolin-1, CaM and hsp90. Aortas from
hypertensive rats contained increased eNOS-caveolin complexes compared to
normotensive rats and complexes were not disrupted upon carbachol treatment.
Furthermore CaM and hsp90 binding to eNOS were reduced in hypertensive animals
(Murata et al., 2002).
Alterations in caveolar structure, although not specifically eNOS-caveolin
interactions, were also observed during ED in the SHR. Scanning electron
microscopy revealed that in 10 week old SHR (i.e. the onset of hypertension) there
were significantly increased numbers of caveolae compared with aged matched
WKY and 5 week old prehypertensive SHR suggesting that structural changes may
be associated with hypertension (Goto et al., 1990). However, these observations
were not supported by McGuire et al who reported no changes in caveolar density in
SHR at 4, 10 and 24 weeks (McGuire & Twietmeyer, 1985).
Finally acute changes in shear stress, which are proposed to transmit through
caveolae as described in section 1.3.6.3 and by Rizzo et al, may also be affected
during ED (Rizzo et al., 1998). Increases in shear stress as a consequence of higher
blood pressure during hypertension may alter caveolar structure and eNOS-caveolin
interactions. Together, these studies suggest that there is a high probability that
during ED eNOS protein-protein interactions may be disturbed and pose a potential
pathogenic mechanism either in causing or maintaining ED.
In summary, eNOS plays a pivotal role in normal renal physiology, in particular
control of natriuresis/diuresis. ET-1, acting via ETB, is thought to be one of the major
regulators of eNOS activity within the kidney. However, eNOS activity is also
tightly regulated in a number of different ways. During ED renal eNOS activation
and regulation may be altered and physiological outcomes disturbed.
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1.4 HYPOTHESES AND AIMS
General hypotheses
Together the renal ET and NO systems play a vital role in the inhibition of sodium
and water reabsorption and thus contribute to the maintenance of normal blood
pressure and the prevention of hypertension. It is hypothesised that the inability of
eNOS to generate NO as a result of ED in the kidney results in sodium retention and
the sustained elevation of blood pressure. There are several reasons for why eNOS
activity may be altered. This thesis explores the following two general hypotheses:
(i) ED is associated with alterations in caveolar structure and interactions between
eNOS and regulatory proteins such as caveolin and ETB.
(ii) ED is associated with the inability of ET-1 to activate eNOS via ETB resulting
from either reduced activity of the renal ET system, reduced responsiveness of eNOS
to ET-1 activation or a combination of both.
Since these areas are too vast to be fully addressed within the scope of this thesis, I
have chosen to address the following specific aims:
Aims
In order to investigate the first hypothesis, I used an animal model of ED, the SHR,
to determine if these animals display abnormalities in renal eNOS, caveolin and ETB
protein expression and if interactions between these proteins are altered within the
kidney.
In order to address the second hypothesis first requires further knowledge of the
fundamental cellular and molecular mechanisms involved in ET-1 induced
natriuresis through ETB and eNOS activation. It is hypothesised that ET-1 acts as a
paracrine hormone, released from IMCD cells and activates eNOS by binding to ETB
located on endothelial cells of the vasa recta. To address this hypothesis, precise
localisation of ETB in the kidney medulla is required. This was achieved using an
EDNRB-LacZ transgene resulting in transgenic animals which express LacZ
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wherever EDNRB is expressed thereby producing a precise in vivo expression profile
of ETb.
The use of these animals was extended to investigate if ETB expression is altered
during salt loading.
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Chapter 2 - Methods
2.1 MATERIALS
All chemicals were supplied by Sigma-Aldrich Company Ltd unless otherwise
stated. All stock solutions were prepared using reverse osmosis distilled water (Milli-
Q50, Millipore UK Ltd) and where necessary were autoclaved before use.
Adjustment of pH of solutions was performed using acids supplied by Fisher
Scientific UK. Further information on specific materials used is provided within each
section. A list of all companies mentioned is found in section 2.7 at the end of the
chapter.
2.2 FUNCTIONAL STUDIES ON ISOLATED BLOOD VESSELS
2.2.1 Materials
All drugs were dissolved in distilled water, aliquoted and stored at -20°C until use.
The stock concentrations and working concentration range for each drug used are
shown in table 2-1. Drugs were diluted in physiological salt solution (PSS) before
use (see table 2-2 for composition of PSS).
Table 2-1. Drugs and concentrations used in functional studies
Drug Stock concentration (M) Working dose range (M)
Noradrenaline (NA) lxlO"2 lxlO"8 to lxlO"5
Phenylephrine (PE) lxlO"1 lxlO"8 to 3x10"5
Acetylcholine (ACh) lxlO2 lxlO"9 to 1 x 10"5
The compositions of solutions used in functional studies are listed in table 2-2.
2.2.2 Animals
Male SHR and WKY rats (16 weeks old) were supplied by Harlan UK Ltd and were
housed in the Hugh Robson Building animal house, University of Edinburgh under
the Animals (Scientific Procedures) Act 1986 (UK Home Office, project licence
number PPL 60/2813). Animals had free access to food (standard commercial animal
chow) and water. Animals were sacrificed by dislocation of the neck.
47
Chapter 2 - Methods



















NAK 10|lM NA in KPSS
Abbreviations: PSS, physiological salt solution; KPSS, PSS containing 123.7mM KC1; NAK, KPSS
containing lOpM noradrenaline (NA); EDTA, ethylenediaminetetra-acetic acid.
2.2.3 Functional studies using mesenteric arteries
2.2.3.1 Preparation ofmesenteric arteries
The mesentery was removed from the animal and placed in cold, oxygenated PSS.
Four third order mesenteric arteries were isolated by microdissection, cleaned of
connective tissue and suspended between two wires, 40|lm in diameter, in a
myograph organ bath (Multimyograph Model 61OM, Danish Myo Technology A/S).
Vessel lengths were 1.82 ± 0.03mm (WKY, n=5) and 1.90 ± 0.04mm (SHR, n=6).
The chambers were filled with warmed PSS (37°C), aerated with 95% 02, 5% C02
and vessels were allowed to equilibrate for 15 minutes. A resting stretch of 0.4g was
applied to each vessel and maintained for 1 hour during which time the PSS was
replaced every 15 minutes. Each chamber was connected to a force transducer and
changes in isometric tension were processed by a MacLab/4e analogue-digital
converter and recorded by MacLab Chart v3.4 software (ADInstruments).
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2.2.3.2 Experimental protocol
Vessels were constricted with NAK (3x), NA (lx) and KPSS (lx) as shown in figure
2-1. Each incubation was for 5 minutes and was separated by 5 minute washes with
PSS. Following the wake-up procedure vessels were allowed to rest for 30 minutes -
1 hour with PSS being replaced every 15 minutes. Vessels were then exposed to
cumulative additions of PE (lxlO"8 to 3xlO~5M) followed by washout with PSS. The
concentration of PE that produced 80% contraction of the maximum PE dose was
used to preconstrict vessels, following which relaxation responses to cumulative
additions of ACh (lxlO 9 to 1x10~5M) were measured to test for endothelial integrity.
Responses to ACh were expressed as the % relaxation of contraction to PE.
ACh
5fc sfc 5k 5k |
/lAMTLv^W
f t t t t t t
NAK NAK NA KPSS NAK PE EC80 PE
Figure 2-1. Schematic diagram of experimental protocol for mesenteric myography. *
denotes washout with PSS. See text for further details.
2.2.4 Functional studies using aorta
2.2.4.1 Preparation ofaortic rings
The thoracic aorta was removed from the animal and immediately placed in cold,
oxygenated PSS. After removal of connective tissue, the aorta was cut into 4 rings
approximately 3mm in length and mounted between two wires in organ bath
chambers (Organ bath model 700MO, Danish Myo Technology A/S) which
contained PSS (37°C) aerated with 95% 02, 5% C02. Vessels were allowed to
equilibrate for 15 minutes. A resting stretch of 1.5g was applied to each vessel and
maintained for 1 hour during which time the PSS was replaced every 15 minutes.
Changes in isometric tension were recorded as described in section 2.2.3.1.
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2.2.4.2 Experimental protocol
Vessels were constricted with NAK (3x) as shown in figure 2-2. Each incubation was
for 5 minutes and was separated by 15-20 minute washes with PSS. Following the
wake-up procedure vessels were allowed to rest for 30 minutes - 1 hour with PSS
being replaced every 15 minutes. Vessels were then exposed to cumulative additions
ofNA (lxlO"8 to lxlO"5M) followed by washout with PSS. The concentration ofNA
that produced 80% contraction of the maximum NA dose was used to preconstrict
vessels, following which relaxation responses to cumulative additions of ACh (lxl 0"9
to 1 xlO 'M) were measured to test for endothelial integrity. Responses to ACh were
expressed as the % relaxation of contraction to NA.
ACh
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Figure 2-2. Schematic diagram of experimental protocol for functional studies
in aortic rings. * denotes washout with PSS. See text for further details.
2.3 BIOCHEMICAL PROCEDURES
2.3.1 Materials
Anti-caveolin polyclonal antibodies were supplied by Autogen Bioclear UK Ltd (cat.
no. sc-894). Anti-eNOS monoclonal antibodies (clone 3) were from BD Biosciences
UK Ltd (cat. no. 610297). Anti-ETB polyclonal antibodies were supplied by
Biogenesis Ltd (cat. no. 4113-3059), Research Diagnostics Inc (cat. no. RDI-
ENDTHLHBRabS) or AbCam Ltd (cat. no. abl922). Secondary antibodies were
purchased from Sigma-Aldrieh Company Ltd.
Cell culture reagents were supplied by Invitrogen Ltd (Gibco) and tissue culture
plastic-ware by Corning (Bibby Sterilin Ltd).
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2.3.2 Preparation of tissue and cellular protein extracts
2.3.2.1 Animals
Animals were as described in section 2.2.2.
2.3.2.2 Preparation and culture conditions for HUVECs
Human umbilical vein endothelial cells (HUVECs) were supplied by Dr. Peter
Henriksen, University of Edinburgh prepared using a method described by Jaffe et al
(Jaffe et al., 1973).
2.3.2.3 Isolation ofcaveolin-rich domains by sucrose gradient ultracentrifugation
Caveolin-rich domains were isolated from rat lung and kidney using a method
described by T.isanti et al (Lisanti et al., 1994). 400mg (wet weight) of tissue was
minced with scissors in 2ml Mes-buffered saline, MBS (25mM Mes (2-[N-
morpholino]ethanesulfonic acid monohydrate), 0.15M NaCl, pH 6.5) containing 1%
Triton-XlOO and ImM phenylmethylsulfonylfluoride (PMSF) at 4°C. The tissue was
homogenised using a Polytron tissue grinder (two 5 second bursts) followed by 10
strokes of a Dounce homogeniser. Homogenates were incubated on ice for 30
minutes following which 2ml of 80% sucrose prepared in MBS was added to the
homogenate to yield a 40% sucrose solution.
5-30% linear sucrose gradients were formed in SW41 centrifuge tubes (Beckman
Coulter UK Ltd) using a Bio-Rad gradient former (Bio-Rad Laboratories Ltd). 5ml
of 5% and 30% sucrose solutions prepared in MBS were used for each gradient. The
homogenates (4ml) were carefully transferred to the bottom of the sucrose gradient
using a syringe. Gradients were centrifuged at 39000rpm, 4°C for 20 hours in an L8-
55 ultracentrifuge using a SW41 Ti rotor (Beckman Coulter UK Ltd).
Following centrifugation, twelve 1ml fractions were collected, of which fraction 9
corresponded to a visible light scattering band. This was also confirmed by
measuring absorbance at 600nm. The insoluble pellet was resuspended in 500pl
MBS. All samples were stored at -20°C until protein measurement and western blot
analysis was performed.
2.3.2.4 Protein extraction from tissue
Immediately following excision from the animal, tissues were immersed in ice cold
Nonidet P-40 (NP-40) lysis buffer (50mM Tris-HCl pH 7.4, 125mM NaCl, ImM
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EDTA, ImM EGTA, 1% NP-40 (v/v), ImM PMSF, lpg/ml pepstatin A), lg (wet
weight) of tissue was transferred to 5ml of fresh lysis buffer and roughly minced
with scissors followed by homogenisation using a Polytron tissue grinder (two 5
second bursts) and 10 strokes of a Dounce homogeniser. Homogenates were
incubated for 1 hour at 4°C. To remove insoluble material homogenates were
centrifuged in a microcentrifuge at lOOOOrpm, 4°C for 15 minutes. Supernatants
were collected and aliquoted into 500pl samples. Pellets were resuspended in 500|il
ofNP-40 lysis buffer. Samples were stored at -20°C until protein measurements and
western blot analysis were performed.
2.3.2.5 Protein extraction from cultured endothelial cells
HUVEC cells were lysed as described by Feron et al (Feron et al., 1998b). HUVEC
cells were grown to approximately 80% confluency in a 150cm2 flask. Following
aspiration of medium, cells were rinsed in PBS (2.7mM KC1, 137mM NaCl, 1.5mM
KH2P04, 4.3mM Na2HP04, pH 7.4) and either 5ml of cold Octyl-Glucoside (OG)
lysis buffer (50mM Tris-HCl pH7.4, 125mM NaCl, 2mM dithiothreitol, O.lmM
EGTA, 60mM OG, ImM PMSF, l|ig/ml pepstatin A, lpg/ml leupeptin) or NP-40
lysis buffer (see section 2.3.2.4 for composition) was added. Cells were scraped from
the flask using a rubber policeman and transferred to a 15ml centrifuge tube. The cell
suspension was either homogenised or sonicated (three 10 second bursts at output
power 10 microns) using a Soniprep 150 sonicator (Sanyo). Insoluble material was
removed by centrifugation at 10000 rpm in a microcentrifuge. Supernatants were
aliquoted in 500|ll samples and pellets were resuspended in 100|il of the appropriate
lysis buffer. Samples were stored at -20°C until protein measurements and western
blot analysis were performed.
2.3.3 Measurement of protein concentration
Protein concentration measurements were performed using Bradford's reagent
(Bradford, 1976) according to the manufacturer's protocol for micro (0-25|lg/ml) or
standard (0-1400|lg/ml) assays (Sigma-Aldrich Company Ltd). Bovine serum
albumin (BSA) was used to prepare the standard curve. Briefly, BSA was diluted
52
Chapter 2 - Methods
accordingly depending on the type of assay used (micro or standard). 50pl of each
standard was mixed with 1.5ml of Bradford's solution, incubated for 5 minutes and
absorbance was measured at 595nm using a SmartSpec 3000 spectrophotometer
(Bio-Rad Laboratories Ltd). Samples of unknown protein concentration were diluted
appropriately in order to obtain an absorbance which would fall within the linear
region of the standard curve. 50|il of each sample was mixed with 1.5ml of
Bradford's solution, incubated for 5 minutes and absorbance was read at 595nm.
2.3.4 Co-immunoprecipitation of eNOS-caveolin-1 complexes
Co-immunoprecipitation was performed as described by Feron et al (Feron et ai,
1998b). All incubations were performed at 4°C. Aliquots of cell and tissue
homogenates (approximately 100|ig total protein) were incubated with 10|ig of either
anti-caveolin or anti-eNOS antibodies for 2 hours with continuous rotation. In some
samples immune antibody was omitted in order to assess non-specific binding. 50|il
of a 50% slurry of protein G Sepbarose (PGS) (Protein G Sepharose 4 Fast Flow,
Amersham Pharmacia Biotech UK Ltd) was added to the samples for a further 1 hour
incubation. Prior to use the PGS was washed 3 times by centrifugation in lysis buffer
(NP-40 or OG depending on method of protein extraction). Following incubation
with PGS, bound immune complexes were washed 3 times by centrifugation
(5000rpm for 1 minute at 4°C) in lysis buffer and then once in wash buffer (50mM
Tris-HCl, pH 7.4, 150mM NaCl). In all experiments the first supernatant fraction
after incubation with protein G Sepharose was kept for analysis. After washing,
bound complexes were eluted in 50|il of 2x Laemmli sample buffer by boiling for 5
minutes. Immunoprecipitated samples were stored at -20°C until western blot
analysis was performed.
2.3.5 Western blot analysis
2.3.5.1 Solutions
Western blot analysis was performed using standard protocols (Hames & Rickwood,
1990). The composition of common solutions used in SDS-polyacrylamide
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electrophoresis (SDS-PAGE), western transfer and subsequent immunodetection are
listed in table 2-3.
Table 2-3. Composition of solutions used in western blotting
Buffer Composition
2x Laemmli sample buffer 0.063M Tris-HCl (pH 6.8)
10% (v/v) glycerol
2% (w/v) SDS
0.05% (w/v) bromophenol blue
5% (v/v) 2-mercaptoethanol










TBS-T (wash buffer) 0.02M Tris-HCl (pH 7.6)
0.14M NaCl
0.1% (v/v) Tween-20 (Bio-Rad
Laboratories Ltd.)
Blocking solution 5% (w/v) non-fat dried milk in
TBS-T
Abbreviations: SDS, sodium dodecyl sulfate; TBS, tris-buffered saline; T, Tween-20.
2.3.5.2 Separation ofproteins by SDS-PAGE
Following extraction, protein samples were denatured in an equal volume of
Laemmli sample buffer and incubated at 95°C for 5 minutes. Molecular weight
standards (broad range 200-6.5 kDa, Bio-Rad Laboratories Ltd) were also diluted
1:20 in sample buffer and boiled for 5 minutes. Proteins (1 pig-1OOpig) and molecular
weight standards (20|il/lane) were separated on denaturing SDS polyacrylamide gels
using Bio-Rad Mini-PROTEAN II Cell gel apparatus assembled according to
manufacturer's instructions (Bio-Rad Laboratories Ltd). 1mm thick gels were
routinely used, the compositions of which are shown in table 2-4. Gels were
immersed in electrophoresis running buffer and a voltage of 100V applied for
approximately 2 hours or until the dye front had reached the bottom edge of the gel.
Following separation, gels were either processed for western blot transfer and
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immunodetection (refer to section 2.3.5.3) or used for visualisation of proteins by
Coomassie or silver staining (refer to section 2.3.6.1 and 2.3.6.2).
Table 2-4. Composition of SDS-PAGE gels
% gel Composition
6% 6% acrylamide mix a




12% 12% acrylamide mix




5% (stacking gel) 5% acrylamide mix




a Acrylamide mix was comprised of acrylamide : N,N'-methylene-bis-acryl-
amide, 37.5:1 (Bio-Rad Laboratories Ltd)
Abbreviations: SDS, sodium dodecyl sulfate; TEMED, N,N,N',N'-tetramethylethylene
diamine
2.3.5.3 Immobilisation ofproteins by western transfer
Following electrophoresis, proteins were transferred from the polyacrylamide gel to a
positively charged polyvinylidene difluoride (PVDF) membrane (Hybond-P,
Amersham Pharmacia Biotech UK Ltd) using a Bio-Rad Mini Trans-Blot
Electrophoretic Transfer Cell (Bio-Rad Laboratories Ltd). During western transfer
the gel and membrane were sandwiched between two stacks of filter paper and fibre
pads with the membrane placed nearest the anode and the gel nearest the cathode so
that SDS-coated negatively charged proteins were transferred to the membrane when
the current was applied.
Prior to assembly of the gel sandwich, the membrane was pre-wetted in 100%
methanol and rinsed in distilled water for 5 minutes. The membrane and all
components of the sandwich were equilibrated for 20 minutes in cold transfer buffer
(see table 2-3 for composition) following which the electroblotting cassette was
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assembled and submerged in cold transfer buffer. A current of 400mA
(approximately 100V) was applied for 2 hours.
Following transfer, the cassette was dismantled and the PVDF membrane, now
containing immobilised proteins was immediately placed in blocking solution to
block non-specific binding sites and incubated overnight at 4°C with continuous
shaking. If molecular weight standards were to be visualised, the lane carrying these
markers was cut from the membrane and processed by Coomassie staining (refer to
section 2.3.6.1).
2.3.5.4 Immunodetection ofimmobilised caveolin, eNOS and ETB
After blocking of non-specific binding sites, membranes were incubated with
primary antibodies diluted in blocking solution (5ml final volume). Dilutions for all
antibodies are listed in table 2-5. Incubations were performed in 50ml centrifuge
tubes at room temperature with continuous rotation. After 2 hours, membranes were
rinsed briefly in wash buffer and then extensively washed for 15 minutes (x2)
followed by three 5 minutes washes to remove non-specifically bound antibody.
Table 2-5. Antibodies, suppliers and working dilutions for western blotting


























anti-rabbit - HRP Sigma-Aldrich
A2074
1:5000
anti-mouse IgGl - HRP Sigma-Aldrich
A8924
1:5000
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After each wash the buffer was removed and fresh buffer applied. Excess wash
buffer was removed by blotting on tissue paper and membranes were incubated with
horseradish peroxidase (HRP) conjugated secondary antibodies for 2 hours at room
temperature. Membranes were washed as described above. Specific antibody binding
was detected by Enhanced Chemiluminescent (ECL) reagents according to the
manufacturer's protocol (ECL Plus, Amersham Pharmacia Biotech). This method
detects immobilised specific antigens conjugated to HRP labelled antibodies which
catalyse the oxidation of Lumigen resulting in detectable emission of light. Briefly,
excess wash buffer was drained from the membrane and was placed on SaranWrap,
protein side up. Solutions A and B were mixed in a ratio of 40:1 and l-2ml was
applied per membrane ensuring that the entire surface of the membrane was covered.
Blots were incubated for 5 minutes at room temperature. Excess ECL was removed
by blotting on tissue paper and blots were wrapped in Saranwrap and exposed to
Hyperfilm ECL autoradiography film (Amersham Pharmacia Biotech UK Ltd).
Exposure times ranged from 10 seconds to 30 minutes. Films were processed using a
Konica SRX-101 A developer.
2.3.6 Visualisation of proteins on SDS-PAGE gels
2.3.6.1 Coomassie staining
Gels containing 10-100|ig of protein were stained with Coomassie staining solution
(0.05% (w/v) Coomassie Brilliant Blue R-250 (Bio-Rad Laboratories Ltd), 40% (v/v)
methanol, 10% (v/v) glacial acetic acid). Following electrophoresis gels were
submerged in the solution for 2 hours with gentle shaking. The stained gels were
destained overnight in destaining solution (40% (v/v) methanol, 10% (v/v) glacial
acetic acid) and then transferred to distilled water for storage. The same protocol was
used for visualising proteins on PVDF membranes (e.g. protein standards).
2.3.6.2 Silver staining
Silver staining was used for gels containing less than 10|ig protein (Gottlieb &
Chavko, 1987). The Silver Stain Plus kit (Bio-Rad Laboratories Ltd) was used
according to the manufacturer's instructions. Following electrophoresis, gels were
placed in Fixative Enhancer Solution (50% (v/v) methanol, 10% (v/v) glacial acetic
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acid, 10% (v/v) Fixative Enhancer Concentrate) for 20 minutes with gentle shaking
after which they were rinsed in distilled water for 20 minutes. During washing the
Staining Solution was prepared comprising 50% (v/v) Development Accelerator
Solution, 5% (v/v) Silver Complex Solution, 5% (v/v) Reduction Moderator
Solution, 5% (v/v) Image Development Reagent. After gels had been washed they
were stained in the Staining Solution for 10-20 minutes. The time of incubation was
dependant on the quantity of protein present. Once desired staining was reached the
reaction was stopped by placing the gels in 5% glacial acetic acid for 15 minutes
following which they were stored in distilled water.
2.3.7 Drying of SDS-PAGE gels
Stained gels were vacuum dried using a Hoefer Drygel slab gel dryer (Amersham
Pharmacia Biotech UK Ltd). Gels were covered in clingfilm and sandwiched
between two pieces of filter paper. The sealing gasket was placed over the gel and
the vacuum applied. Gels were dried at 80°C for 40 minutes.
2.3.8 Densitometry and statistical analysis
Gels and western blots were scanned and densitometry was performed using Aida
2.11 2D densitometry (Raytest Scientific Ltd). Comparisons between two groups
were made using a Student's unpaired t test. Values are given as mean ± S.E.M. and
P values of less than 0.05 were considered significant.
2.3.9 Visualisation of eNOS and caveolin expression by immunofluorescence
eNOS and caveolin expression were analysed in HUVECS using antibodies to eNOS
and caveolin and fluorescent conjugated secondary antibodies (see table 2-6).
HUVECS were cultured overnight on glass coverslips 13mm in diameter (BDH,
VWR International Ltd) in 24-well plates in cell culture medium (DMEM, 10% (v/v)
foetal calf serum, lOOU/ml penicillin, lOOug/ml streptomycin, 25mM HEPES,
2.0mM glutamine). They were plated at low density to produce an evenly spread
population of cells. The following day cells were rinsed in PBS and fixed by
incubation for 10 minutes in 4% (w/v) paraformaldehyde, pH 7.4. Fixative was
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removed and cells washed twice in PBS followed by permeabilisation in 0.2% (v/v)
Triton X100/PBS for 5 minutes. Cells were then washed 4 times in PBS. After
blocking in 2% (w/v) BSA/PBS for 1 hour, primary antibody was applied for 1 hour.
Antibodies were diluted in blocking solution and a minimal volume applied. See
table 2-6 for dilutions used. For controls, samples were incubated with the
appropriate non-immune serum to assess for non-specific binding of primary
antibodies (e.g. rabbit serum for anti-caveolin and mouse IgG for anti-eNOS).
Following 3 washes in PBS, fluorescent secondary antibodies were applied for a
further hour. Excess antibody was removed by further washing in PBS. In some
cases nuclei were stained using TO-PRO-3 (Molecular Probes Europe BV) by
incubation for 5 minutes in l(iM TO-PRO-3 (diluted from ImM stock dissolved in
DMSO) followed by a brief rinse in PBS. After antibody incubations were
completed, coverslips were inverted onto glass slides and the edges sealed with nail
varnish. Cells were viewed using a Leica TCS-NT 3-channel confocal microscope
(Leica Microsystems (UK) Ltd). FITC was detected by green emission and TRITCI
by red emission.
Table 2-6. Antibodies, suppliers and working dilutions for immunofluorescence

















a Fluorescein (excitation 495nm, emission 525nm)
b Rhodamine (excitation 552nm, emission 570nm)
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2.4 MOLECULAR BIOLOGY PROCEDURES
All molecular procedures were carried out using standard techniques (Sambrook et
al., 1989).
2.4.1 Materials
2.4.1.1 Chemicals and solutions
Absolute ethanol, chloroform, isoamyl alcohol and phenol were supplied by Fisher
Scientific UK. SeaKem LE agarose was supplied by Cambrex Bioscience Ltd.
Oligodeoxynucleotide primers were synthesised by MWG Biotech UK Ltd. They
were diluted upon arrival in distilled water to 100pmol/|ll and stored at -20°C.
Luria-Bertani (LB) medium was prepared from lOg bacto-tryptone, 5g bacto-yeast
extract and lOg NaCl per litre. pH was adjusted to 7.5 with ION NaOH and
autoclaved before use. Agar selection plates were prepared from 15g agar/L of LB.
Unless otherwise stated, ampicillin (Sigma-Aldrich Company Ltd) was added to LB
and agar plates at a final concentration of 100pg/ml. Bacto-tryptone, bacto-yeast
extract and agar were supplied by Invitrogen Ltd.
MB1 Fermentas DNA molecular weight markers were supplied by Helena
Biosciences Europe. Either GeneRuler lOObp DNA ladder (lOOO-lOObp) or Lambda
DNA///mdIII (23130, 9416, 6511, 4361, 2322, 2027, 564bp) were used depending
on the size ofDNA to be analysed.
2.4.1.2 Enzymes
All restriction enzymes, Klenow, alkaline phosphatase and T4 DNA polymerase
were supplied by Roche Diagnostics Ltd. MBI Fermentas T4 polynucleotide kinase
and T4 DNA ligase were supplied by Helena Biosciences Europe and M-MLV
Reverse Transcriptase and Pfiu DNA Polymerase were from Promega UK Ltd.
2.4.1.3 Bacterial strains
All plasmids were maintained in Escherichia coli strain XLl-blue cells (genotype
supE44 hsdR17 recAl endAl gyrA46 thi relAl lac" F'[proABr laclq lacZAM15
TnlO(tef)]) (Sambrook et al., 1989).
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2.4.1.4 Cloning vectors andplasmids
The vectors and plasmids used during cloning are shown in figures 2-3 - 2-8. Further
detailed information will be given in chapter 4.
2.4.2 Preparation of electrocompetent cells
Prior to use all glass- and plastic-ware was thoroughly rinsed in 5% acetic acid
followed by several washes with distilled water and stored at 4°C. A single XLl-blue
colony from a freshly streaked agar plate (without ampicillin) was incubated at 37°C
in 50ml LB medium (without ampicillin) with shaking (200-225rpm) for 12-16
hours. The following day the 50ml culture was used to inoculate 1 litre of LB
medium and the culture incubated at 37°C with shaking for approximately 2-3 hours
or until the OD550 was between 0.5 and 0.6 after which the culture was transferred to
two sterile 500ml Sorvall centrifuge bottles and incubated on ice for 30 minutes. All
subsequent steps were performed at 4°C. Cells were centrifuged at 5000rpm for 15
minutes at 4°C in a precooled Beckman J2-21 centrifuge, rotor JAM (Beckman
Coulter UK Ltd. The medium was discarded and the cell pellet resuspended in 500ml
of cold sterile water. After a further centrifugation the supernatant was discarded and
the pellet resuspended in 250ml sterile water and again centrifuged for 15 minutes.
Washing of the cells is necessary to ensure that salts are removed to reduce the
conductivity of the cell solution. High conductivity may result in arcing during
electroporation. The cell pellet was resuspended in 20ml of cold sterile 10% glycerol
and centrifuged at 6000rpm for 15 minutes following which the pellet was
resuspended in 1ml 10% glycerol. Cells were snap frozen in 1.5ml microcentrifuge
tubes (40[il aliquots) in a dry ice/ethanol bath before being transferred to -70°C until
required.
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BamH 118"2
Figure 2-3. Plasmid pA,PXho. pAPXho is a genomic clone spanning from the last 12kb of intron 1 to
54bp of exon 5 of the EDNRB gene. It was obtained by screening a /.phage library (created by Dr. A
Smith, Institute for Stem Cell Research, University of Edinburgh) using EDNRB cDNA as a probe
and cloned into pBluescript II SK (pBS). Only restriction sites of relevance to this thesis are marked.
Reference/Source: a gift from Dr. A. Bagnall, University of Edinburgh. Constructed by Dr. A.
Bagnall
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Figure 2-4. Plasmid pKL53. pKL53 contains an internal ribosome entry site (IRES) followed by the
LacZ gene ((3-galactosidase) cloned into pBS II SK. Preceding LacZ is a 29bp nuclear localisation
signal (NLS). There is also the neomycin phosphotransferase resistance gene (neo), simian virus 40
polyadenylation site (SV40 polyA) and engrailed-2 (En-2). Only restriction sites of relevance to this
thesis are marked.
Reference/Source: a gift from Dr. M. Sharp, University of Edinburgh. Constructed by Dr K. Lee and
Dr. P. Mountford, Institute for Stem Cell Research, University ofEdinburgh.
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Figure 2-5. Plasmid pl049. pl049 contains an internal ribosome entry site (IRES) followed by the
LacZ gene ((3-galactosidase) cloned into pBS II SK. There is also the neomycin phosphotransferase
resistance gene whose expression is driven by the MCI promoter (MClneopA) and a simian virus
polyadenylation site (SV40 polyA). Only restriction sites of relevance to this thesis are marked.
Reference/Source: a gift from Dr. Andrew Smith, Institute for Stem Cell Research, University of
Edinburgh. Constructed by Dr A. Smith, Institute for Stem Cell Research, University of Edinburgh.
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Sacl Notl Xbal Spel BamHI EcoRI EcoRV Hindlll Clal Sail Kpnl
Figure 2-6. Plasmid pBluescript II SK. pBluescript II SK (pBS) is a cloning vector possessing a
polylinker site containing 21 unique restriction sites (not all of them are shown here) flanked by T3
and T7 promoters. Also present is the ampicillin resistance gene.
Reference/Source: Stratagene Europe (cat. no. 212206).
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Notl Spel Xbal Bglll Ncol BamHI Xhol Muni Kspl Sful Spel
Figure 2-7. Plasmid pSP72poly3. pSP72poly3 is a pSP72 based vector (Promega UK Ltd)
containing an altered polylinker flanked by T7 and SP6 promoters. Also present is the ampicillin
resistance gene.
Reference/Source: a gift from Professor J. Mullins, University of Edinburgh. Constructed by A.
Popplewell and S. Morley.
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Figure 2-8. Plasmid pCRII-6.18. pCRII-6.18 is a pCRII based vector (Invitrogen Ltd) containing
EDNRB genomic DNA spanning exon 2 to part of exon 6.
Reference/Source: a gift from Dr. A. Bagnall, University of Edinburgh. Constructed by Dr. A.
Bagnall
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2.4.3 Transformation of electrocompetent cells
One aliquot (40|il) of competent cells was used per transformation. Frozen aliquots
were thawed on ice and between 0.5 and 4|il of plasmid DNA or ligation mix
(approximately 10-100ng) were added to the cells and gently mixed by pipetting. The
mix was transferred to a prechilled 0.2cm electroporation cuvette pre-washed with
70% ethanol and rinsed with water. Electroporation was performed in a Bio-Rad
Gene-Pulser (Bio-Rad Laboratories Ltd) with the capacitor set to 25jO.F, 2.5KV and
the pulse controller unit set to 200Q. One pulse was applied resulting in a pulse of
12.5KV/cm with a time constant of 4.6-4.8msec. Immediately following
electroporation, 300pl of SOC (20g/L bacto-tryptone, 5g/L bacto-yeast extract,
lOmM NaCl, 2.5mM KC1, lOmM MgCl2, lOmM MgS04 and 20mM glucose) was
added to the transformation mix and incubated for 30 minutes at 37°C to allow
expression of antibiotic resistance. Cells were plated on selection plates with
approximately 100-200|il plated per plate. Plates were incubated overnight at 37°C.
2.4.4 Preparation of plasmid DNA
A single bacterial colony containing plasmid DNA of interest was picked from a
freshly streaked plate and used to inoculate a starter culture of 2ml LB medium.
Cultures were incubated at 37°C for 8 hours with shaking after which the starter
culture was diluted 1/1000 in LB medium (final volume 50ml) and incubated
overnight at 37°C with shaking. Cells were harvested by centrifugation at 3000rpm
(Beckman J-6B, rotor JS 4.2, Beckman Coulter UK (Ltd)) for 15 minutes at 4°C
followed by resuspension of the pellet in 50mM Tris-Cl pH 8, lOmM EDTA,
100pg/ml RNaseA.
Plasmid DNA was prepared using HiSpeed Plasmid Midi/Maxi kits supplied by
QIAGEN (QIAGEN Ltd). A detailed description of the procedure is given in the
manufacturer's instruction manual. This method involved alkaline lysis of the cells in
200mM NaOH, 0.1% SDS followed by neutralisation in 3M potassium acetate
pH5.5. Precipitated material (proteins, chromosomal DNA and cellular debris) was
removed by filtration and the cleared lysate passed through HiSpeed QIAGEN
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columns containing DNA binding resin. RNA and proteins were removed by
washing in medium salt wash buffer (1M NaCl, 50mM MOPS pH7, 15%
isopropanol). Bound DNA was then eluted from the column in high salt buffer
(1.25M NaCl, 50mM Tris-Cl pH8.5, 15% isopropanol) and the resulting eluate
precipitated in 0.7 volumes of isopropanol resulting in high quality DNA. The midi
and maxi kits routinely yielded approximately 200|ig and 750(lg plasmid DNA
respectively. The DNA concentration was determined by UV spectrophotometry
(refer to section 2.4.5) and the identity of the plasmid was confirmed by restriction
mapping (refer to 2.4.8).
2.4.5 Quantification of DNA
DNA concentration was determined by measuring the absorbance at 260nm (OD260)
in a SmartSpec 3000 spectrophotometer (Bio-Rad Laboratories Ltd) using a quartz
cuvette zeroed with TE (lOmM Tris-HCl pH8.0, ImM EDTA). Plasmid DNA was
diluted in TE and absorbance measured at 260 and 280nm to obtain a reading which
was between 0.1 and 1.0 units. An absorbance of 1 unit at 260nm corresponds to
50jig plasmid DNA/ml. This relationship was used to calculate DNA concentrations
taking into account the dilution factor.
2.4.6 Agarose gel electrophoresis
DNA fragments were separated according to size by agarose gel electrophoresis.
Agarose gels were 0.8-2.0% (w/v) containing lx TAE (40mM Tris-acetate, ImM
EDTA) and 0.5|ig/ml ethidium bromide. Prior to loading 6x gel loading buffer (0.2%
bromophenol blue, 0.2% xylene cyanol FF, 10% glycerol, MBI Fermentas) was
added to each sample to give a final concentration of lx loading buffer. Samples
were always run alongside molecular weight markers. Electrophoresis was
performed in 1 x TAE running buffer at 100V until the dye front had migrated an
appropriate distance. Ethidium bromide - DNA complexes were visualised under UV
light (UVP Transilluminator, UVP Inc.) and photographed by a Sony Video Graphic
Printer UP-890CE (Sony UK Ltd).
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2.4.7 Nucleic acid extraction and precipitation
Phenol:chloroform extraction and alcohol precipitation was used to desalt and
concentrate DNA preparations. An equal volume of phenol:chloroform:isoamyl
alcohol (25:24:1) was added to the DNA solution, vortexed and centrifuged for 2
minutes at 12000x g at 4°C. The upper phase was transferred to a fresh tube and 2
volumes of ice cold 100% ethanol and 0.1 volumes of 3M sodium acetate pH 5.2
were added to precipitate the DNA. The solution was incubated at -20°C for 30-60
minutes. For the recovery of small quantities ofDNA, samples were left overnight at
-20°C. DNA was pelleted by centrifugation in a microcentrifuge at maximum speed
for 15 minutes at 4°C. The DNA pellets were washed in 70% ethanol to remove co-
precipitated salt and respun for 5 minutes. Pellets were air dried and resuspended in a
suitable volume ofTE.
2.4.8 Restriction enzyme digests
DNA was digested using restriction endonucleases for either analytical or
downstream cloning purposes. For analytical purposes l(lg plasmid DNA was
digested with 10 units of enzyme in the appropriate restriction buffer made up to a
final volume of 20|il with distilled water. Digests were usually incubated at 37°C for
3 hours to ensure complete restriction. However, some enzymes required higher
incubation temperatures as indicated on the product data sheet. Following digestion,
15pl of the sample was analysed by agarose gel electrophoresis.
For downstream applications (e.g. ligation) approximately lOpg plasmid DNA was
digested with 50 units of enzyme in the appropriate restriction buffer made up to a
final volume of 50|il. Digests were incubated overnight at the appropriate
temperature. Following digestion, the enzyme was heat-inactivated by incubation at
65°C for 15 minutes. Digested DNA was then used for further manipulations.
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2.4.9 Preparation of PCR products for ligation
2.4.9.1 PCR conditions
PCR reactions were performed in 4x 25jil volumes. A "master mix" containing all
components except DNA was made for each PCR. The master mix comprised lx Pfu
DNA polymerase buffer (20mM Tris-HCl pH 8.8, lOmM KC1, lOmM (NH4)2S04,
2mM MgS04, 100|lg/ml BSA, 0.1% Triton X-100), 200|dM dNTP mix, 0.3jiM
forward and reverse primers and 1.125 units Pfu DNA polymerase. Primer sequences
are documented in section 4.2.1.3. For the purposes of cloning, PCR was performed
using Pfu proofreading enzyme to minimise the chance of introducing random
mutations. The master mix was aliquoted into PCR tubes and template DNA
(approximately lng) added. PCR was performed on an MJ Research PTC-200 DNA
Engine (Genetic Research Instrumentation) and DNA amplified as follows: initial
denaturation at 92°C for 2 minutes, amplification for 3Q cycles of denaturation for 30
seconds at 92°C, annealing for 30 seconds at 50°C, extension for 2 minutes at 68°C
followed by a final extension period of 10 minutes at 68°C. A heated lid was used to
prevent evaporation. 5(il of PCR reaction was checked on an agarose gel before
proceeding with Klenow, Kinase, Ligase reactions.
2.4.9.2 Klenow, Kinase, Ligase
The Klenow, Kinase, Ligase reaction creates concatermeric DNA from PCR
products by polishing (Klenow), phosphorylating (Kinase) and ligating (Ligase) PCR
termini in a single. The concatermeric DNA can then be used for restriction enzyme
digestion and ligation to the vector. PCR reactions (4x 25jil) were pooled and
phenolxhloroform extracted and precipitated (refer to section 2.4.7). DNA was
resuspended in 12.6[il distilled water. Ligase buffer (30mM Tris-HCl pH 7.8, lOmM
MgCl2, lOmM DTT, 0.5mM ATP), 0.2mM dNTP mix, 5 units Klenow, 4 units T4
polynucleotide kinase and 2 units T4 DNA ligase were added to give a final reaction
volume of 25pl. The reaction was incubated at room temperature for 2 hours
followed by another round of phenol:chloroform extraction and precipitation.
2.4.9.3 Restriction enzyme digest ofPCR concatamers
Precipitated DNA was redissolved in 36|il distilled water and digested with the
appropriate restriction enzymes (20 units) and restriction buffer in a final volume of
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50|il and incubated overnight at 37°C. The digested PCR products were
phenol:chloroform extracted and precipitated and DNA resuspended in 40|ll distilled
water ready for ligation.
2.4.10 Purification of DNA fragments from agarose gels
Digested DNA fragments were purified from agarose gels using silica gel based
purification. QIAEX II Agarose Gel Extraction kits were used (QIAGEN Ltd) and
the supplied protocol followed. Briefly, digested DNA was separated on a 0.8%
agarose gel and the DNA band of interest excised under UV light. The gel was
solubilised in QX1 buffer (3M NaCl, 4M sodium perchlorate, lOmM Tris-HCl pH 7,
lOmM sodium thiosulphate) and DNA bound to QIAEX beads by incubation at 50°C
for 10 minutes. The beads were washed by centrifugation once in buffer QX1 and
then twice in buffer PE (70% ethanol, lOOmM NaCl, lOmM Tris-HCl pH 7.5).
Bound DNA was eluted by incubation of the beads in 20pl TE at 50°C for 5 minutes
followed by centrifugation and recovery of the purified DNA in the supernatant. In
order to increase the yield a second elution step was performed and the supernatants
combined.
2.4.11 Conversion of a 3' -overhang to a blunt end terminus
Before ligation some DNA fragments with incompatible restriction sites had to be
blunt-ended using T4 DNA polymerase (e.g. BamHI and SphI). Following
purification of DNA (described in section 2.4.10) approximately 2-5p,g DNA was
used per reaction in a final volume of 50|il. Reactions were performed in lx
incubation buffer (50mM Tris-HCl pH8.8, 15mM (NH4)2S04, 7mM MgCl2, O.lmM
EDTA, lOmM 2-mercaptoethanol, 20 jig/ml bovine serum albumin) supplemented
with 100pM dNTP and 5 units of T4 DNA polymerase. Reactions were performed at
11°C for 30 minutes before being phenol:chloroform extracted and precipitated (refer
to section 2.4.7) ready for ligation.
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2.4.12 Ligation of DNA
Ligations were set up with insert:vector molar ratio of 3:1 for sticky ends and 5:1 for
blunt ends. Concentrations of vector and insert were estimated by running a sample
of each alongside molecular weight standards of known concentration on an agarose
gel. Approximately 50-100ng of vector DNA was used in a final reaction volume of
25(0,1. Reactions were performed in lx ligase buffer (40mM Tris-HCl pH7.8, 10mM
MgCl2, lOmM DTT, 0.5mM ATP) and with 1 unit T4 DNA ligase. A control
reaction using vector alone with ligase was set up with every ligation. The ligation
reaction was performed on a MJ Research PTC-200 DNA Engine (Genetic Research
Instrumentation) using a program cycling between 16°C for 30 seconds and 25°C for
30 seconds repeated 60 times. Following ligation, the ligated DNA was used for
transformation of competent cells (refer to section 2.4.3).
2.4.13 Analysis of transformants
Recombinants obtained from ligation reactions were screened by one of the
following methods.
2.4.13.1 DNA minipreps and restriction enzyme digest analysis
2ml LB was inoculated with a single bacterial clone picked from the transformation
plate and incubated overnight at 37°C with shaking. Approximately 24 colonies were
analysed per ligation. 1.5ml aliquots were centrifuged at 12000x g in a
microcentrifuge for 1 minute at 4°C. Cell pellets were resuspended in 1 OOjo.1 cell
resuspension buffer (50mM glucose, 25mM Tris-HCl pH 8.0, lOmM EDTA) by
vortexing and incubated for 5 minutes at room temperature after which 200(tl of
freshly prepared lysis buffer (0.2N NaOH, 1% SDS) was added and mixed by
inversion. Lysates were incubated for 5 minutes on ice before being neutralised by
the addition of 150(tl ice cold potassium acetate solution pEl 4.8 (3M potassium, 5M
acetate) and gently vortexed for 10 seconds. Following a further 5 minute incubation
on ice, lysates were centrifuged at 12000x g for 5 minutes at 4°C and the supernatant
transferred to a fresh tube. DNA was phenokchloroform extracted and ethanol
precipitated (refer to section 2.4.7). DNA was resuspended in 50pl TE containing
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20|ig/ml RNase A and used for analytical restriction enzyme digest analysis (refer to
section 2.4.8).
2.4.13.2 Colony lift and hybridisation
The composition of solutions used in colony lift and hybridisation are listed in table
2-7. Cells were plated to give an optimal density of 200 colonies per 83mm agar
plate. After overnight incubation at 37°C, plates were pre-cooled to 4°C for 30
minutes. Colonies were transferred onto Hybond-N nylon membrane discs
(Amersham Pharmacia Biotech UK Ltd) by placing the membrane onto the plate for
30-60 seconds. The orientation of the colonies was marked with a needle. The
membrane was transferred colony side uppermost onto a fresh agar plate and
incubated for 2 hours at 37°C. DNA was liberated from bacteria by placing the
membrane on filter paper (colony side up) soaked in denaturation buffer for 4
minutes and then onto filter paper soaked in neutralisation buffer for 2x 3 minutes.
Table 2-7. Composition of solutions used in colony lifts and Southern blotting
Solution Composition
Denaturation buffer 1.5M NaCl
0.5M NaOH
Neutralisation buffer 1.5M NaCl
1M Tris-HCl pH 7.5
20x SSC 0.3M tri-sodium citrate
3M NaCl pH 7.2
Hybridisation buffer 50% formamide





lOOx Denhardt's reagent 20g/L Ficoll 400
20g/L polyvinylpyrrolidone
20g/L BSA fraction V
(filtered and stored at -20°C)
Wash buffer 1 6x SSC
0.1% SDS
Wash buffer 2 2x SSC
0.1% SDS
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Membranes were then washed vigorously in 2x SSC to remove any debris and
allowed to air dry. DNA was fixed to the membrane by baking at 120°C for 1 hour
and stored at 4°C until hybridisation.
For hybridisation, probes were labelled with Redivue [32P] dCTP (Amersham
Pharmacia Biotech UK Ltd) using Rediprime II random prime labelling system
(Amersham Pharmacia Biotech UK Ltd). Denatured DNA (approximately 25ng of
DNA diluted in 45|il TE) was added to the reaction tube (containing dATP, dGTP,
dTTP, Klenow and random primers in a dried pellet) along with 5pl of [32P] dCTP
and incubated for 30 minutes at 37°C. Unincorporated nucleotides were removed on
ProbeQuant G-50 Micro columns (Amersham Pharmacia Biotech UK Ltd) according
to the manufacturer's instructions. Membranes, prewet in 2x SSC, were placed in a
prewarmed hybridisation bottle (Techne Ltd) and pre-hybridised for one hour in
hybridisation buffer at 42°C in a Techne hybridisation oven (Techne Ltd). The
labelled probe was denatured by incubation at 100°C, added to the membranes and
hybridised overnight at 68°C. Upon completion of hybridisation, the probe was
discarded and membranes rinsed briefly in 2x SSC. The blots were then washed for
10 minutes in wash buffer 1 and then a further 10 minutes in wash buffer 2. If
necessary a further wash of 10 minutes in 0.2x SSC, 0.1% SDS was performed.
Membranes were wrapped in Saran Wrap and placed in a cassette with intensifying
screens for autoradiography using Kodak XOMAT XAR-5 film (Sigma-Aldrich
Company Ltd). After 24 hours at -70°C films were developed using a Konica SRX-
101 A developer and if necessary re-exposed for a suitable amount of time to detect
the desired signal. Resulting dark spots on the film were aligned with the original
tranformation plate and the corresponding colonies picked and used to inoculate 2ml
LB which were grown up overnight at 37°C and analysed by DNA minipreps and
restriction enzyme digest as described in section 2.4.13.1.
2.4.14 Sequencing of plasmid DNA
Sequencing was performed by Mrs. N. Kotelevtseva, University of Edinburgh using
an ABI Prism sequencer with BigDye Terminator chemistry (Applied Biosystems).
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2.4.15 Analysis of DNA sequences
Sequences were analysed with Gene Jockey Sequence Processor software (Biosoft,
Cambridge, UK).
2.5 ES CELL CULTURE AND GENERATION OF KNOCK-IN MICE
2.5.1 Materials
All cell culture reagents were supplied by Invitrogen Ltd (Gibco) except for foetal
calf serum (FCS) which was from Globepharm (Surrey, UK). Embryonic stem (ES)
cells were grown on Corning culture grade plastic-ware (Bibby Sterilin Ltd, Stone,
UK). G418 was supplied by Invitrogen Ltd (Gibco). Leukaemia inhibitory factor
(LIF) was purified in-house (Institute for Stem Cell Research, University of
Edinburgh).
The composition of standard ES cell culture media is shown in table 2-8. Media was
prepared under sterile conditions and stored as 500ml aliquots at 4°C. Fresh media
was tested for bacterial contamination by incubating 5ml with 5ml tryptose
phosphate broth a 37°C for at least 2 days before use.
Table 2-8. Composition of ES cell culture media
Solution Composition
ES cell culture media lx GMEM
10% FCS
0.23% (w/v) sodium bicarbonate






Abbreviations: GMEM, Glasgow minimal essential media; FCS, foetal calf serum; MEM, minimal
essential media; DIA, differentiation inhibitory factor; LIF, leukaemia inhibitory factor.
2.5.2 ES cell culture conditions
E14Tg2a ES cells were grown in ES cell culture medium on gelatinised tissue culture
flasks (0.1% gelatin) in a humidified incubator (Heraeus model B5060 EC/C02) at
37°C, 6-7.5% C02. ES cells were maintained in an undifferentiated state by growing
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in the presence of leukaemia inhibitory factor (LIF). Manipulations were performed
inside a laminar flow sterile hood (Gelair ICN Flow Hood (class 3), ICN
Pharmaceuticals Ltd, Thame, UK). Before performing manipulations, all surfaces
(including arms and hands) were sterilised with 70% industrial methylated spirits.
2.5.3 Passage of ES cells
ES cells were maintained in 25cm2 flasks and passaged every 2-3 days. Prior to
passaging, media, TVP and PBS were warmed to 37°C. Following aspiration of
media, cells were washed twice with 10ml PBS to remove any dead cells. Cells were
trypsinised with 5ml TVP (0.025% trypsin, 1% chicken serum, 0.5mM EDTA in
PBS) and the flask incubated at 37°C for 1-2 minutes. Cells were dissociated by
tapping the flask and by pipetting up and down to obtain a single cell suspension.
TVP was neutralised by the addition of 15ml ES cell culture media and cells were
transferred to a sterile universal tube. Cells were pelleted by centrifugation at
1300rpm for 5 minutes in a benchtop centrifuge before being resuspended in 5ml
PBS and counted in a haemocytometer. lxlO6 cells were seeded in a 25 cm2
gelatinised flask.
2.5.4 Freezing and thawing ES cells
Cells were trypsinised and pelleted as described above and resuspended in 1ml
freezing medium (10% (v/v) DMSO in ES cell culture medium) before transfer to
cryotubes. Cells were immediately frozen at -70°C for 1-2 days before transfer to
liquid nitrogen for long term storage. Frozen cells were thawed in a 37°C water bath
and diluted in 9ml ES cell culture medium. Cells were seeded in a 25cm2 gelatinised
flask and incubated at 37°C for 8 hours before replacing the media with fresh ES cell
culture medium to remove traces ofDMSO.
2.5.5 Electroporation of ES cells
150|lg and 75pg of DNA construct was linearised with the appropriate restriction
enzyme (100 units enzyme), precipitated as described in section 2.4.7 and allowed to
air dry. DNA was resuspended in 100pl PBS.
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Four 150cm2 flasks (approximately lxlO8 cells) were grown to confluency.
Approximately 3-4 hours before electroporation the cells were fed with fresh ES cell
culture medium. In addition, twenty 100mm round tissue culture plates were
gelatinised, 10ml ES cell culture medium added to each plate and stored in the
incubator until use. For electroporation, ES cells were trypsinised as described
above, pooled and counted. Cells were pelleted and resuspended in an appropriate
volume of PBS to give lxlO8 cells in 600|il. This was equivalent to 5xl06 cells per
plate. At this stage 5pl and 20(ll of cells were seeded onto two of the plates to
represent non-electroporated controls. To the remainder of the cells, 100|il linearised
DNA construct was added and transferred to a sterile 0.4cm cuvette. Electroporation
was performed in a Bio-Rad Gene Pulser (Bio-Rad Laboratories Ltd) with the
capacitor set to 3|aF, 0.8kV. One pulse was applied resulting in a time constant of
0.1msec. Cells were immediately transferred to 10ml ES cell culture medium. Cells
were plated either neat (undiluted) or diluted (1:2, 4 and 8). In each case, 1ml of cells
was added to each plate. Twenty-four hours after electroporation, selection was
started by adding 160(J,g/ml G418 to the medium. Selection medium was replaced
every 2 days or more frequently depending on the number of dead cells.
2.5.6 Expansion of G418 ES cell colonies
After selection in G418 for 7-8 days, clones were picked and expanded for either
freezing (storage, refer to section 2.5.7) or DNA preparation (screening, refer to
section 2.5.8). Media was aspirated and ES cells rinsed in PBS. Individual colonies
were picked by scraping the colony with a P20 tip fitted to a P20 pipette. Colonies,
along with 20|J,1 PBS, were transferred to individual wells containing 150|ll selection
medium per well, in a round bottomed 96 well plate. Once 96 colonies had been
picked, cells were dispersed by pipetting up and down with a multi-channel pipette
(MCP) and then transferred to a gelatinised 96 well plate containing 150pl selection
medium/well (final volume of medium was 300|l11). 960 colonies were picked
resulting in a total of ten 96 well plates. Clones were grown to confluence and were
fed every 1-2 days before being processed for freezing (section 2.5.7) or DNA
preparation (section 2.5.8).
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2.5.7 Splitting and freezing of 96 well plates
Cells were split 1:2 onto replica 96 well plates, one of which was gelatinised.
Medium was aspirated from the wells and 150|il PBS added using a MCP. 30(il of
TVP was added to each well and the plate incubated for 3-5 minutes at 37°C after
which cells were dissociated by pipetting up and down. Following trypsinisation,
70|il of quench medium (50% (v/v) medium, 50% (v/v) FCS) was added to each well
to neutralise the trypsin. From this plate, 50jnl was seeded onto the fresh gelatinised
96 well plate and 150|il of selection medium added. This plate, termed the "DNA
plate", was returned to the incubator and grown to confluency for DNA preparation
(refer to section 2.5.8). The remainder of the trypsinised cells were used for "freezing
plates" by the addition of 50pl 2x freezing medium (25% (v/v) DMSO in ES cell
culture medium) to each well. Plates were immediately sealed with adhesive tape and
stored at -70°C.
2.5.8 ES cell DNA preparation
Once cells in the "DNA plate" had reached confluency they were processed for DNA
extraction. Medium was aspirated and cells lysed overnight at 37°C in 50|j.l of lysis
buffer (lOOmM Tris-HCl pH8.5, 200mM NaCl, 5mM EDTA, 0.2% (w/v) SDS,
lOOpg/ml Proteinase K). After transfer of the lysates to a fresh 96 well plate, 50jil of
room temperature isopropanol was added to precipitate DNA and incubated for 10
minutes on a plate shaker. DNA was pelleted by centrifugation at 2700rpm for 15
minutes in a 96 well plate bench top centrifuge and washed in 70% ethanol. Excess
ethanol was removed by incubation at room temperature for 5-10 minutes and DNA
redissolved in 50)0.1 TE by incubation on a heated (55°C) plate shaker for 2 hours. To
ensure all DNA was resuspended, the solution was pipetted up and down several
times. DNA was frozen at -20°C in the 96 well plate until screening was performed
(refer to section 2.5.9).
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2.5.9 Screening by Southern blotting
Southern blotting was performed from a modified version of the original method of
Southern (Southern, 1975).
2.5.9.1 Restriction enzyme digest and electrophoresis
Restriction enzyme digests were set up using approximately 10|ag ES cell DNA, lx
BSA, lx restriction buffer and 20 units of the appropriate restriction enzyme in a
final volume of 25(ll. Digests were performed in round bottomed 96 well plates and
incubated at 37°C overnight. A further 10 units of enzyme was added the following
morning and the plate incubated for 2-3 hours to ensure complete digestion.
Digested DNA, alongside lambda DNA///z«dIII ladder, was separated on 0.8%
agarose gels (refer to section 2.4.6) using Bio-Rad Sub-Cell Model 96 Cell
electrophoresis apparatus (Bio-Rad Laboratories Ltd). This apparatus is designed for
running 96 samples simultaneously enabling gels to be loaded using a MCP.
Ethidium bromide was not included in the gel since electrophoresis was carried out
overnight at 10V. Ethidium bromide migrates in the opposite direction of current and
would not produce an even staining pattern if included in the gel during prolonged
electrophoresis. Instead gels were stained in an ethidium bromide bath (0.5|lg/ml in
TAE) for 10 minutes with shaking after electrophoresis was complete. After
photographing, gels were denatured in denaturation buffer (refer to table 2-7) for 2x
10 minutes with shaking, rinsed in distilled water and neutralised in neutralisation
buffer (refer to table 2-7) for 30 minutes.
2.5.9.2 Transfer ofDNA by Southern blotting
A Pyrex dish containing transfer buffer (20x SSC, refer to table 2-7) with a glass
plate on top was set up with two sheets ofWhatman 3mm paper acting as a wick into
the SSC solution. The inverted gel was positioned on top and surrounded by
Parafilm. Hybond-N nylon membrane (Amersham Pharmacia Biotech UK Ltd), cut
to the size of the gel, was soaked in transfer buffer for 10 minutes and placed on top
of the gel ensuring there were no trapped air bubbles, followed by two pieces of
3mm paper soaked in transfer buffer (cut to gel size) and a stack of paper towels.
Finally a glass plate was placed on top and the whole apparatus weighted down with
a 500g weight and left overnight to allow capillary transfer to take place. After
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blotting the membrane was rinsed briefly in 2x SSC and baked between two sheets of
dry 3mm paper for 40 minutes at 120°C.
2.5.9.3 Hybridisation
Hybridisation and washing was performed as described in section 2.4.13.2 with the
following modifications. Hybridisation buffer was 5x SSC, 0.2mM Dextran sulphate,
0.5% SDS, 4x Denhardt's reagent and 200|ig/ml denatured sheared salmon sperm
DNA and hybridisation was performed at 68°C. The lambda DNA//7mdIII ladder
was also detected using labelled lambda DNA (supplied with Rediprime kit). 25ng of
lambda DNA was used for this purpose and labelled using lpl of [22P] dCTP and 9pl
of cold dCTP.
2.5.10 Screening by 96-well Expand PCR
ES cell colonies were also screened by PCR using Expand Long Template PCR
System (Roche Diagnostics Ltd). This system uses two thermostable DNA
polymerases, Taq and Pwo specifically designed to amplify genomic DNA (i.e. long
templates up to 20kb) (Cheng et ai, 1994). PCR was performed in a 96 well format
in a final reaction volume of 25|al. A "master mix" containing all components except
DNA, comprised lx PCR buffer 3 (exact composition unknown, final Mg2'
concentration was 2.25mM), 500|im dNTP mix, 0.3pM forward and reverse primers
and 1.3 units Expand enzyme mix. Primer sequences are documented in section
4.3.2.3. The master mix was aliquoted into thin-walled PCR tubes (Robbins Strip-
Ease-8 PCR tubes, Genetic Research Instrumentation), using an MCP and l|il of ES
cell DNA added and mixed thoroughly. PCR was performed on an MJ Research
PTC-200 DNA Engine (Genetic Research Instrumentation) with a 96 well block.
DNA was amplified as follows: initial denaturation at 92°C for 2 minutes,
amplification for 10 cycles of denaturation for 10 seconds at 92°C, annealing for 30
seconds at 60°C, extension for 3 minutes at 68°C followed by 25 cycles of
denaturation for 10 seconds at 92°C, annealing for 60 seconds at 30°C and extension
at 68°C for 3 minutes + 20 seconds/cycle. The program was completed with a final
elongation step of 7 minutes at 68°C. A heated lid was used to prevent evaporation.
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After PCR reactions were completed, 20|il of each reaction was analysed on an
agarose gel.
2.5.11 Expansion of positive clones
Once positive homologously targeted clones had been identified by Southern blotting
or by PCR screening, the replica "freezing" plate was defrosted and the appropriate
clone revived. 96-well plates were removed from the -70°C freezer and were
immediately thawed by floatation in a 37°C water bath for 30 seconds. Cells were
then transferred to a gelatinised 96-well plate containing 250)il medium/well and
incubated at 37°C for 8 hours or until the cells had adhered to the plate. The medium
was replaced with fresh ES cell culture medium to remove traces ofDMSO and dead
cells. Cells were then cultured at 37°C until confluent, replacing medium when
required. Once confluent, cells were seeded in 25cm2 flasks where they were
maintained for use in further analysis (e.g. Southern blotting, in vitro analysis) and
for blastocyst microinjection.
2.5.12 ES cell differentiation
To confirm expression of the knocked-in gene in homologously targeted clones, ES
cells were differentiated into endothelial cells using one of the following methods.
2.5.12.1 Differentiation ofES cells in hanging drops
ES cells were cultured in hanging drops as previously described (Bloch et al., 1997;
Gustafsson et al., 2000). ES cells were trypsinised and counted as described in
section 2.5.3. 6x105 cells were diluted in 20ml ES cell culture medium and
transferred to a sterile trough. Using a MCP set to dispense lOpl, cells were grown in
rows on ten 100mm2 bacteriological grade square plates each containing 8ml of
sterile water and incubated in an inverted position (i.e. drops hanging down) for 2
days at 37°C during which time ES cells develop into embryoid bodies (EB). To
harvest the EB, the plates were gently tapped and cells collected into a centrifuge
tube. Cells were centrifuged for 3 minutes on a low speed (800rpm) in a benchtop
centrifuge, resuspended in 20ml ES cell culture medium and transferred to a
bacteriological grade petri dish. At this point penicillin (lOOU/ml) and streptomycin
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(100|lg/ml) was added to prevent bacterial contamination. EB were incubated for a
further 4 days at 37°C with medium being replaced after 2 days. At this stage EB
were either disaggregated into single cells or kept as EB (4-5 EB per well). In both
cases cells were cultured on gelatin (0.1%) coated 6 well plates in the absence of LIF
to initiate differentiation.
For disaggregation, EB were collected into a centrifuge tube and allowed to settle by
gravity. After washing in PBS, cells were incubated with shaking for 1 hour at 37°C
in dispase solution (1.2U/ml dispase (Roche Diagnostics Ltd), 70(ig/ml DNase in
PBS). Cells were dissociated by passing through a blue needle several times. After
addition of 4ml ES cell culture medium cells were incubated for 5-10 minutes at
room temperature followed by centrifugation at lOOOrpm for 5 minutes. Finally, cells
were washed once in PBS by centrifugation and resuspended in 1ml medium before
transfer to a fresh plate containing 5ml medium (with penicillin/streptomycin). Cells
were incubated at 37°C and medium changed when required before being processed
for LacZ staining (refer to section 2.6.1).
2.5.12.2 Differentiation ofES cells on collagen IVplates
Differentiation of ES cells on collagen IV plates was performed as described by
Nishikawa et al (Nishikawa et al., 1998). ES cells were maintained as described in
section 2.5.2. Once confluent, cells were trypsinised and counted as described in
section 2.5.3. lxlO4 cells were plated per well on a 6 well plate coated with mouse
collagen IV (BD Biosciences UK Ltd) in 2ml of ES cell culture medium with or
without LIF (refer to chapter 4 for further details). Medium was replaced every 2
days. Cells were grown for 5-6 days after which they were processed for either
FACS analysis (refer to section 2.5.12.3) or LacZ staining (refer to section 2.6.1).
2.5.12.3 Flow cytometry ofdifferentiated ES cells
ES cells were trypsinised and counted as described in section 2.5.3 before being
washed twice in PBS (supplemented with 0.1% BSA, 0.1% sodium azide). Cells
were resuspended in PBS at a concentration of 2x106 cells/ml and aliquots of 2x105
cells were incubated with phycoerythrin (PE) conjugated antibodies (anti-mouse -
Flk-1, -Sca-1, -ICAM-1, all supplied by Caltag Medsystems Ltd) for 40 minutes at
4°C. Following removal of unbound antibody by washing twice in PBS, cells were
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resuspended in PBS and positively stained cells counted using FACSCaliber and
CellQuest software (BD Biosciences UK Ltd). Data for 10000-40000 cells were
acquired. Unstained cells were included as negative controls.
2.5.13 Microinjection of ES cells, generation of chimeric mice and germline
transmission
ES cells which were found to contain the targeted gene, were expanded as described
in section 2.5.11 and used in the microinjection of blastocysts and production of
transgenic mice. Microinjection of ES cells and all steps involved in production of
chimeric mice were performed by Dr. J. Ure (Institute for Stem Cell Research,
University of Edinburgh) according to the method described by Bradley et al
(Bradley et al., 1984).
Blastocysts were obtained from the fallopian tubes of C57BL/6J female mice on day
4 of pregnancy by flushing with PB1 medium supplemented with 10% (v/v) FCS
(140mM NaCl, 3mM KC1, 21.1mM Na2HP04, 1.5mM KH2P04, 5.8mM glucose,
0.4mM sodium pyruvate, 0.2mM penicillin, 0.1 mM CaCl2, 0.1mM MgCl2, 0.01%
(v/v) phenol red, pH 7.0-7.2) and were immediately transferred to ES cell culture
medium and incubated at 37°C to promote expansion of the blastocoel cavity. They
were then transferred to pre-prepared hanging drops of PB1 medium/10% FCS on
siliconised coverslips (Repelcote, BDH) suspended over a custom-made
manipulation chamber. Trypsinised ES cells were also placed in the hanging drops.
The chamber was filled with liquid paraffin and chilled at 4°C for 10 minutes.
Injection of blastocysts was performed using an IMT2 image-corrected microscope
(Olympus Optical Company (UK) Ltd). Blastocysts were held in place by suction to
a rounded holding pipette (20pm internal diameter) and ES cells injected using a flat-
ended injection pipette (15pm internal diameter). Between 15 and 20 ES cells were
injected into each blastocyst. Both the holding and injection pipettes were prepared
in-house by stretching glass capillary tubing (100pm internal diameter) on an
electrode puller (Camden Instruments). Before use, the pipettes were heat polished
with a microforge (Micro Instruments Ltd). Pipettes were attached to instrument
holders and controlled by Leica manipulators (Leica Microsystems (UK) Ltd).
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Vacuum pressure was controlled by injectors connected to pipettes via paraffin-filled
plastic tubes (Narashige International Ltd for holding pipette and Micro Instruments
Ltd for injection pipette).
Following injection, blastocysts were transferred to ES cells culture medium and
incubated at 37°C for 2-3 hours before implantation into pseudopregnant MF1
female mice. The recipient females had been mated with vasectomised DBA/2J
males 2.5 days prior to implantation. Between 5 and 10 blastocysts were transferred
to one uterine horn of each recipient. The resulting pups were assessed by coat
colour. Chimeric pups were identified by the presence of beige-coloured patches,
derived from ES cell derived 129 cells, amongst the host blastocyst derived black fur.
Germline transmission of targeted ES cell DNA was assessed by crossing chimeras
with BKW mice. Again, resulting pups were assessed by coat colour and germline
transmission was confirmed by PCR genotyping (see section 2.5.14).
2.5.14 Maintenance of transgenic colonies
All transgenic animals were housed in the Hugh Robson Building animal house,
University of Edinburgh and maintained under the Animals (Scientific Procedures)
Act 1986 (UK Home Office, project licence number PPL 60/2813). Animals had free
access to food (standard commercial animal chow) and water. Animals were
genotyped by PCR of tail tip DNA.
2.5.14.1 Extraction of tailDNA
For each animal, approximately 0.5cm of tail was removed under anaesthetic
(halothane). Tails were digested in 600pl tail buffer (50mM Tris-HCl pH 8.0,
lOOmM EDTA pH 8.0, lOOmM NaCl, 1% (w/v) SDS) supplemented with 35(J.l of
lOmg/ml proteinase K and incubated overnight at 55°C. The following day, 20(il of
20(ig/ml RNAse was added to each sample and incubated for a further 1 hour at
37°C. Samples were placed on ice for 10 minutes before being centrifuged at
12000rpm for 2 minutes. DNA was precipitated by adding an equal volume of
isopropanol to the resulting supernatants and rotating for 20 minutes at room
temperature. DNA was pelleted by centrifugation and the pellet washed in 70%
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ethanol. Pellets were allowed to air-dry briefly before being resuspended in 200pl of
TE buffer. To aid resuspension, samples were incubated at 37°C for 1 hour.
2.5.14.2 Genotyping of transgenic animals by PCR analysis
Tail DNA was analysed by PCR. PCR was performed in a final reaction volume of
25|il. A "master mix" containing all components except DNA comprised lx NH4
PCR buffer, 500pM dNTP mix, 0.3|iM forward and reverse primers, 2.25mM Mg2+
and 1 unit DNA polymerase (Bioline (UK) Ltd). Primer sequences are documented
in section 4.2.4 and 4.2.5. The master mix was aliquoted into thick-walled 0.5ml
microcentrifuge tubes, l|ll of mouse tail DNA added and mixed thoroughly. PCR
was performed on an MJ Research PTC-200 DNA Engine (Genetic Research
Instrumentation) and DNA amplified as follows: initial denaturation at 92°C for 2
minutes, amplification for 30 cycles of denaturation for 30 seconds at 92°C,
annealing for 30 seconds at 57°C, extension for 1 minute at 72°C followed by a final
extension period of 10 minutes at 72°C. A heated lid was used to prevent
evaporation. After PCR reactions were completed, 20|i,l of each reaction was
analysed on an agarose gel.
2.6 LACZ STAINING AND HISTOLOGY
LacZ gene expression can be visualised by the formation of a blue precipitate
resulting from hydrolysis of substrate 5-bromo-4-chloro-indolyl-B-D-galactoside (X-
gal) (Pearson et al., 1961; Horwitz et al., 1964). X-gal was therefore utilised to
analyse (3-gal activity in targeted ES cells and in tissues obtained from knock-in
animals (Fire, 1992). X-gal was supplied by Invitrogen Ltd.
2.6.1 Staining of differentiated ES cells
Cells were washed twice in PBS before fixation in fix buffer (0.2% (v/v)
gluteraldehyde, 5mM EDTA pH 7.4, 2mM MgCl2 in PBS pH 7.4) for 10 minutes at
room temperature. Fixative was removed and cells were washed thoroughly in wash
buffer (0.004% (v/v) NP-40, 0.002% (v/v) sodium deoxycholate, 2mM MgCl2 in
PBS pH 7.4) before being stained overnight at 37°C in X-gal staining solution. The
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staining solution was prepared in wash buffer with the addition of lmg/ml X-gal
(from stock solution of 25mg/ml X-gal in DMSO), 4mM potassium ferrocyanide and
4mM potassium ferricyanide. Following staining, cells were washed in wash buffer,
viewed under a Zeiss Axiovert 25 inverted microscope (Carl Zeiss Ltd) and
photographed using a Zeiss Axiocam with Axiovision 3.1 software (Carl Zeiss Ltd).
2.6.2 Staining of tissues
Tissues from knock-in animals were removed, rinsed in PBS and fixed at 4°C in 4%
(w/v) paraformaldehyde in PBS pH 7.4. Fixation times differed depending on the
type of tissue and the level of LacZ expression. Since P-gal activity is inactivated by
paraformaldehyde fixation, the optimal fixation time had to be determined at the
outset. For kidney samples, fixation was for 1 hour. For lung samples, fixation was
for 15 minutes. For further information refer to chapter 5. Tissues were then washed
thoroughly in PBS pH 7.4 and equilibrated in 30% (w/v) sucrose in PBS overnight at
4°C. The following day tissues were snap-frozen in liquid nitrogen and stored at -
70°C until use. For frozen sections, tissues were placed in the cryostat (Model OFT,
Bright Instruments Co Ltd) for at least 30 minutes prior to sectioning to allow the
tissue to reach the chamber temperature of -20°C. Samples were mounted in CRYO-
M-BED embedding compound (Bright Instruments Co Ltd) and 10-15pm sections
cut. Sections were collected onto TESPA coated slides and allowed to air-dry for 1
hour before being stored at -20°C until use. TESPA coated slides were prepared as
follows. Slides were cleaned by immersion in 10% HCl/70% ethanol followed by
rinsing in water and then acetone. Slides were allowed to air-dry before further
immersion in 2% (v/v) aminopropylethoxysilane (TESPA)/acetone for 10 seconds.
After two final rinses in 100% acetone, slides were again allowed to air-dry and were
ready to use.
For staining, sections were briefly rinsed in PBS pH 7.4 and transferred to X-gal
staining solution (lmg/ml X-gal (from stock solution of 25mg/ml X-gal in DMSO),
4mM potassium ferrocyanide and 4mM potassium ferricyanide, 2mM MgCl2, 0.02%
(v/v) NP-40 prepared in PBS pH 7.4). Tissues were stained overnight at 37°C.
Following a final rinse in PBS for 20 minutes, sections were counterstained with
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eosin to allow visualisation of individual cells. This involved immersion of slides in
eosin for 3 minutes followed by washing in tap water for 20-60 seconds. Sections
were then mounted and photographed using a Kontron Elektronik ProgRes 3012
camera attached to a Zeiss Axioskop microscope (Carl Zeiss Ltd). Images were
manipulated using Prog Res 3012 v3.05 software (Carl Zeiss Ltd). Renal localisation
was verified by an independent kidney histologist (Professor Stewart Fleming,
University of Dundee).
2.6.3 Quantification of P-gal activity
(3-gal activity was quantified in tissue extracts using an assay based on the
methylumbelliferone fluorescence method which measures the hydrolysis of 4-
methylumbelliferyl-P-D-galactoside catalysed by P-gal (Braell, 1991). This reaction
yields 4-methylumbelliferone (MU), a fluorescent product that emits fluorescence at
460nm when excited at 365nm. 4-methylumbelliferyl- p-D-galactoside was supplied
by Sigma-Aldrich Company Ltd.
Tissues from knock-in animals were removed and rinsed in PBS, pH 7.4. Kidney and
lung were routinely used. Whole kidneys (approximately 0.2g) and 0.2g (wet weight)
of lung were homogenised in 2ml of ice cold lx reporter lysis buffer (Promega UK
Ltd, exact composition unknown) supplemented with ImM PMSF. Tissue
homogenates were centrifuged at 12000g for 5 minutes at 4°C and supernatants
stored at -20°C until use. Protein concentration was determined by the Bradford's
assay (see section 2.3.3) and approximately 100)lg used for quantification of P-gal
activity.
Prior to measurement of P-gal activity in tissues, the fluorometer (TKO 100 mini-
fluorometer, Hoeffer Scientific Instruments) was calibrated according to the
manufacturer's instructions with a standard 50nM MU solution to give a reading of
400 fluorescence units. Linearity of fluorescence was checked with a set of MU
standards (0-200nM MU). A typical standard curve is shown in figure 2-9a. The
assay was also performed using known quantities ofE. Coli. P-gal enzyme (Promega
UK Ltd) to produce the standard curve shown in figure 2-9b.
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Figure 2-9. P-gal fluorescence assay, (a) Fluorescent standard curve of 0-200nM MU. (b) Linear
relationship between amount of fluorescence produced from increasing amounts of p-gal (0-4 mU).
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100(J.g of tissue homogenate was diluted to 40pl in lx reporter lysis buffer. This was
added to 160pl of reaction buffer (25mM Tris-HCl pH 7.5, 125mM NaCl, 2mM
MgCl2, 12mM 2-mercaptoethanol, 0.3mM 4-methylumbelliferyl- ^D-galactoside
(dissolved in dimethyl formamide)) and incubated at 37°C for 30 minutes. The
reaction was stopped by adding 50|il of 25% (w/v) trichloroacetic acid and cooled on
ice. The solution was clarified by centrifugation for 2 minutes following which 100p.l
of clear supernatant was added to 1.9ml glycine-carbonate reagent (133mM glycine,
83mM Na2C03 pH 10.7) and mixed. The mixture was transferred to a 3ml glass
cuvette and fluorescence determined using the Hoeffer mini-fluorometer. If
fluorescence levels in lOOjal were too high (i.e. greater than 1000 units), the samples
were diluted (xlO or xlOO depending on the level of (3-gal activity) and fluorescence
re-measured.
2.6.4 Salt loading of transgenic mice
Male knock-in mice (aged 10 weeks) were maintained on either a normal (0.3%) or
high (3%) sodium diet for 3 weeks. Food was supplied in powdered form from B. S.
and S. (Scotland) Ltd and was given to the mice by means of custom made feeding
pots. The amount of food and water consumed each day was recorded. At the end of
3 weeks animals were transferred to metabolic cages for urine collection. Urine was
collected over 12 hours, during which time animals had free access to water but not
to food. After 12 hours, mice were sacrificed and (3-gal activity determined in
kidneys and lungs as described in sections 2.6.2 and 2.6.3.
Comparisons between two groups were made using a Student's unpaired t test.
Values are given as mean ± S.E.M. and P values of less than 0.05 were considered
significant.
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2.7 LIST OF SUPPLIERS
AbCam Ltd Cambridge, UK
AD Instruments Sussex, UK
Amersham Pharmacia Biotech UK Ltd Little Chalfont, UK
Applied Biosystems Warrington, UK
Autogen Bioclear UK Ltd Calne, UK
BD Biosciences UK Ltd Oxford, UK
BDH (VWR International Ltd) Poole, UK
Beckman Coulter UK Ltd High Wycombe, UK
Bibby Sterilin Ltd Stone, UK
Biogenesis Ltd Poole, UK
Bioline (UK) Ltd London, UK
Bio-Rad Laboratories Ltd Hemel Hempstead, UK
Biosoft Cambridge, UK
Bright Instruments Co Ltd Huntingdon, UK
B. S. and S. (Scotland) Ltd Edinburgh, UK
Caltag-Medsystems Ltd Silverstone, UK
Cambrex Bioscience Ltd Wokingham, UK
Camden Instruments Loughborough, UK
Carl Zeiss Ltd Welwyn Garden City, UK
Danish Myo Technology A/S Copenhagen, Denmark
Dynal UK Ltd Bromborough, UK
Fisher Scientific UK Loughborough, UK
Genetic Research Instrumentation Essex, UK
Harlan UK Ltd Oxford, UK
Helena Biosciences Europe Sunderland, UK
Hoeffer Scientific Instruments San Francisco, California, USA
Invitrogen Ltd Paisley, UK
Leica Microsystems (UK) Ltd Milton Keynes, UK
Micro Instruments Ltd Witney, UK
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Chapter 3 - Alterations in caveolar structure during ED
3.1 INTRODUCTION
Given the importance of the kidney in the control of blood pressure and the
physiological role of NO as an important mediator of natriuresis/diuresis, it is
surprising that little is known of whether renal endothelial cells are affected by ED.
Perhaps even more surprising is the lack of data on eNOS regulation within the
kidney. It is hypothesised that ET-1 is one of the major physiological activators of
NO production within the kidney eliciting its effects via the activation of ETB and
eNOS (refer to section 1.2.2.8 and (Kotelevtsev & Webb, 2001)). Alterations in this
pathway that lead to decreased NO availability, for example through changes in
eNOS regulation, may result in sodium retention and elevation of blood pressure.
One of the potential reasons for altered eNOS regulation may be abnormalities in
interactions with regulatory proteins. eNOS is negatively regulated by caveolin-1
(refer to section 1.3.6.3). However, this relationship has not been investigated within
the kidney. Although western blot analysis demonstrated that the kidney expresses
very low amounts of caveolin compared to the lung (Lisanti et al., 1994), precise
immunohistochemical analysis revealed high expression within the descending vasa
recta corresponding to large numbers of caveolae as shown by immunogold labelling
and electron microscopy (Breton et al., 1998). Interestingly, this vascular bed is also
a major site of renal eNOS expression (Teichert et al., 2000). Therefore, this
circumstantial evidence suggests that caveolin may be a potential regulatory
mechanism controlling renal eNOS activity.
eNOS has also recently been reported to interact with GPCRs (see section 1.3.7). In
vitro binding studies revealed that eNOS directly binds ETB (Marrero et al., 1999).
This interaction most likely mimics the interaction of eNOS with other GPCRs (e.g.
the BK receptor) in which eNOS activity is inhibited. However, as yet no in vivo
studies have been published to support this observation and there are no direct data
localising ETB to caveolae by conventional biochemical methods.
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There is now emerging evidence suggesting that the pathogenic mechanisms
associated with ED may involve alterations in eNOS protein-protein interactions
within caveolae (refer to section 1.3.9.5). Incubation of bovine aortic endothelial
cells with hypercholesterolemic human serum was associated with upregulation of
caveolin-1 levels, increased numbers of inhibitory eNOS-caveolin complexes and
impairment of basal NO release (Feron et al., 1999). Increased eNOS-caveolin
complexes were also observed in aortas from pulmonary hypertensive rats compared
to their normotensive counterparts (Murata et al., 2002). The SHR also experiences
changes in caveolar architecture. Goto et al reported that in 10 week old SHR (i.e.
the onset of hypertension) there were significantly increased numbers of caveolae in
intracellular membranes of cardiac muscles compared with aged matched WKY
(Goto et al., 1990). Although caveolin protein levels were not measured in this study,
circumstantial evidence demonstrating a structural role for caveolin in caveolae
formation (Fra et al., 1995), predicts that caveolin levels may be elevated, potentially
resulting in increased eNOS-caveolin complex formation.
Based on these studies it is hypothesised that alterations in caveolar structure may
occur in ED associated with hypertension. In particular, it is proposed that increased
protein-protein interactions of eNOS with inhibitory proteins (e.g. caveolin and ETB)
will reduce eNOS activity and may be a potential mechanism behind diminished NO
availability in ED. Therefore, the aim of this chapter was to investigate whether ED
is associated with alterations in caveolar structure, particularly within the kidney.
Firstly, I wanted to investigate whether eNOS, caveolin-1 and ETB reside in the same
subcellular fraction (i.e. isolated caveolae) and then determine whether expression
within these fractions is altered during ED using western blot analysis. I also
endeavoured to demonstrate the physical interactions between eNOS and caveolin,
and eNOS and ETB, using co-immunoprecipitation with an ultimate goal to identify
alterations within these interactions in animals with ED. In order to address these
aims, an animal model of ED, the SHR, was used.
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Developed in Japan in 1963, the SHR remains the most commonly used animal
model of hypertension. By inbreeding WKY rats with elevated blood pressure,
Okamoto et al generated a strain of rat which is characterised by sustained high
blood pressure throughout adulthood (Okamoto & Aoki, 1963). Following a pre-
hypertensive phase at 6 to 8 weeks of age where systolic blood pressures (SBPs) are
around 100-120mmHg, the SHR develops spontaneous hypertension between 12 to
14 weeks of age, with SBPs reaching up to 200mmHg. From 14 to 30 weeks blood
pressure remains constant after which it continues to climb to around 220mmHg in
animals up to the age of 50 weeks (figure 3-1). In contrast, the WKY control animals
remain normotensive with blood pressures reaching around 130mmHg. Konishi and
Su were first to observe impaired endothelium-dependent relaxations to ACh in
aortic rings isolated from SHR compared to WKY (Konishi & Su, 1983), an
observation that has since been confirmed in other vascular beds (Luscher et al.,
1990). The SHR also develop other features of hypertensive end-organ damage (e.g.
hypertrophy, cardiac failure and renal failure) (Pinto & Ganten, 1998). For these
reasons, as well as the morphological observations regarding caveolae and SHR
described above, it was decided that the SHR would provide a good animal model to
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3.2 RESULTS
3.2.1 General parameters of SHR and WKY
General parameters ofWKY and SHR rats are shown in table 3-1. Ages and body
weights were similar between groups (n=6 in each group). See section 3.2.4 for
further information regarding animal numbers.
Table 3-1. Characteristics of WKY and SHR rats.
Rat strain Age (weeks) Body weight (g)
WKY 23.2 ±0.7 401.3 ± 17.4
SHR 23.5 ±0.6 375.2 ± 11.8
3.2.2 Confirmation of ED in SHR
Endothelial integrity was assessed by measuring responses of isolated vessels to ACh
(refer to section 2.2). In both mesenteric arteries and aorta, SHR animals responded
differently to ACh compared to WKY (figure 3-2). In mesenteric vessels, there was a
rapid relaxation followed by a marked contractile response at higher doses of ACh.
The early and complete relaxation of these arteries, though surprising, has been
reported elsewhere (Luscher et al., 1990). In contrast, vessels from WKY animals
relaxed to the baseline and remained there. In the aorta, relaxation was impaired by
around 20% of WKY at low doses of ACh. Again, vessels from SHR animals
contracted at higher concentrations ofACh compared to WKY. Figure 3-3 shows an
example of an original trace in which the biphasic response of relaxation followed by
constriction can be seen more clearly. As previously reported contractile responses to
PE or NA did not differ between groups (figure 3-4). These alterations in response to
ACh confirm that the SHR displayed characteristics of ED.
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(a) Mesenteric arteries
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Figure 3-2. ACh-induced relaxation of vessels isolated from SHR and WKY. Mesenteric
arteries (a) and aortas (b) were preconstricted with phenylephrine and noradrenaline respectively
followed by relaxation in response to increasing doses of ACh. Values are expressed as %
relaxation of maximal contraction to preconstrictor and are displayed as the mean ± S.E.M.
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ACh (10"9— 10"6M) washout
1 minute
NA NA
Figure 3-3. Myograph traces of vessel responses to ACh. Examples of original traces showing
responses to ACh following pre-constriction in (a) mesenteric and (b) aortic vessels isolated from
WKY and SHR. Note the biphasic response in SHR vessels. Abbreviations: PE, phenylephrine;
NA, noradrenaline.
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(a) Mesenteric arteries
log PE cone (M)
(b) Aorta
log NA cone (M)
Figure 3-4. Contractile responses of vessels isolated from SHR and WKY. Mesenteric arteries
(a) and aorta (b) were constricted with increasing doses of PE and NA respectively. Results are
expressed as a percentage of the maximal NAK response. Values are mean ± S.E.M.
Abbreviations: PE, phenylephrine; NA, noradrenaline; NAK, lOpM NA in KPSS.
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3.2.3 eNOS, caveolin and ETB expression in caveolin-rich domains
3.2.3.1 Isolation ofcaveolin-rich domainsfrom lung tissue
To investigate whether eNOS, caveolin-1 and ETB reside in the same subcellular
fraction, caveolin-rich domains were isolated from rat tissue using sucrose density
ultracentrifugation (refer to section 2.3.2.3). As the name suggests, these fractions
are rich in caveolin and represent isolated caveolae. This method of isolation, first
described by Lisanti et al (Lisanti et al., 1994), relies on two properties of caveolae;
(1) resistance to solubilisation by Triton X-100 and (2) buoyancy at a specific density
in sucrose gradients. Due to the abundance of endothelial cells and caveolae, the lung
was initially used in order to optimise this method of subcellular fractionation.
A single light scattering band (fraction 8) corresponded to the low-density Triton-
insoluble complex (figure 3-5a). Analysis of protein content revealed that these
fractions excluded most of the cellular protein which remained within the pellet (P)
(figure 3-5b). Western blot analysis using antibodies against caveolin-1 clearly
demonstrated that fractions 7-9 were enriched with caveolin-1 (figure 3-5c).
Furthermore, when compared to equal amounts of whole lung homogenate, caveolin
levels were around 1.5 times higher in caveolin-rich domains as determined by
densitometry (figure 3-5d), a considerable increase taking into account the low
protein concentration of the caveolin-rich domain samples.
Caveolin-rich domains were also analysed for the presence of eNOS and ETB. As
with caveolin, high levels of eNOS were observed in fraction 8 and in the insoluble
pellet compared to the other fractions (figure 3-6a). Again, when compared to equal
amounts of whole lung homogenate, eNOS was approximately 3 fold higher in
caveolin-rich domains (figure 3-6b). Analysis of ETB expression proved to be more
problematic largely resulting from the inaccessibility of good commercial ETB
antibodies. Three different ETB antibodies were used (refer to table 2-5). However,
on no occasion was satisfactory staining achieved. All three antibodies resulted in
consistently high non-specificity and therefore made it impossible to analyse ETB by
this method.
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Figure 3-5. Isolation of lung caveolin-rich domains, (a) Isolation of caveolin-rich domains by
sucrose gradient centrifugation produces a light scattering band (fraction 8). (b) Coomassie protein
stain of fractions 4-11 and pellet (P). An equal volume of each fraction was loaded, (c) Western
blot of caveolin expression in fractions 4-11 and pellet. An equal volume of each fraction was
loaded, (d) Comparison of caveolin expression in whole lung homogenates (WH) and sucrose
gradient fractions (SG). An equal amount was loaded for each sample.
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(a)
fraction no.
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eNOS
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(b) WH SG WH SG
eNOS
(140kDa)
Figure 3-6. eNOS expression in lung caveolin-rich domains, (a) Western blot of eNOS
expression in fractions 4-11 and pellet. An equal volume of each fraction was loaded, (b)
Comparison of eNOS expression in whole lung homogenates (WH) and sucrose gradient fractions
(SG). An equal amount of protein was used in each sample.
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Therefore, although it was not possible to detect ETB expression in these samples,
they do represent subcellular fractions highly enriched in both caveolin-1 and eNOS.
3.2.3.2 Isolation ofcaveolin-rich domainsfrom kidney tissue
Preparation of similar caveolin-rich domains was then attempted using the kidney.
Firstly, to illustrate the low level of caveolin expression in the kidney, renal
homogenates were compared to lung, a source of abundant endothelial cells. Figure
3-7 shows significantly higher caveolin-1 expression in the lung compared to the
kidney. Densitometric analysis revealed that caveolin-1 was expressed almost 10 fold
more in the lung.
Therefore, since the kidney expresses such low amounts of caveolin-1, 1 did not
expect to be able to reproduce similar data to those observed from caveolin-rich
domains of the lung. However a similar pattern for caveolin-1 expression was
obtained, albeit at a much lower signal (figure 3-8). As with the lung, a light
scattering band was visible and this sample corresponded to increased caveolin-1
expression (fraction 8). However, when the same fractions were analysed for eNOS
expression, no eNOS protein was detected probably resulting from the limitations of
the detection system.
3.2.4 Caveolin-1 and eNOS expression are not altered in caveolin-rich
domains isolated from SHR
In order to investigate whether changes in caveolin and eNOS expression are
associated with ED, caveolin-rich domains were isolated from lungs and kidneys of
WKY and SHR animals and analysed for caveolin-1 and eNOS protein expression.
Within the lung, there were no significant differences in caveolin-1 (figure 3-9) and
eNOS (figure 3-10) expression between groups. Likewise, caveolin protein levels
were similar in caveolin-rich domains isolated from kidneys of SHR and WKY
(figure 3-11). Equal loading was confirmed by coomassie protein stains.
105




























Figure 3-7. Expression of lung and renal caveolin-1. (a) Representative western blot of renal
caveolin-1 (K) versus lung caveolin-1 (L) expression in WKY rat. 40pg of protein from each
sample was loaded, (b) Coomassie stain of identical gel to demonstrate equal loading, (c)
Densitometric analysis ofwestern blot.
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fraction no.
45678 9 10 11 12 P
caveolin-1
(22kDa) -
Figure 3-8. Isolation of renal caveolin-rich domains. Western blot of caveolin-1 expression in
caveolin-rich domains (fractions 4-12 and pellet (P)) isolated from kidney. An equal volume of
each fraction was loaded.
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(a)
WKY SHR
Figure 3-9. Caveolin-l expression in lung caveolin-rieh domains from SHR and WKY. (a)
Representative western blot of caveolin-l expression in caveolin-rich domains isolated from lung,
lpg of protein was loaded for each sample, (b) Coomassie staining of an identical gel
demonstrates equal loading (c) Densitometric analysis ofwestern blot. n=6 in each group.
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Figure 3-10. eNOS expression in lung caveolin-rich domains from SHR and WKY. (a)
Representative western blot of eNOS expression in caveolin-rich domains isolated from lung.
lOpg of protein was loaded for each sample, (b) Coomassie staining of an identical gel
demonstrates equal loading (c) Densitometric analysis ofwestern blot. n=6 in each group.
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Figure 3-11. Caveolin-1 expression in kidney caveolin-rich domains from SHR and WKY. (a)
Representative western blot of caveolin-1 expression in caveolin-rich domains isolated from
kidney. 1 Opg of protein was loaded for each sample, (b) Coomassie staining of an identical gel
demonstrates equal loading (c) Densitometric analysis of western blot. n=6 in each group. This
experiment was performed on one set of animals only (see section 3.2.4 for details).
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It should be noted at this point that in all SHR/WKY comparative experiments, six
animals were analysed in each group. However, in all cases, except where indicated,
experiments were repeated on a secondary set of animals, again with six in each
group. Due to the nature of western blotting, it was not possible to directly compare
protein expression between these groups since only samples that have been loaded on
the same gel can be compared directly. Therefore, these sets of animals were
analysed separately. Since there were no obvious differences between experimental
sets, only one group of data has been shown.
3.2.5 Renal eNOS expression is increased in SHR
Due to the inability of being able to measure eNOS expression in caveolin-rich
domains isolated from kidney, whole kidney homogenates were analysed for eNOS
expression instead. Kidneys from SHR exhibited a modest increase in eNOS levels
(figure 3-12). Although significance was not reached, eNOS expression was almost 2
times higher in SHR kidneys compared to WKY. In contrast, caveolin expression
was not altered in SHR kidneys (n=6, one group only). Due to high background, this
blot has not been shown. Finally, to confirm that eNOS expression is upregulated
during ED, heart tissue was used as a positive control. Elevated eNOS expression in
the heart has been previously reported in SHR (Nava et al., 1998). As with the
kidney, eNOS expression was increased in SHR hearts compared to WKY (figure 3-
13). However, although caveolin-1 was highly expressed in the heart, expression
levels were comparable between WKY and SHR (figure 3-14).
These results suggest that ED in the SHR is not associated with alterations in
caveolin-1 or eNOS expression within caveolin-rich domains. On the other hand,
eNOS expression in the kidney and heart is upregulated in SHR and may therefore be
associated with ED.
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Figure 3-12. Renal eNOS expression in SHR and WKY. (a) Representative western blot of
renal eNOS expression from WKY and SHR kidney whole homogenates. lOOpg of protein was
loaded for each sample, (b) Coomassie stain of identical gel confirms equal loading, (c)
Densitometric analysis ofwestern blots. n=6 in each group.
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Figure 3-13. eNOS expression in hearts from SHR and WKY. (a) Representative western blot
of eNOS expression in whole heart homogenates from WKY and SHR. lOOpg of protein from
each sample was loaded, (b) Coomassie stain of identical gel confirms equal loading, (c)
Densitometric analysis ofwestern blots. n=6 in each group.* P<0.05 versus WKY.
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Figure 3-14. Caveolin-1 expression in hearts from SHR and WKY. (a) Representative western
blot of caveolin-1 expression in whole heart homogenates from WKY and SHR. lpg of protein
from each sample was loaded, (b) Coomassie stain of identical gel confirms equal loading, (c)
Densitometric analysis ofwestern blots. n=6 in each group.
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3.2.6 Analysis of eNOS-caveolin protein interactions
Although no differences in caveolin expression levels in caveolin-rich domains or
whole tissue were observed between SHR and WKY, this did not eliminate the
possibility of changes in caveolin-1 - eNOS protein interactions. Therefore, co-
immunopreciptation was performed to investigate whether alterations in caveolin-1-
eNOS protein interactions are associated with ED.
Much of the present data on eNOS-caveolin interactions has arisen from two
independent groups. However, their methods for co-immunoprecipitation are similar.
(Feron et al., 1996; Garcia-Cardena et al., 1996a; Michel et al., 1997a; Michel et al.,
1997b; Feron et al., 1998a; Feron et al., 1998b). From careful analysis of the
literature it became clear that co-immunoprecipitation critically depends on the
method of lysis, in particular the type of detergent used. Strong ionic detergents such
as SDS will destroy protein-protein interactions. Therefore mild, non-ionic
detergents (e.g. NP-40, Triton X-100 or octylglucoside) are required which should
still be strong enough to solubilise the proteins of interest. For this reason I began
this series of analytical experiments by testing different types of buffers in order to
establish which would provide optimal co-immunoprecipitation conditions.
Another important point to note is that, to my knowledge, co-immunoprecipitation of
eNOS-caveolin complexes has not been reported in tissue until very recently (Murata
et al., 2002). Most reports have performed co-immunoprecipitation on cultured cells
(e.g. cardiac myocytes, bovine aortic endothelial cells (BAEC), bovine lung
microvascular endothelial cells (BLMEC) or transfected COS-7 cells). Therefore, it
was decided to optimise the co-immunoprecipitation protocol using cultured
endothelial cells and then extend this to tissue and caveolin-rich domains samples.
3.2.6.1 eNOS and caveolin interact in isolated endothelial cells
HUVECS were used to optimise co-immunoprecipitation of eNOS-caveolin
complexes using two different types of detergent, Nonidet P-40 (NP-40) and
octylglucoside (OG). Cells were lysed in either NP-40 buffer or OG buffer followed
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by immunoprecipitation with either caveolin-1 or eNOS antibodies (refer to sections
2.3.2 & 2.3.4). Resulting immune complexes were immunoblotted with
complementary antibodies to assess for eNOS-caveolin interactions. For example,
antibodies directed against eNOS were used for caveolin immunoprecipitates whilst
antibodies directed against caveolin were used for eNOS immunoprecipitates. Figure
3-15 shows the results of immunoprecipitating HUVECS lysates (solubilised in NP-
40 or OG) with caveolin antibodies followed by immunoblotting for eNOS. The
success of immunoprecipitation was assessed by firstly probing the
immunoprecipitates with antibodies towards caveolin (figure 3-15a). Enrichment of
the caveolin signal appeared only in those samples which were incubated with anti-
caveolin antibodies (C). On the other hand, omission of immune antibody resulted in
no caveolin signal (-). A similar result was achieved regardless of the type of lysis
buffer used. Immunoblotting of the same immunoprecipitates was then performed
using eNOS antibodies to determine if caveolin and eNOS interact in these cellular
preparations. The immunoblot shown in figure 3-15b reveals that
immunoprecipitation of caveolin (C) did indeed result in co-precipitation of eNOS.
However, the signal was extremely weak particularly for OG lysates. Again,
immunoprecipitation without immune antibody (-) did not result in detection of
eNOS. It should be noted that these experiments were repeated five different times.
On two occasions no interaction between eNOS and caveolin were observed which
suggests that this technique is highly variable between preparations.
A complementary experiment was then performed in which lysates were
immunoprecipitated with eNOS antibodies followed by immunoblotting with
caveolin. Again, immunoprecipitation was firstly evaluated by immunoblotting with
eNOS antibodies (figure 3-16a). As with caveolin, a strong signal for eNOS appeared
only in those samples which were precipitated with anti-eNOS antibodies (E) and not
in those in which immune antibody had been omitted (-). However, this time there
was a significant difference in the intensity of the signal depending on the lysis
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Figure 3-15. Immunoprecipitation of HUVEC lysates with caveolin-1 antibodies. HUVEC
NP-40 or OG lysates were immunoprecipitated with either caveolin-1 antibodies (C) or without
immune antibody (-) and then immunoblotted with (a) caveolin-1 or (b) eNOS antibodies. The
blots shown are representative of three independent experiments.
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Figure 3-16. Immunoprecipitation of HUVEC lysates with eNOS antibodies. HUVEC NP-40
or OG lysates were immunoprecipitated with either eNOS antibodies (E) or without immune
antibody (-) and then immunoblotted with (a) eNOS or (b) caveolin antibodies. A positive control
(+) for caveolin is included in (b). The blots shown are representative of two independent
experiments.
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buffer used. NP-40 buffer resulted in increased precipitation of eNOS compared to
OG buffer. The eNOS-precipitated NP-40 lysates were then immunoblotted for
caveolin (figure 3-16b) and confirmed that caveolin co-precipitated with eNOS
although again the signal was extremely low. This is obvious by comparing the
signal to the positive control shown in figure 3-16b which was taken from a non-
precipitated sample.
Therefore, although eNOS-caveolin interactions were observed in HUVEC lysates,
the quantity of protein participating in these interactions appeared to be very low.
This series of experiments also demonstrated that of the two buffers tested, lysis with
NP-40 produced the more encouraging result. Therefore, this lysis buffer was used in
further experiments.
3.2.6.2 eNOS-caveolin interactions cannot be detected in lung tissue
In order to determine if eNOS-caveolin interactions also exist in vivo, the co-
immunoprecipitation technique described for HUVECS was applied to lung
homogenates. Lung was chosen due to the abundance of eNOS and caveolin in this
tissue. Whole lung homogenates were prepared in NP-40 lysis buffer and
immunoprecipitated with anti-eNOS antibodies. Resulting immunocomplexes were
immunoblotted for eNOS and caveolin as shown in figure 3-17. eNOS was again
enriched following eNOS immunoprecipitation and analysis of the supernatants
following immunoprecipitation revealed that the majority of eNOS had been
captured in these samples (figure 3-17a). However, on no occasion did eNOS
immunoprecipitation result in the co-precipitation of caveolin (figure 3-17b). Instead,
all caveolin appeared in the corresponding supernatant (S/E). These results imply
that in these lung samples eNOS and caveolin did not physically interact.
3.2.6.3 eNOS-caveolin interactions cannot be detected in caveolin-rich domains
Proteins interactions were also investigated in caveolin-rich domains. However,
despite the abundance of caveolin and eNOS in these caveolar preparations, it was
not possible to detect any interaction between the proteins.
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Figure 3-17. Immunoprecipitation of lung NP-40 lysates with eNOS antibodies. Lung lysates
were immunoprecipitated with either eNOS antibodies (E) or without immune antibody (-).
Immunocomplexes (IP) and their corresponding supernatants remaining after pelleting (S) were
immunoblotted with (a) eNOS or (b) caveolin antibodies. A positive control (+) for caveolin is
included in (b). The blots shown are representative of three independent experiments.
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3.2.7 Quantification of eNOS-caveolin interaction in isolated endothelial cells
The previous set of experiments demonstrated that although eNOS and caveolin
interacted in endothelial cells, the amount of interacting protein was very small.
Furthermore, given that no interactions were observed in either lung or caveolin-rich
domains, it was decided to investigate what proportion of cellular eNOS is in fact
bound to caveolin in HUVECS. Therefore, to quantify the eNOS-caveolin interaction
a similar series of experiments to those described above were performed. However,
as well as analysing the proteins which were immunoprecipitated by either eNOS or
caveolin, the supernatants remaining after immunopreciptation were also analysed.
This gives an indication of the proportion of protein that has not been
immunoprecipitated. eNOS immunoprecipitates were immunoblotted for eNOS and
caveolin (figure 3-18). As before, eNOS immunoprecipitation resulted in enrichment
of eNOS only in the sample which had been incubated with anti-eNOS antibody (E)
and not in those in which antibody had been omitted (-) (figure 3-18a). Conversely in
the corresponding supernatants, the opposite pattern was observed. Here, the
majority of eNOS was found in the supernatant of the immunoprecipitates which had
non-immune antibody. A fainter signal was observed in the supernatant of eNOS
immunoprecipitates indicating that most eNOS had been successfully
immunoprecipitated. On the other hand, when these samples were immunoblotted for
caveolin (figure 3-18b), signals for the supernatants of both eNOS
immunoprecipitates (E) and non-immune immunoprecipitates (-) were equally strong
whereas the amount of caveolin immunoprecipitated by eNOS antibodies was
extremely low in comparison. Therefore, it can be concluded that the amount of
caveolin interacting with eNOS in these cellular preparations is very low compared
to the total cellular caveolin pool and that the majority of caveolin does not interact
with eNOS.
A similar conclusion can be drawn from analysing the amount of eNOS remaining
following caveolin immunoprecipitation of HUVEC lysates (figure 3-19). Although
caveolin immunoprecipitation resulted in co-precipitation of eNOS, a significant
amount of eNOS remained in the corresponding supernatant.
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Figure 3-18. Immunoprecipitation of HUVEC NP-40 lysates with eNOS antibodies. HUVEC
lysates were immunoprecipitated with either eNOS antibodies (E) or without immune antibody (-).
Immunocomplexes (IP) and their corresponding supernatants remaining after pelleting (S) were
immunoblotted with (a) eNOS or (b) caveolin antibodies. A positive control (+) for caveolin is
included in (b). The blots shown are representative of two independent experiments.
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Figure 3-19. Immunoprecipitation of HUVEC NP-40 lysates with caveolin antibodies.
HUVEC lysates were immunoprecipitated with either caveolin antibodies (C) or without immune
antibody (-). Immunocomplexes (IP) and their corresponding supernatants remaining after
pelleting (S) were immunoblotted with eNOS antibodies. The blots shown are representative of
two independent experiments.
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This set of experiments shows that in these cellular preparations only a small
proportion of cellular eNOS and caveolin interact.
3.2.8 eNOS and caveolin do not colocalise in HUVECS by immunofluoresence
The results of the co-immunoprecipitation experiments were surprising given that
previous data from Feron et al demonstrated that the majority of eNOS was found in
association with caveolin (Feron et al., 1996). In order to investigate these
discrepancies further, I used fluorescent antibodies towards caveolin and eNOS to
visualise intracellular localisation of these proteins in HUVECS (refer to section
2.3.9). This powerful method allows colocalisation of proteins to be detected
directly. As shown in figure 3-20, caveolin (green) was found concentrated to the
edges of the plasma membrane (figure 3-20a) whereas eNOS (red) was clearly
confined to the cytoplasm of the cell, in particular the perinuclear and Golgi regions
(figure 3-20b). Double staining of HUVECS revealed that eNOS and caveolin did
not colocalise in these cells (figure 3-20c).
124
Chapter 3 - Alterations in caveolar structure during ED
Figure 3-20. Intracellular localisation of caveolin and eNOS in HUVECS (continued overleaf).
HUVECS were stained with fluorescent antibodies towards (a) caveolin (green) and (b) eNOS
(red). In (a) nuclei are stained in blue. Scale bar = 10pm.
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Figure 3-20. Intracellular localisation of caveolin and eNOS in HUVECS (continued), (c)
Double staining of HUVECS with antibodies towards caveolin (green) and eNOS (red). Scale bar
= 10p.m.
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3.3 DISCUSSION
In most animal models of hypertension, endothelium-dependent relaxations to ACh
are impaired (Pinto & Ganten, 1998). One of these models, the SHR, has been
extensively studied and collectively reports have resulted in numerous hypotheses for
why the SHR develops ED. These range from the concomitant release of prostanoid
constricting factors which antagonize the relaxing properties of NO (Luscher et al.,
1990) to overproduction of 02~which inactivates NO (Bauersachs et al., 1998).
Interestingly, many groups have documented an increase in eNOS expression in SHR
compared to normotensive WKY counterparts (see below). This may at first appear
contradictory given that NO availability is reduced during ED. However, eNOS-
mediated NO production is a tightly regulated process and relies on several
additional post-translational regulatory mechanisms, any of which may be altered
during ED (refer to section 1.3). Thus, augmented eNOS expression does not
necessarily signify increased NO production.
Recent studies have documented that protein-protein interactions between eNOS and
regulatory protein, caveolin, may be altered in conditions such as
hypercholesterolemia (Feron et al., 1999) and hypertension (Murata et al., 2002).
Both groups reported increased numbers of eNOS-caveolin inhibitory complexes,
implying that in these conditions, eNOS activity is reduced. Changes in caveolar
morphology have also been observed during ED associated with hypertension (Goto
et al., 1990). Together, these studies prompted the hypothesis that alterations in
caveolar structure, caveolar protein expression and, in particular, abnormalities in
eNOS-caveolin interactions may be associated with ED. This chapter has described
experiments which sought to address these questions, with particular emphasis on the
kidney.
Isolation of caveolin-rich domains provided a useful tool for the analysis of eNOS
and caveolin expression in SHR and WKY. These domains were highly enriched in
caveolin and eNOS and are thought to represent isolated caveolae (Lisanti et al.,
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1994). There are now several reports documenting isolation of caveolae ranging from
immunopurification to flotation on OptiPrep gradients (Anderson, 1998). Initially,
attempts were made to replicate a recently published method involving organ
perfusion of silica beads (data not shown) (Chaney & Jacobson, 1983; Schnitzer et
al., 1995). Positively charged silica beads are used to coat the endothelial layers of
blood vessels but are of a sufficient enough size that they do not penetrate caveolae.
Due to the density of the silica, the beads, with attached membranes, can be
separated from the rest of the tissue by centrifugation, followed by shearing away of
non-caveolar membranes resulting in a pure caveolar population. My attempts to
replicate this procedure did not yield useful results largely due to the difficulties in
reproducing consistent data. Instead, a different method of caveolar isolation was
employed. Sucrose density centrifugation has been widely used in the caveolar field.
First described by Sargiacomo et al on cultured cell preparations (Sargiacomo et al.,
1993), it has since been applied to tissues (Lisanti et al., 1994). This method exploits
the resistance of solubilisation of caveolae to detergents, mainly attributed to their
cholesterol and glycosphingolipid rich core. It also makes use of their light buoyant
density and ability to float on sucrose gradients. I found this method of subcellular
fractionation to be highly reproducible, consistently producing fractions enriched in
caveolin. However, it should be noted that some reports question the property of
detergent insolubility in ascribing proteins to a caveolar location (Kurzchalia et al.,
1995). On the other hand, some reports maintain that physical aids used during
caveolar purification can, in fact, alter the molecular composition of caveolae. In
particular, detergents, such as Triton-XlOO, may solubilise resident proteins (e.g.
eNOS) thereby yielding extracted preparations of caveolae (Smart et al., 1995; Shaul
et al., 1996). I did not find this to be the case and consistently observed that the
caveolin-rich fractions were also enriched in eNOS, at least those obtained from the
lung. Although caveolin-rich domains isolated from kidneys were also enriched in
caveolin, eNOS was not detectable in these fractions, possibly due to limitations of
the detection system.
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After confirming that SHR animals displayed characteristics of ED by assessing
endothelial responses to ACh, caveolin and eNOS expression in caveolin-rich
domains from these animals were compared with WKY. Analysis of protein
expression within these domains demonstrated that there were no differences in
eNOS or caveolin levels between groups implying that alterations in eNOS and
caveolin expression within caveolin-rich domains do not account for ED in the SHR.
Although caveolin expression within SHR has not been previously addressed, several
reports document changes in eNOS expression in SHR. Vaziri et al and Nava et al
demonstrated increased eNOS expression in SHR kidney, heart and aorta, paralleled
by increased eNOS activity (Nava et al., 1996; Nava et al., 1998; Vaziri et al., 1998;
Vaziri et al., 2000). However, these observations have not always been confirmed
elsewhere. Chou et al reported downregulation of eNOS expression and activity in
aortas of SHR (Chou et al., 1998), a finding which was also documented by
Bauersachs et al (Bauersachs et al., 1998). These discrepancies may result from
differences in the ages at which the animals were studied. Nevertheless, the results
presented here agree with the former observations. In this study, analysis of eNOS
expression in whole homogenates of kidney and heart clearly demonstrated that
protein levels were increased in SHR compared to WKY and provides evidence
supporting the view that ED in the SHR is not associated with eNOS translational
abnormalities. Despite increased eNOS production, it is clear that NO bioavailability
is diminished in these animals, manifested as impaired endothelium-dependent
vasodilatation (Konishi & Su, 1983; Luscher & Vanhoutte, 1986; Luscher et al.,
1990) and lower flow induced dilatation (Qiu et al., 1998). Although not directly
measured in this study, eNOS activity may be reduced and may provide an
explanation for reduced NO availability.
As described above, one of the potential mechanisms for altered eNOS activity in
SHR could be alterations in the relationship between eNOS and it's inhibitor,
caveolin. Therefore, the second aim of this chapter was to investigate whether eNOS-
caveolin interactions are altered during ED. Co-immunopreciptation using antibodies
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against eNOS and caveolin resulted in detection of eNOS-caveolin interactions in
HUVECS. However, these data were not reproduced in lung tissue or in caveolin-
rich domains. The reasons for this have not been fully elucidated. The explanation
may be simply that the proteins do not interact in vivo. However, a recent study
demonstrated eNOS-caveolin interactions within rat aorta by co-immunoprecipitation
(Murata et al., 2002). In addition, data from caveolin knockout mice do not support
this argument (Drab et al., 2001; Razani et al., 2001). Another explanation is that
eNOS and caveolin do interact but harsh solubilisation conditions have destroyed
these interactions. As alluded to earlier the choice of detergent is critical in the
detection of interacting proteins. NP-40 was chosen for the encouraging results
observed in HUVECS and as NP-40 is a relatively mild detergent it is unlikely that
protein-protein interactions would be destroyed. On the other hand TX-100, which
was used during sucrose density centrifugation, may have had a detrimental effect on
eNOS-caveolin co-precipitation. Although, in this study, eNOS expression was
detected in caveolin-rich domains, some reports argue that TX-100 based methods of
caveolar purification do not always allow co-isolation of eNOS (see above and
(Shaul et al., 1996)). Furthermore, Feron et al reported that two different detergents
(OG and CHAPS) used for examining eNOS-caveolin interactions resulted in
different outcomes depending on their abilities to solubilise the eNOS-caveolin
complex (Feron et al., 1998a).
Interestingly, the method of lysis may also play an important role in preserving
eNOS-caveolin interactions. All of the papers documenting the presence of eNOS-
caveolin complexes in cultured endothelial cells have used sonication to lyse cells.
Sonication is a vigorous method of lysis using ultrasonic waves to disrupt cells by
agitation. Although the data have not been shown here, a preliminary experiment
using sonication instead of mechanical homogenisation to lyse HUVEC cells,
resulted in a dramatic increase in the amount of eNOS co-precipitated by anti-
caveolin antibodies. This may provide a reason for the discrepancies concerning the
extent to which eNOS and caveolin interact. Sonication is most commonly used for
small scale cell suspensions and is obviously not a practical method for the
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preparation of tissue protein extracts and was therefore not attempted. Nevertheless,
the report by Murata et al who showed interactions between eNOS and caveolin in
aorta used a similar method of homogenisation to myself (Murata et al., 2002).
From their experimental procedures it would appear that all other components of co-
immunoprecipitation were the same apart from their choice of lysis buffer.
Therefore, in the future, it will be interesting to investigate if this protocol can be
used to identify eNOS-caveolin interactions within the lung and kidney.
A further explanation for why eNOS-caveolin interactions were not observed in the
lung, concerns the limitations of the detection method. As described above, in
homogenised HUVECS eNOS co-precipitated a very small proportion of the total
caveolin protein pool. The same was observed for caveolin co-precipitation of eNOS
and in some preparations no interactions were observed at all. If this is a true
reflection of the intracellular situation, it can be concluded that the relative quantities
of interacting proteins were extremely low. Therefore, if this situation is mirrored in
vivo, then it is possible that the number of eNOS-caveolin complexes in tissue were
too few to be detected by this method.
However, it was surprising that the interactions between eNOS and caveolin
observed here were extremely low considering that Feron et al had previously
published that the majority of eNOS is found in association with caveolin (Feron et
al., 1996). The data presented here clearly showed that a significant proportion of
eNOS remained within the supernatant after immunoprecipitation. Therefore, there
appears to be some discrepancy concerning exactly what proportion of cellular eNOS
is bound to caveolin. As described above these differences may be the result of
differing lysis conditions (i.e. sonication versus homgenisation). Other factors may
be involved, for example, the type of endothelial cells used (e.g. HUVECS versus
BAEC). It is possible that different cells will exhibit different eNOS-caveolin
interactions. Culturing conditions may also affect results. Not only has the degree of
confluency been shown to alter eNOS-caveolin colocalisation (Sowa et al., 1999),
prolonged culture caused loss of caveolae in endothelial cells (Schnitzer et al., 1994).
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Furthermore, the same report documented that BLMECs retained 5-10 times more
caveolae than BAECs. To my knowledge there are no similar data for HUVECS.
One of the major inconsistencies concerning the subject of eNOS-caveolin
interactions is the lack of histochemical data supporting the biochemical evidence for
the existence of this interaction. Immunofluoresence microscopy revealed that the
majority of eNOS did not co-localise with caveolin intracellularly (Garcia-Cardena et
al., 1996b). In the present study immunofluoresence failed to show intracellular
colocalisation of the proteins. Instead, eNOS was found within the perinuclear
region of the cell, a finding which is in agreement with earlier studies on eNOS
intracellular localisation (O'Brien et al., 1995; Sessa et al., 1995) and caveolin at the
cell periphery. It is clear that further studies are required to investigate these
discrepancies.
The lack of histochemical data showing eNOS-caveolin colocalisation throws doubt
upon the physiological presence and importance of eNOS-caveolin interactions.
Until recently it would have been easy to simply dismiss the biochemical
observations as an artifact of the methods used in subcellular fractionation and co-
immunoprecipitation. However, the recent insight into the potential physiological
relevance of eNOS-caveolin interactions was discovered through the use of caveolin
knockout mice (refer to section 1.3.6.4). Therefore, the importance of eNOS-caveolin
interactions in vivo remains an attractive area of eNOS regulation.
One of the important areas to address now is how the multitude of in vitro studies on
eNOS regulation, particularly those describing caveolin-eNOS interactions, translate
to the in vivo situation and how eNOS is differentially regulated within different
tissues, especially within the kidney. In this study, I have shown that caveolin is
expressed within the kidney. However, I have not been able to prove if renal eNOS
and caveolin directly interact. Furthermore, renal caveolin expression was not altered
during ED, at least not within caveolin-rich domains or whole homogenates. On the
other hand, renal eNOS expression was modestly increased in SHR. As mentioned
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earlier, other groups have also reported elevated eNOS protein levels within SHR
kidneys (Vaziri et al., 1998; Vaziri et al., 2000) complemented by increased renal
eNOS activity (Nava et al., 1996) compared to the WKY. Furthermore, Nava et al
reported significantly higher eNOS activity in the renal medulla of the SHR and to a
lesser extent in the cortex compared to the same tissue portions of the WKY (Nava et
al., 1996). Since medullary eNOS is thought to play a critical role in
natriuresis/diuresis and lowering blood pressure, this may be a compensatory
response to prolonged hypertension in SHR. However, this remains to be confirmed.
Other animal models of ED also exhibit alterations in renal eNOS expression.
Studies on DOCA-salt hypertensive rats revealed augmented expression of eNOS in
both the renal cortex and medulla (Allcock et al., 1999). In contrast, both Dahl salt
sensitive and two-kidney, one-clip hypertensive rats displayed reduced renal eNOS
expression compared to their normotensive counterparts (Ni et al., 1999; Wickman et
al., 2001). Therefore, it is clear that eNOS expression is affected differentially
depending on the type of hypertension. Further studies are required before any firm
conclusions concerning eNOS expression and hypertension can be made.
As described in section 1.2.2.8, ET-1 and ETB are potential major physiological
activators of eNOS and natriuresis/diuresis within the kidney. One of the aims of this
chapter was to determine if ETB, like caveolin, directly interacts with eNOS, if it is
localised to caveolae and if these characteristics are altered during ED (see section
1.3.7). Unfortunately, I was unable to detect the presence of ETB in isolated caveole,
whole tissue or in HUVECS due to the lack of good commercial antibodies. Since
the synthesis of "in-house" antibodies was beyond the scope of this thesis, I have
been unable to address the role of ETB mediated regulation of eNOS activity by these
methods. However, the remainder of this thesis describes further experiments
focusing on the role of ETB in mediating eNOS activation and NO production within
the kidney using different molecular methods.
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3.4 SUMMARY
In summary, this chapter has investigated whether alterations in caveolar structure
are associated with ED in hypertension. The main findings were:
• Alterations in eNOS and caveolin expression within caveolin-rich domains
do not account for ED in SHR.
• ED in SHR is not associated with translational abnormalities of eNOS, on the
contrary eNOS expression levels are augmented in the kidney and the heart.
• Caveolin and eNOS protein interactions were detected within HUVEC
lysates by co-immunoprecipitation.
• Immunofluorescence did not support intracellular co-localisation of eNOS
and caveolin in HUVECS. eNOS was found to reside in the Golgi apparatus,
whereas caveolin was localised to the plasma membrane.
• Caveolin and eNOS did not interact in lung preparations, raising questions
concerning the extent to which these proteins interact in vivo.
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4.1 INTRODUCTION
Due to the difficulties in analysing eNOS protein-protein interactions as described in
the previous chapter, a different approach to investigating renal eNOS regulation was
adopted. Instead of pursuing the nature of eNOS protein-protein interactions within
the kidney and how these may be altered during ED, the remainder of the thesis
focuses on the upstream mechanisms involved in eNOS activation. Much of the
evidence to date implies that the renal endothelin system, in particular ET-1 and ETB,
is a major physiological activator of eNOS (see section 1.2.2.7). It is hypothesised
that the inability of ET-1 to stimulate ETB-mediated NO production may lead to ED
within the kidney ultimately resulting in reduced natriuresis and elevation of blood
pressure. In order to address this hypothesis first requires knowledge of the cellular
and molecular mechanisms involved in ET-1 induced natriuresis through ETB and
eNOS activation. As described in section 1.2.2.8, the major site of expression of ET-
1, ETb and eNOS within the kidney is the medulla. However, confusing localisation
and expression data makes it difficult to ascertain precisely which cells are involved.
This has led to the conflicting proposals of both an autocrine and paracrine
mechanism as discussed in section 1.2.2.8. It is particularly important to establish
precise localisation of these components in order to unravel the mechanisms
involved. Therefore, the aim of the next two chapters was to determine which cells
within the renal medulla are responsible for sensing ET-1; in other words, which
cells express ETB.
Of course the use of conventional techniques such as autoradiography and
immunohistochemistry have already led to numerous studies on ETB localisation in
the kidney. However, close analysis of the literature reveals that the results are
somewhat conflicting. This may be due to the occurrence of false positives resulting
from the difficulties in distinguishing localisation between adjacent cells particularly
since IMCD cells and endothelial cells of the vasa recta are separated only by a basal
membrane. Therefore, techniques such as immunohistochemistry and radioligand
binding may have resulted in problems in identifying localisation to individual cell
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types (Hagiwara et al., 1993; Dean et al., 1994; Yukimura et al., 1996; Zhuo et al.,
1998). Also, techniques that rely on micro-dissection of nephrons, such as RT-PCR,
may have been hampered by cross-contamination (Terada et al., 1992a). These
localisation studies will be discussed in more detail in chapter 5 (see section 5.3).
Therefore, in order to address the difficulties of localising ETB to the kidney a
molecular approach was adopted. This approach was based on a "knock-in" strategy
using an EDNRB-LacZ reporter transgene. The bacterial Escherichia coli LacZ gene
encodes for (3-galactosidase ((3-gal), an enzyme which produces a blue colour on
staining with X-gal (5-bromo-4-chloro-3-indolyl-[3-D-galactosidase). This allows
LacZ expression and activity to be assayed colorimetrically (see section 2.6).
Introduction of this reporter gene into the EDNRB locus resulted in transgenic mice
that express LacZ wherever EDNRB are expressed and therefore provided a means of
obtaining an accurate in vivo ETB gene expression profile by colorimetric staining of
p-gal.
This chapter documents the generation of the EDNRB-LacZ transgenic mice. It
describes in detail the construction of the targeting cassette, targeting of the EDNRB
locus by homologous recombination in ES cells, verification of targeted ES cells by
analysing LacZ expression in vitro and the generation of chimeric mice and germline
transmission. Chapter 5 describes analysis of these mice and determination of ETB
expression within the kidney.
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4.2 RESULTS
4.2.1 Construction of EDNRB-LacZ transgene
4.2.1.1 The targeting construct
The targeting construct shown in figure 4-1 was based on the fusion of the LacZ
reporter cassette to exon three of the EDNRB gene. The EDNRB mouse gene, found
on chromosome 14, spans 26 kb and consists of 7 exons and 6 introns Previously, a
genomic clone containing around 16kb of the EDNRB mouse sequence had been
obtained by screening a Xphage library (performed by Dr. A. Bagnall, University of
Edinburgh). This clone encompassed the last 12 kb of intron 1 to the first 54 bp of
exon 5 of the EDNRB sequence (see figure 2-3) and was used in the construction of
the EDNRB-LacZ transgene. Exon 3 was chosen as the site of insertion of the LacZ
cassette because it contains the unique restriction site, Sphl. In addition, previous
reports have documented that regulatory transcriptional elements in intron one of
EDNRB are important for efficient transcription of the gene (Shin et cil., 1997).
Therefore, it was important that these should remain intact. The genomic sequences
of EDNRB located either side of exon 3 provided the 5' and 3' homology arms
required for insertion of the transgene into the EDNRB locus in ES cells by
homologous recombination.
A combination of other DNA elements were also present in the reporter cassette.
Firstly, translation of LacZ was under the control of a picornaviral internal ribosome
entry site (IRES). This sequence acts as a ribosome binding site and allows internal
initiation of translation of the reporter gene regardless of the ETB reading frame
(Mountford et al., 1994). Stop codons, present in all three reading frames preceding
IRES, stop read-through of the ETB protein.
1 The genomic sequence of the mouse EDNRB gene can be found in full using Ensemble gene I.D.
ENSMUSG00000022122 at http://www.ensembl.org/Mus_musculus
The cDNA sequence of the mouse EDNRB gene is documented at
http://www.ncbi.nlm.nih.gov/Entrez/ using accession number U32329.
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Figure 4-1. EDNRB-LacZ targeting construct. Abbreviations: pBS, pBluescript II SK; IRES,
internal ribosome entry site; NLS, nuclear localisation signal; SV40pA, simian virus 40
polyadenylation signal; MClneopA, promoter driven neomycin phosphotransferase resistance
gene. See text for further details. Diagram is not drawn to scale.
139
Chapter 4 - Generation of EDNRB-L&C.Z mice
A nuclear localisation signal (NLS) was also included. This 29 base pair sequence
encodes a 10 amino acid consensus sequence as shown.
NLS 5'- GGG CCC AAG AAG AAA CGC AAA GTG GGG AG - 3'
GPKKKRKVGS
The five consecutive positively charged residues (KKKRK) are thought to aid
transport into the nucleus thereby confining LacZ expression to the nucleus
(Kalderon et al., 1984). This sequence is identical to that used by Teichert et al in the
eNOS promoter-reporter construct in which they observed precise LacZ expression
within the nucleus (Teichert et al., 2000). It is therefore anticipated that the NLS
would improve localisation of LacZ staining thereby reducing the incidence of false
positives.
The simian virus 40 polyadenylation signal (SV40pA), was also required to add a
poly(A) tail to the 3' end of the LacZ transcript. This is necessary to protect against
3' degradation of the transcript.
Finally, a modified version of the neomycin phosphotransferase resistance gene,
pMCl Neo, was present in the targeting construct. The neomycin resistance gene has
been used for some time in the selection of targeted ES cells during gene targeting
events. However, Thomas and Capecchi recognised that the targeting of genes which
are either poorly expressed or not expressed at all in ES cells, resulted in low
transfection efficiencies (Thomas & Capecchi, 1987). By introducing a promoter to
drive expression of the neomycin resistance gene, they improved targeting
efficiency. pMCl Neo, named after the founder, Mario Capecchi, contains the herpes
simplex virus thymidine kinase (hsv-tk) promoter which drives the expression of
neomycin. Also included are two repeats of the F9 polyoma enhancer which
increases the efficiency of the hsv-tk promoter. Since the level of ETB expression in
ES cells is not known, the use of the MCI promoter ensures high expression of the
neomycin resistance gene regardless of the level of ETB expression. An equivalent
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promoterless construct would rely on high expression of ETB to drive neomycin
expression.
4.2.1.2 The cloning strategy - an overview
A detailed description of the cloning strategy is given below. Briefly, the plasmids
pictured in figures 2-3 - 2-8 were used in the construction of the EDNRB-ha.cZ
transgene. As described in section 4.2.1.1, pAJPXho is a genomic clone spanning
from intron 1 to part of exon 5 of the mouse EDNRB gene and provided the
homology arms for the targeting construct. pKL53 and pl049 both encode for LacZ.
In pKL53, LacZ is preceded by an NLS but it contains a promoterless neomycin
resistance gene. On the other hand, pi049 has the promoter driven neomycin gene
(pMCl Neo) but lacks NLS. Therefore, these plasmids were combined by inserting
the NLS signal from pKL53 into pi049 to generate pl049NLS. BamHI-digested
pl049NLS was then subcloned into exon 3 of a modified version of pZPXho. In
order to perform this step the BamHI site present in NLS of pKL53 was mutated to a
Bglll site.
All DNA digests, purification of DNA fragments and ligations were performed
according to the protocols given in sections 2.4.8, 2.4.10 and 2.4.12 respectively.
Recombinants obtained from ligation reactions were screened by restriction enzyme
digest ofmini-prep DNA (see section 2.4.13.1) unless otherwise stated.
4.2.1.3 Site-directed mutagenesis ofBamHI in pKL53
In order to manipulate pKL53 more easily, the region to be mutated was first
subcloned into pBS (see figure 2-6) to produce pKS. This was achieved by digesting
pKL53 with Kpnl and Sacl. The resulting 2.1kb fragment was purified and ligated to
KpnI/SacI sites in the polylinker of pBS. Resulting colonies were screened by
analysis of DNA mini-preps digested with Sacl/Clal (see figure 4-2). All colonies
contained the insert indicated by the presence of two bands of 4 and 1.1 kb on the
agarose gel in figure 4-2. One of these colonies was used for further cloning and was
named pKS.
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Figure 4-2. Subeloning of pKL53 into pBS. Diagram illustrating how pKL53 and pBS were used
to create pKS. See text for details (section 4.2.1.3). Also pictured is a DNA gel of Sacl/Clal digested
DNA prepared from pKL53/pBS recombinant colonies. Positive clones are indicated (+).
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Mutation of BamHI was achieved by PCR site-directed mutagenesis using primers
designed from the pKL53 sequence. The sequences and positions of the primers are
shown in figure 4-3. One of the primers, NLSBgl, incorporated the base changes (G-
A252i and C-T2526) which were necessary to mutate BamHI (GGATCC) to Bglll
(AGATCT). Although these sites have compatible sticky ends, which were required
for subsequent cloning, ligation to each other destroys both sites. The reverse primer
(KLCla) was identical to the wild type pKL53 sequence. As shown in figure 4-4 the
mutations introduced into pKL53 did not dramatically alter the translated amino acid
sequence. A change in amino acid from proline (P) to leucine (L) was generated.
However, it was not expected to have any adverse structural effects on the protein.
As described in section 2.4.9.1, PCR was performed on pKS to produce an 833bp
product (see figure 4-3). PCR was performed using a Pfu proofreading enzyme to
ensure that the frequency of introducing random mutations was kept to a minimum.
Following PCR, the PCR products were treated to the Klenow, Kinase and Ligase
reaction (see section 2.4.9.2) which resulted in the formation of concatamers (see
figure 4-5). Concatamers were then prepared for ligation by digestion with
Bglll/Clal. Meanwhile, the vector was prepared by digesting pKS with BamHI/Clal
and the resulting 4.2kb DNA fragment purified. Ligation of PCR products and the
purified fragment was performed and resulting colonies were screened by restriction
enzyme digest of mini-prep DNA using BamHI/Clal as analytical restriction
enzymes. Since BamHI was destroyed during PCR, those clones which contained
the PCR product produced a single 5kb band upon BamHI/Clal digestion. On the
other hand, colonies containing the wild type plasmid generated two bands (4.2kb
and 0.8kb) as the BamHI site was still present (see figure 4-5). One of the positive
clones, named pKSw/oBamHI, was selected and used for further cloning.
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NLSBgl (2516-2542bp of pKL53)
5' - ATG GCA GAT CTC GTC GTT TTA CAA CG - 3'
KLCIa (3325-3349bp of pKL53)








Figure 4-3. PCR site-directed mutagenesis of pKS. Mutagenesis of BamHI was performed by
PCR using primers NLSBgl and KLCIa. Base changes are shown in red. See text for details (section
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Figure 4-5. Subcloning of mutated PCR products into pKS. Diagram illustrating restriction
enzyme digests of PCR concatamers and pKS and subsequent ligation to produce pKSw/oBamHI.
See text for details (section 4.2.1.3). Also pictured is a DNA gel of BamHI/Clal digested DNA
prepared from PCR/pKS recombinant clones. Positive clones are indicated (+).
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4.2.1.4 Introduction ofNLS intopl049
The next stage was to subclone the DNA fragment from pKSw/oBamHI containing
the NLS signal into pi049. This was done using KpnI/SacI to digest both plasmids
followed by ligation. However, before pi049 could be digested the additional Kpnl
and SacI sites present in the polylinker of pBS had to be removed. Therefore, the
5.2kb cassette from pi049 was excised by BamHI digestion, purified and cloned into
BamHI in the polylinker of pSP72poly3 (see figure 4-6). This vector contained no
Kpnl or SacI sites (see figure 2-7). Colonies were screened by restriction enzyme
digestion analysis with BamHI. Those colonies which contained the insert were
identifiable by the presence of the 5.2kb band upon BamHI digestion, whereas
negative colonies contained only the vector (2.4kb). The resulting positive plasmid
was named pl049SP72. pKSw/oBamHI and pl049SP72 were then digested with
KpnI/SacI. The resulting 2.1kb fragment obtained from pKSw/oBamHI was used to
replace the corresponding fragment in pl049SP72 (see figure 4-7). Colonies were
screened by PCR to identify those clones which contained the NLS sequence.
Primers were designed from the pKL53 sequence (see figure 4-7). One of the
primers, pKL53NLS, corresponded to the NLS sequence of pKL53. A PCR product
of 866bp was generated only in clones containing the NLS sequence as shown in
figure 4-7. The resulting positive clone was named pl049NLS.
4.2.1.5 Sequencing ofpl049NLS
Before proceeding with the final stages of insertion of pl049NLS into exon 3 of
EDNRB, pl049NLS was extensively sequenced. The reason for this was that there
was a possibility that additional mutations may have been introduced during PCR
despite Pfu polymerase having an error rate of LlOOOObp. Therefore, the entire
region that was subject to PCR was sequenced using overlapping primers and
carefully checked for discrepancies against the pKL53 sequence. Two additional
base changes were found (A-G2812 and T-C3073). It is possible that this was simply a
mistake in the sequencing of either pl049NLS or the original pKL53 sequence.
Nevertheless, both mutations occurred in the third position of the codon and
therefore did not alter the translated sequence.
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Figure 4-6. Subcloning of pl049 into pSP72poly3. Diagram illustrating how pi049 and
pSP72poly3 were used to create pl049SP72. See text for details (section 4.2.1.4). Also pictured is a
DNA gel of BamHI digested DNA prepared from pl049/pSP72poly3 recombinant clones. Positive
clones are indicated (+).
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pKL53NLS (2483-2506 of pKL53) 5' - ATG GGG CCC AAG AAG AAA CGC AAA - 3'
KLCIa (3325-3349bp of pKL53) 5' - ACG CTC ATC GAT AAT TTC ACC GCC - 3'
Figure 4-7. Subcloning of NLS from pKSw/oBamHI into pl049SP72. Diagram illustrating how
pKSw/oBamHI and pl049SP72 were used to create pl049NLS. See text for details (section
4.2.1.4). Also pictured is a DNA gel of the PCR reaction used to screen pKSw/oBamHI/pl049SP72
recombinant clones. Positive clones are indicated (+).
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4.2.1.6 Shortening of the 5' homology arm ofpXPXho
The penultimate step before inserting the cassette from pl049NLS into exon 3 of the
EDNRB locus was to modify p^PXho. p^PXho contains a very large section of
EDNRB intron 1 exceeding lOkb in size. Since this contributes to part of the 5'
homology arm it would have proven extremely difficult to develop an efficient 5'
screening strategy for homologous recombination. Therefore, it was decided to
modify pA,PXho to produce a plasmid (p^PXhoS) with a shorter homology arm of
approximately 6.7kb. This was achieved by digesting pA,PXho with Sack The
resulting 9kb DNA fragment was purified and subcloned into Sacl-digested pBS (see
figure 4-8). Resulting colonies were screened by restriction enzyme digestion
analysis of DNA mini-preps using Sail. One colony was found to contain the insert
as indicated by the appearance of a larger band shown on the gel in figure 4-8 and
was named pXPXhoS. All other colonies contained only the pBS vector.
4.2.1.7 Insertion ofcassette from pl049NLS into exon 3 ofpXPXho
To complete the construct, the modified cassette from pl049NLS was inserted into
p?iPXhoS. The 5.2kb fragment generated from BamHI-digested pl049NLS was
purified and the ends blunt-ended using T4 DNA polymerase as described in section
2.4.11. p^PXhoS was digested with SphI and also blunt-ended with T4 DNA
polymerase followed by ligation to the 5.2kb insert to produce pEDNRB~NLS+ (see
figure 4-9). Since blunt-ended ligations have a lower success rate compared to
sticky-end ligations, it was deemed necessary to screen a greater number of colonies
than usual. An efficient method of doing this is by colony lift and hybridisation using
a radioactive probe complementary to the insert DNA (see section 2.4.13.2). This
allows several hundred colonies to be screened at once. Only those colonies
containing the insert will be identified by the probe. Therefore, colony lifts and
hybridisation were performed. The probe was isolated as an EcoRI fragment from
pi049 as shown in figure 4-10 and used to screen the recombinant colonies. Several
colonies were found to contain the insert, the presence of which was confirmed by
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Figure 4-8. Shortening of 5' homology arm of pA,PXho. Diagram illustrating how pXPXho and
pBS were used to create p^PXhoS. See text for details (section 4.2.1.6). Also pictured is a DNA gel
of Sail digested DNA prepared from pA,PXho/pBS recombinant colonies. Positive clones are
indicated (+).
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Figure 4-9. Generation of pEDNRBNLS+ (continued overleaf). Diagram illustrating digestion of
pl049NLS and p/.PXhoS to generate the DNA fragments which were used to make pEDNRB~NLS+.
See text for details (section 4.2.1.7).
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Notl Sacl 1
Figure 4-9. Generation of pEDNRBNLS+ (continued).
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Figure 4-10. Preparation of probe for colony lifts. A lkb fragment was isolated from EcoRI -
digested pl049 for use as the probe in pl049NLS/ pAPXhoS recombinant colony lifts. See text for
details (section 4.2.1.7).
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Figure 4-11. Restriction enzyme digests of pEDNRBNLS+. The presence of the insert was
confirmed by Sacl digestion. Correct orientation was determined by Clal digestion. See text for
details (section 4.2.1.7). Positive clones are indicated (+).
155
Chapter 4 - Generation ofEDNRB-LacZ mice
analysis with SacI which generated fragments of 9.6kb, 4.6kb and 2.9kb (see figure
4-11). Orientation of the insert was analysed by Clal digestion. Colonies containing
the insert in the correct orientation generated fragments of 8.7 and 8.4kb upon Clal
digestion (see figure 4-11). On the other hand, incorrect orientation yielded
fragments of 10.7 and 6.4kb.
4.2.1.8 Sequencing across the junction of the cassette and exon 3 ofEDNRB
As a final verification that pEDNRBNLS+ had been correctly constructed, the
junction between the cassette and the 3' end ofEDNRB exon 3 was sequenced using
a primer designed from the Stratagene pMClneopA sequence 1441-1466bp
(p££>M?5NLSNeoF 5'- GCG AAT GGG CTG ACC GCT TCC TCG - 3'). The
resulting sequence was then compared to the pMClneopA and the EDNRB cDNA
sequences. Alignment of these sequences is shown in figure 4-12 where a dot
represents homology between the sequences. It should be noted that homology
between pMClneopA and pEDNRBNLS+ stopped at the BamHI site indicating the
end of the cassette and entry into exon 3 of EDNRB (figure 4-12a). Likewise,
alignment of EDNRB cDNA and ipEDNRB~NLS+ sequences resulted in homology
only after the SphI site in exon 3 ofEDNRB cDNA (figure 4-12b). Homology ceased
at the start of exon 4 in the cDNA and intron 3 in $EDNRB'NLS+. This provided
further evidence that the reporter cassette had been cloned into exon 3 of EDNRB in
the correct orientation.
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(a) Alignment of pMCIneopA (top) with p£DNR6RNLS+ (bottom)
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Figure 4-12. Sequence analysis of pEDNRBNES+. pEDNRB~NLS>+ was aligned with (a)
pMCIneopA and (b) EDNRB cDNA. See text for details (section 4.2.1.8).
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4.2.2 Targeting of the EDNRB locus with pEDNRBNL,S+
4.2.2.1 Introduction ofpEDNRBTVLSM- into ES cells
The construct was introduced into the EDNRB locus by homologous recombination
in ES cells. pEDNRBNLS+ was linearised with NotI and was electroporated into ES
cells as described in section 2.5.5. Twenty-four hours after electroporation, selection
was started by adding G418 to the medium. Only those cells which had taken up the
construct expressed neomycin and were able to survive in the presence of G418. All
other cells died. After selection in G418 for 7-8 days, clones were picked and
expanded in 96 well plates for either freezing or for DNA preparation (see section
2.5.6). Altogether 960 colonies were picked. The next stage was to distinguish
between clones in which the targeting construct had been inserted randomly and
those in which homologous recombination had occurred. Colonies were screened by
either Southern blot analysis (section 4.2.2.2) or PCR (section 4.2.2.3).
4.2.2.2 Southern blot analysis ofG418-resistant clones
In order to determine if homologous recombination had taken place in any of the
colonies, all colonies were screened by Southern blot analysis (see section 2.5.9).
Rare-cutting restriction enzymes, SacI and SphI, were used to digest genomic DNA
isolated from the ES cells followed by detection of homologously targeted loci with
radioactive probes complementary to the EDNRB locus. SacI and SphI sites were
chosen based on information obtained from the EDNRB genomic sequence (see
footnote on pagel38). The probes were positioned outwith the ends of the 5' and 3'
homology arms of the construct and therefore only identified clones which were
homologously targeted to the EDNRB locus and not clones in which the construct
had been randomly integrated. A diagram of the Southern screening strategy is
depicted in figure 4-13 and predicted fragment sizes from targeted and wild type
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Table 4-1. Predicted sizes for wild type and targeted bands in Southern blot analysis.
Digest and probe used Wild type (EDNRB) Targeted (LacZ)
SacI and 3' probe 13kb 8.8kb
SphI and 5' probe 14.8kb 19.8kb
SacI and IRES probe 9.4kb
The 5' and 3' probes were prepared from plasmids pA,Pxho (see figure 2-3) and
pCRII-6.18 (see figure 2-8) respectively as shown in figure 4-14. The 5' probe was
prepared by PCR of p)iPXho using primers designed from the EDNRB genomic
sequence. This generated a 1,2kb fragment. The 3' probe was prepared from BamHI-
digested pCRII-6.18 and subsequent purification of the resulting lkb fragment.
DNA digestion, separation of DNA on agarose gels and Southern blots were all
performed in a 96 well format in order to speed up the screening process. Initially 3'
Southern analysis was performed by SacI digestion followed by probing with the 3'
probe. As expected, the wild type band of 13kb was present in all colonies (figure 4-
15). However, out of 960 colonies screened only two appeared to be targeted to the
EDNRB locus indicated by the presence of a shorter band (see figure 4-15c, clones
10D8 and 2G11). Curiously, the bands from these clones were of different sizes.
Since the targeted band should have been approximately 8.8kb, it would appear that
clone 10D8 was probably correct. 5' Southern analysis was then performed on these
two clones. DNA was digested with SphI followed by Southern blotting using the 5'
probe which resulted in a wild type band of 14.8kb (see figure 4-16). However, only
one of the clones, 2G11 was targeted correctly at the 5' end shown by the presence of
a larger band corresponding to the predicted size of 19.8kb. Therefore, only clone
2G11 appeared to be targeted to the EDNRB locus at both the 5' and 3' ends.
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5' For 5' - GAT TCC TGA TTT GAT CTA ATC TGT - 3'
5' Rev 5' - GCT GGC TCA TAT ATT ACT CCT CGC - 3'
Figure 4-14. Preparation of 5' and 3' probes for Southern blotting. pA-PXho and pCRII-6.18
were used to make the 5' and 3' probes respectively, (a) PCR of p^.PXho using the primers shown
generated a 1.2kb fragment, (b) Digestion of pCRII-6.18 with BamHI yielded a lkb fragment. 25ng
of each probe was used for each Southern blot. Refer to text for details (section 4.2.2.2).
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5' homology arm (6.7kb) 3' homology arm (2.2kb)
► < ►
Sacl
2 3 NEO 3 4 5
Figure 4-15. 3' Southern analysis of G418-resistant ES cell colonies. In order to identify
homologously targeted clones, genomic DNA isolated from ES cells was digested with restriction
enzyme, Sacl and probed with the 3' probe, (a) 3' Southern screening strategy, (b) DNA gel of
digested genomic DNA, (c) Southern blot of Sacl-digested DNA using 3' probe. WT, wild type. See
text for further details (section 4.2.2.2).
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(a) 5' homology arm (6.7kb) 3' homology arm (2.2kb)
•4 ► ►
Sphl
Figure 4-16. 5' Southern analysis of G418-resistant ES cell colonies. Genomic DNA isolated from
ES cells was digested with restriction enzyme, Sphl and probed with the 5' probe, (a) 5' Southern
screening strategy, (b) Southern blot of Sphl-digested DNA using 5' probe. WT, wild type. See text
for further details (section 4.2.2.2).
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In order to further characterise clone 2G11, an additional Southern blot was
performed using a probe complementary to the cassette. The IRES probe was
prepared from pl049 digested with Kpnl and BamHI (see figure 4-17a). The
resulting 0.5kb band was purified and used as the probe for Sacl-digested 2G11
DNA. As predicted this resulted in a band of 9.4kb (see figure 4-13 and 4-17b). This
also confirmed that only one copy of the transgene had been integrated into the
EDNRB locus.
4.2.2.3 Analysis ofG418-resistant clones by PCR screening
In order to speed up the screening process, a PCR-based screening strategy was used
in parallel with Southern analysis. The Expand Long Template PCR System is
specifically designed to amplify long templates and was used in conjunction with a
96-well PCR block to screen G418-resistant colonies (see section 2.5.10). Screening
was only attempted at the 3' end of homology since the 5' end was too long to
develop a reliable PCR protocol. A diagram of this strategy showing primer positions
and expected sizes of bands is shown in figure 4-18. Primer sequences are also
documented there. Three separate sets of primers were used (see table 4.2). Two sets
of primers, NeoF/417R and 78F/5to4R, acted as internal controls to confirm that the
PCR was optimal. The third set of primers, NeoF/5to4R, only produced a band of
2.5kb in homologously recombined clones since the 5to4R primer lay outwith the
end of the 3' homology arm.
Table 4-2. Primer pairs and predicted sizes for wild type and targeted bands in PCR analysis.
Primers Predicted size Comment
NeoF / 417R 1.5kb
positive control for
presence of transgene
78F / 5 to 4R 2.5kb
positive control for wild
type allele
NeoF / 5 to 4R 2.5kb
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(a)
Figure 4-17. Southern blotting of clone 2G11 using IRES probe, (a) A probe was prepared from
pi049 digested with KpnI/BamHI. The 0.5kb fragment was purified and used in Southern blotting,
(b) Southern blot of Sacl-digested 2G11 DNA using IRES probe. Refer to figure 4-13 for predicted
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Several colonies were screened by this method and two, 10D8 and 1H3, were found
to produce the correct band with NeoF/5 to 4R primers (see figure 4-19). Clone 10D8
had already been identified by 3' Southern analysis (see section 4.2.2.2). However
clone 2G11, which was also identified as being positive by 3' Southern analysis, was
not amplified by PCR suggesting that the 3' arm of this clone was not completely
correct. This may account for the shorter band produced during 3' Southern analysis
(see section 4.2.2.2).
A summary of the results of screening for homologous recombination by Southern
blotting and PCR analysis is shown in table 4-3. Unfortunately clone 1H3 did not
survive defrosting. Of the two remaining targeted clones 2G11 appeared to be the
best candidate for microinjection, the primary reason being that this was the only
clone that was correctly targeted at the 5' end. The 5' end of integration is essential
for driving EDNRB and consequently LacZ expression.
Table 4-3. Summary of targeted clones and methods used to identify them.
Method of screening No. of colonies
screened
Clone ID % positive
3' Southern 960 2G11, 10D8 0.2
3'PCR 480 10D8, 1H3 0.4
5' Southern 1 N/A 2G11 N/A
1 5' Southern analysis was only performed on clones which were found to be positive by 3' Southern
analysis (i.e. clone 2G11 and clone 10D8). Other clones were also included as wild type controls.
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Figure 4-19. PCR analysis of G418-resistant ES cell clones for 3' homologous recombination.
(a) Clone 1H3 was identified as being homologously targeted to the EDNRB locus as shown by the
presence of a 2.7kb band for NeoF/5to4R primers, (b) Two clones, 10D8 and 2G11 previously
identified as being targeted to the EDNRB locus by 3' Southern analysis were analysed by PCR.
Only clone 10D8 produced bands for each set of primers and therefore was identified as being
homologously targeted to the 3' end of the EDNRB locus. Refer to figure 4-18 for predicted sizes ot
bands and see section 4.2.2.3 for further details.
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4.2.3 Clone 2G11 expresses LacZ in vitro
Prior to microinjection of clone 2G11 into blastocysts, it was decided to confirm
expression of the transgene in vitro. Since ETB is probably not highly expressed in
ES cells, a simple differentiation assay was designed. 2G11 and non-transfected ES
cells were cultured as hanging drops to produce embryoid bodies which have the
potential to differentiate into a number of different cell types (see section 2.5.12.1).
Embryoid bodies were allowed to differentiate for several days before being stained
for P-gal activity. Figure 4-20a & b clearly shows that clone 2G11 expressed LacZ as
indicated by the presence of blue cells. On the other hand, wild type, non-transfected
cells did not express LacZ (figure 4-20c). Although these results confirmed that
clone 2G11 expresses LacZ in vitro it was impossible to deduce which type of cells
were expressing LacZ and also if expression was confined to the nucleus given the
presence of the nuclear localisation signal in the transgene. This was largely due to
the nature in which the cells grow when cultured as embyroid bodies (i.e. in close
contact with each other). Therefore, to further investigate expression of the transgene
in vitro a complementary set of differentiation experiments was performed. 2G11 ES
cells were cultured on collagen IV-coated plates in the presence and absence of LIF
in order to produce an endothelial cell population as described in section 2.5.12.2.
Since endothelial cells express ETB, it was anticipated that LacZ expression would be
visible at a subcellular level within these cells. Resulting cells were also compared to
those grown on a gelatin matrix. Flow cytometry analysis (see section 2.5.12.3) of
cells grown on collagen in the absence of LIF revealed that approximately 13% of
total cells counted (lxlO4) were positive for the endothelial marker, Flk-1, compared
to 5.2% of cells grown on gelatin (see figure 4-2la). Visually, cells grown by this
method were more spread out compared to the embryoid bodies making it easier to
identify individual cells. However when assayed for P-gal activity, the absence of
blue staining suggested that none of these cells expressed LacZ (figure 4-2 lb).
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Figure 4-20. Differentiation of ES cells as hanging drops and analysis of LacZ expression.
2G11 and non-transfected ES cells were cultured as hanging drops to produce embryoid bodies and
stained for p-gal activity. The conversion of the substrate, X-gal, to a visible blue product is
indicative of P-gal activity, (a) Low magnification of 2G11 cells which express LacZ (x50), (b)
High magnification of (a) (x200), (c) Non-transfected ES cells do not express LacZ (x50), (d)
Positive control for LacZ expression (x200). See text for further details (section 4.2.3).
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Figure 4-21. Differentiation of ES cells on collagen IV and analysis of LacZ expression. 2G11
and non-transfected ES cells were cultured on collagen IV and gelatin coated plates in the absence
and presence of LIF. The resulting cell population was analysed by flow cytometry and stained for
P-gal activity, (a) FACS analysis of cells stained with anti-Flk-1 antibodies, (b) Staining of cells
for P-gal activity. Differentiated cells do not express LacZ. See text for further details (section
4.2.31.
171
Chapter 4 - Generation ofEDNRB-LacZ mice
Despite the lack of LacZ expression in collagen IV differentiated 2G11 ES cells, this
clone was shown to be correctly targeted to the EDNRB locus by Southern blotting
and did express LacZ when differentiated under the correct conditions (i.e. as
embryoid bodies). Therefore, this clone was used in the generation of EDNRB-LacZ
transgenic mice as described below.
4.2.4 Generation of chimeric mice and germline transmission
Clone 2G11 was successfully defrosted and expanded. ES cells were microinjected
into C57BL/6J mouse blastocysts and implanted into a pseudopregnant mouse as
described in section 2.5.13. In total, one male chimera and one female chimera were
born. Chimeric pups were comprised of cells from two different mouse strains and
therefore were identified by the presence of beige coloured patches amidst the
normal black fur (see figure 4-22a). Beige patches originated from ES cell-derived
129 cells, whilst the dark fur was derived from the host C57BL/6J blastocyst cells.
Chimeras were backcrossed with BKW mice in an attempt to achieve germline
transmission of the targeted gene. Only the male chimera produced offspring
suggesting that the female chimera was probably sterile. Again, offspring were
assessed by coat colour (figure 4-22b). Generation of black pups indicated
inheritance of C57BL/6J chromosomes derived from the parent blastocyst and
therefore did not carry the targeted gene. In contrast, beige coloured pups indicated
inheritance of chromosomes derived from 129 ES cells and had a 1 in 2 chance of
carrying the targeted allele. Germline transmission was confirmed by PCR analysis
of tail tip DNA (refer to section 2.5.14). The primers used were designed from the
LacZ gene of the pKL53 sequence and are documented in figure 4-23. From one
litter, 5 out of 8 beige mice contained the targeted gene as indicated by the presence
of a 701bp band (figure 4-23).
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Figure 4-22. Chimeric mouse and germline transmission of targeted EDNRB gene, (a) A male
chimera derived from 129 ES cells from clone 2G11 (beige) and host C57BL/6J blastocyst derived
cells (black). This chimera was mated with a female BKW mouse and produced offspring of 2
different colours (b). Black pups were derived from chromosomes inherited from C57BL/6J whilst
beige pups were derived from chromosomes inherited from 129 ES cells and therefore had a 1 in 2
chance of carrying the targeted gene.
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beige mice black mice
positive
+ -+ -+ +- + - - control
pl049NLS-PCRF (2648-2671bp of pKL53)
5' - CAA CAG TTG CGC AGC CTG AAT GGC - 3'
KLCla (3325-3349bp of pKL53)
5' - ACG CTC ATC GAT AAT TTC ACC GCC - 3'
Figure 4-23. Germline transmission of LacZ gene to F1 progeny of chimera/BKW crosses.
Tail tip DNA from the offspring of chimera/BKW crosses were analysed for germline transmission
of the targeted EDNRB gene. 5 out of 8 beige mice produced a PCR product of 701 bp using
primers corresponding to the LacZ sequence (sequences are shown). The other 3 beige mice and
black mice were negative for germline transmission.
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4.2.5 A second strain of EDNRB-LacZ mice - EDNRB-LacZ{2)
At around the time of completing ES cell targeting, I became aware that Dr. Myung
Shin in Philadelphia, USA had generated a very similar mouse strain to the one
described here. His work is, as yet, unpublished. This strain also contained the LacZ
reporter gene knocked-in to the EDNRB locus although his targeting construct was
slightly different to mine. Instead of fusion to exon 3, LacZ had been used to replace
exon 1 and part of intron 1 ofEDNRB (see figure 4-24). This construct also lacked an
IRES and an NLS. Due to the risks involved in the completion of generating my own
transgenic mice (e.g. failure to breed chimeras or failure to achieve germline
transmission), it was decided to request mice from Dr. Shin. This would still allow
me to address the aim of this project even if my own mice were not generated. He
very generously agreed and two male mice were transported to our animal house.
These mice were heterozygous for the targeted gene and were immediately bred to
wild type female mice in order to generate our own colony. Genotyping of the
progeny was performed by PCR analysis of tail tip DNA as described in section
2.5.14. An example of the PCR genotyping and the primer sequences which were
used is shown in figure 4-24. The targeted gene was identified by the presence of a
270bp band with primers Ednrb5/Lac4. Heterozygotes were then intercrossed to
produce offspring homozygous for the targeted gene. In the remainder of this thesis,
these mice are known as EDNRB-LacZ(2).
Since my own EDNRB-LacZ mice were only born one month before the submission
of this thesis, much of the data described in the remainder of the thesis have been the
result of analysing EDNRB-LacZ(2) mice.
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Ednrb5 5'- AGA CTG AAA ACA GCA GAG CGG CTA -3'
Lac4 5'- CTG TTG GGA AGG GCG ATC GGT GC -3'
Figure 4-24. EDNRB-LacZ(2) knock-in mice, (a) Targeting construct used by Dr. M. Shin to
generate EDNRB-LacZ(2) knock-in mice, (b) EDNRB-LacZ(2) mice were genotyped using the
primers Ednrb5/Lac4 which resulted in amplification of the targeted EDNRB locus only in EDNRB-
LacZ(2) heterozygotes to produce a 270bp PCR product. Primers sequences are shown. Ednrb5
were designed from the mouse EDNRB cDNA sequence, 151-176bp and Lac4 was designed from
2631-2654bp ofpKL53.
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4.3 DISCUSSION
This chapter documents the generation of the EDNRB-LacZ knock-in mice. The
primary reason for making these mice was to achieve precise localisation of ETB
expression within the kidney. Although analysis of renal ETB expression has been
attempted by other groups using more conventional methods, the results have not
yielded conclusive data (discussed in section 5.3). Therefore, it was decided to use
the reporter gene, LacZ, to create a knock-in transgenic animal in which (3-gal is
expressed wherever ETB is expressed thus providing a precise picture of in vivo ETB
expression.
Reporter genes such as LacZ and green fluorescent protein (GFP) are now widely
used in molecular biology (reviewed in (Alam & Cook, 1990; Spergel et al., 2001)).
By linking reporter genes to endogenous genes of interest, gene expression can be
visualised as a result of enzymatic activity or fluorescence. They therefore provide
powerful tools for visualisation of in vivo gene expression in the embryo through to
the adult. (3-gal catalyses the conversion of the chromogenic substrate, X-gal, to the
visible blue product 5,5'-dibromo-4,4'-dichloroindigo (Pearson et al., 1961; Horwitz
et al., 1964). Each molecule of enzymatic reporter protein catalyses the reaction of
many molecules of substrate to product and therefore makes this a more sensitive
detector of gene expression than non-enzymatic reporter genes. In addition, (3-gal
activity can be quantified using fluorescent and chemiluminescent assays. There are
also commercial antibodies available for the detection of (3-gal in fixed tissues.
Therefore, the use of the LacZ reporter gene offers many possibilities.
LacZ was introduced into the coding region (exon 3) of EDNRB locus by
homologous recombination in ES cells using homology arms of 6.7 and 2.2kb
corresponding to the EDNRB sequence. Also included in the targeting construct was
an IRES which allows translation of the reporter gene by binding the ribosome
directly and eliminates the need to introduce the reporter gene "in-frame" with the
ETb coding region (Mountford et al., 1994). Another important feature of the
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construct was the inclusion of an NLS sequence (Kalderon et al., 1984). Many
reporter genes are now used in conjunction with subcellular localisation signals. In
this case, the use of an NLS sequence will allow precise differentiation between
expressing and non-expressing cells by confining expression of LacZ to the nucleus.
Finally, expression of the neomycin phosphotransferase gene within ES cells was
enhanced by the presence of the MCI promoter (pMCl Neo) (Thomas & Capecchi,
1987). Although not directly compared to a promoterless construct, pMCl Neo
ensured high expression of neomycin phosphotransferase within ES cells regardless
of the expression of ETB and therefore improved survival of targeted ES cells when
exposed to G418. The final construct (see figure 4-1) was generated by a complex,
multi-step cloning strategy involving a combination of PCR manipulation and
subcloning. Before introduction into ES cells the construct was extensively
sequenced and checked by analytical restriction enzyme digests.
Following introduction of the transgene into ES cells by electroporation, a 96-well
targeting strategy was adopted (Ramirez-Solis et al., 1992; Udy & Evans, 1994).
This involved culturing G418-resistant colonies in 96-well tissue culture plates until
confluent. These plates were then split and replica plates produced. For one set of
plates the cells were lysed and DNA prepared for screening for homologous
recombination. The other plates were frozen until screening was complete. If any
positively targeted clones were identified during screening, the "frozen" plate was
defrosted and the corresponding positive clone revived. Screening was also
performed using a 96-well format. Restriction digests were set up in 96-well plates
and DNA was carefully loaded onto 96-well gels using multi-channel pipettes
followed by Southern blotting. This method of targeting has several advantages over
the more conventional 24-well procedures. The major advantage is the simultaneous
analysis ofmultiple samples thereby reducing the time taken to screen large numbers
of colonies. In many cases involving gene targeting, including this one,
recombination frequency can be very low. Therefore, a large number of colonies
have to be screened in order to identify homologously targeted clones. By screening
96 samples at once, this maximises efficiency and allows several hundreds of
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colonies to be screened in a matter of weeks. However, there are also disadvantages
to this approach. In some cases, DNA yields from cells grown in 96-well plates are
limited. Therefore, if several Southern blots need to be performed on the same
sample or if a Southern blot fails and has to be repeated, there may not be enough
DNA. In addition, there may be an increased chance of cells grown in 96-well plates
to die after defrosting. Indeed, one of the positive clones described here was not
viable following ffeeze-thawing. In cases where recombination frequency is low, this
can be a major disadvantage.
As well as screening by the conventional method of Southern blotting, a PCR-based
screening strategy was also attempted. The PCR system that was used is specifically
designed to amplify long templates (Cheng et al., 1994). PCR was also performed in
a 96-well format using a 96-well PCR block. Although initial results using this
system looked promising and two colonies were identified as being correctly targeted
at the 3' end, it was later found to be highly variable between runs. After several
attempts at optimisation, this method was deemed unreliable and the remainder of the
screening was achieved by Southern blotting.
In total, 3 clones were found to be targeted to the EDNRB locus (see table 4-3). 2G11
and 10D8 were targeted at the 3' end as shown by Southern blotting. 10D8 was also
positive by 3' PCR screening. However, only 2G11 was targeted correctly at the 5'
end. In addition a further clone, 1H3, was identified by PCR to be targeted correctly
at the 3' end. Unfortunately this clone did not survive defrosting. Given that the 5'
end of integration is responsible for driving EDNRB and subsequently LacZ
expression, it was decided that 2G11, which had a correctly targeted 5' end, was the
best candidate to proceed with blastocyst microinjection. Usually more than one
clone would be injected to increase the chance of generating chimeras. However,
given the low frequency of recombination (0.1%) this was not possible. Due to time
constraints it was not possible to repeat the targeting experiment. Therefore, it was
decided to proceed with clone 2G11.
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Other researchers have also found the EDNRB locus difficult to target (M.
Yanagisawa, University of Texas Southwestern Medical Center at Dallas, Texas,
personal communication). The reasons for why certain loci are more problematic to
manipulate by gene targeting are unknown. It may be due to the secondary structure
of the chromosome or inaccessibility of the EDNRB gene during recombination. The
extent of homology between donor and target DNA should also be taken into
account. Many reports provide evidence that increased donor-target homology
increases the targeting frequency (Deng & Capecchi, 1992). Indeed, Dr. A. Bagnall
achieved a 6% targeting efficiency for the EDNRB locus using 5' and 3' homology
arms of 12.1 and 2.2 kb respectively (A. Bagnall, University of Edinburgh, personal
communication). This is compared to the 0.1% targeting efficiency observed here
using a shorter 5' homology arm of 6.7kb.
In vitro differentiation of clone 2G11 by culturing ES cells as hanging drops
confirmed that this clone contained a functional LacZ gene. Growth of ES cells as
hanging drops gives rise to a variety of different cell types and so it was impossible
to determine what specific cell types were expressing LacZ without further analysis.
Instead a different method of differentiation was used to investigate if the gene was
expressed in endothelial cells derived from ES cells cultured on collagen IV. This
extracellular matrix provides the correct environment to promote differentiation of
endothelial cells from ES cells (Nishikawa et ai, 1998). The rationale behind this
experiment was that since endothelial cells express ETB, these cells should also
express LacZ. Furthermore, since cells cultured by this method grow as a single cell
layer rather than in tight groups of cells as in embryoid bodies, it was expected to be
able to visualise LacZ expression intracellularly (i.e. within the nucleus). Flow
cytometry revealed that some of these cells were positive for the endothelial cell
marker, Flk-1. However, when assessed for p-gal activity, no blue staining was
observed. While disappointing, it is possible to speculate as to why no staining was
seen. Although a Flk-1 positive population was present, it was not known what type
of endothelial cells were represented here. It is possible that different populations of
endothelial cells express genes differentially depending on their location. For
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example, endothelial cells from the kidney may not necessarily be phenotypically
identical to endothelial cells from the heart. Therefore, it could be that the endothelial
cells studied here simply did not express LacZ. It is also possible that ETB is
expressed at a later stage of endothelial differentiation. Flk-1 is an early marker of
endothelial cell progenitors (Yamaguchi et al., 1993) and therefore these immature
endothelial cells might not have expressed ETB. It may have been interesting to look
for LacZ expression at later stages of differentiation. Finally, it may be that
expression levels were simply too low to be detected by this assay. This could have
been easily investigated by RT-PCR analysis. However, since expression of LacZ in
clone 2G11 had already been documented by the previous method, it was felt that
this was not within the aims of this project and was therefore not pursued.
Nevertheless, this set of experiments did raise concerns over the sensitivity of the (3-
gal assay. If ETB was indeed expressed by these cells but at a level undetectable by
the assay, would the same situation arise in vivo. It is possible that the reason that
LacZ expression was observed in embryoid bodies was that these cells were found in
large clusters, possibly consisting of hundreds of cells. Therefore, the LacZ signal
would be greatly intensified compared to what it might be at a single cell level. Since
the aim of this project is to localise ETB to specific cells within the kidney, the
potential lack of sensitivity is an important point to bear in mind. However, there are
now scientific tools which could help in these situations (e.g. anti-(3-gal antibodies
combined with highly sensitive chemiluminescent detection systems).
Clone 2G11 was used to generate two chimeric mice, one of which produced
progeny in which the transgene had been transmitted to the germline. These mice are
now being bred to generate a colony of EDNRB-LacZ knock-in mice which will be
used to analyse ETB expression patterns. As described in section 4.2.5, a second
strain of EDNRB-LacZ mice, EDNRB-LacZ(2), was obtained from Dr. M. Shin.
These are essentially the same as my mice in that the LacZ gene has been inserted
into the EDNRB locus. It will therefore be extremely interesting to compare the ETB
expression patterns obtained from both strains of mice. However, it should not be
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overlooked that the targeting constructs used to make both strains ofmice were very
different and may therefore lead to different outcomes. In particular, it is worth
noting that in Dr. Shin's construct a large region of intron one was replaced with the
LacZ cassette. However, Shin et al have also reported previously that intron one may
have a regulatory role in EDNRB transcription (Shin et al., 1997). Removal of this
sequence may have a detrimental effect on EDNRB and LacZ expression. It is also
anticipated that the inclusion of an NLS signal in my construct will help in
identifying individual cells and therefore improve specific cellular localisation within
the kidney. These issues will be discussed further in chapter 5.
4.4 SUMMARY
In summary, this chapter has described the generation of EDNRB-LacZ knock-in
mice which will be used to investigate expression of ETB within the kidney.
• Homologous recombination in ES cells enabled the reporter gene, LacZ, to be
introduced into the EDNRB locus.
• One ES cell clone, 2G11, was identified as being correctly targeted to the
EDNRB gene.
• Functional expression of LacZ within this clone was confirmed in vitro.
• Clone 2G11 was used to generate chimeras and produce EDNRB-LacZ
knock-in mice.
• Together with strain EDNRB-LacZ(2), these mice will be used to analyse ET0
expression as described in the following chapter.
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CHAPTER 5
LOCALISATION OF ETB USING EDNRB-
LACZ KNOCK-IN MICE
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5.1 INTRODUCTION
As described in section 4.1, the main purpose for developing knock-in mice
harbouring an EDNRB-LacZ transgene was to determine the expression profile of
ETb within the kidney. Establishing precisely which cells within the inner medulla
express ETB will help to elucidate the cellular mechanisms involved in ETB-mediated
natriuresis as described in section 1.2.2.8. In this thesis it is hypothesised that the
major site of medullary ETB expression is the endothelium of the vasa recta. This is
in line with the paracrine mechanism of action of ET-1 as described in section 1.2.2.8
and figure 1-5. In contrast, the alternative autocrine pathway implies that ETB is
predominantly expressed by IMCD cells. Therefore, the main aim of this chapter was
to determine whether ETB is predominantly localised to the vasa recta or to IMCD
cells.
It is also anticipated that the information obtained from EDNRB-LacZ mice will
provide a more accurate picture of renal ETB expression compared to conventional
methods, which have not led to conclusive data mainly due to technical limitations
(refer to section 4.1). Although most of the literature is in agreement that the highest
expression of ETB is found in the renal medulla and papilla, clearly shown by
macroautoradiography (Davenport et al., 1989; Yukimura et al., 1996; Zhuo et al.,
1998), precise cellular ETB localisation has generated conflicting results. However,
of the many localisation reports those using in vitro and in vivo radioligand ([l25I]-
ET-1) electron microscopy appear to present the most convincing findings (Dean et
al., 1994; Yukimura et al., 1996). These studies showed the majority of [125I]-ET-1
binding was localised to glomeruli, peritubular capillaries and vasa recta. In contrast
there was very low binding in medullary collecting duct cells and tubules. However,
this technique is also limited by technical difficulties since binding sites may be
inaccessible to intravascularly administered [125I]-ET-1. Furthermore Kohan et al
reported high ETB expression in cultured IMCD cells (Kohan et al., 1992).
Therefore, even the most credible results are contradicted by others. It is clear that
further localisation studies are required.
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Therefore, EDNRB-LacZ mice were used to determine ETB localisation within the
kidney. Due to the lack of availability of my own animals at this time, EDNRB-
LacZ(2) were used (see section 4.2.5). This chapter describes the histological
analysis of transgene expression in kidney sections obtained from EDNRB-LacZ(2)
knock-in animals. The results are discussed in the context of existing studies and data
examined in terms of the proposed ET-1 paracrine hypothesis.
5.2 RESULTS
5.2.1 Histological staining of the EDNRB-L,acZ(2) transgene
LacZ expression can be visualised by the formation of a blue precipitate resulting
from hydrolysis of substrate 5-bromo-4-chloro-indolyl-(3-D-galactoside (X-gal).
Therefore, organs from EDNRB-LacZ(2) mice were cryosectioned to obtain sections
10-15|im in thickness, stained with X-gal and counterstained with eosin as described
in section 2.6.2. Both male and female mice were used and no obvious differences
were observed between sexes. Furthermore, LacZ expression was absent in all
corresponding organs of transgene negative littermates. Staining was performed on
several mice (n>5) and consistent staining was observed between animals.
Heterozygous adult EDNRB-LacZ(2) mice (8-10 weeks old) were initially used for
staining. As expected all mice appeared phenotypically normal since only one allele
of the EDNRB locus had been disrupted. The other allele remained intact and
previous studies from ETB heterozygous knockout mice have shown that these
animals do not experience haploinsufficiency (Hosoda et al., 1994). As well as
studying heterozygotes, homozygous EDNRB-LacZ(2) mice were also analysed.
These mice were recognisable by their piebald appearance resulting from a lack of
epidermal melanocytes. In addition, homozygous ETB knockout mice have an
abnormal enteric nervous system. Although viable at birth, they die from aganglionic
megacolon at around 3 weeks of age (Hosoda et al., 1994), Therefore, EDNRB-
LacZ(2) homozygotes were studied at 2.5 weeks of age.
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5.2.2 EDNRB-LacZ(2) expression in lung tissue
Due to the high expression of ETB in lung, this tissue was used as a positive control
to determine if LacZ expression could be detected by this method. Representative
frozen lung sections from heterozygous EDNRB-hacZ(2) transgenic mice are shown
in figure 5-1. As can be clearly seen, blue staining was abundant in these sections.
Staining was observed in pulmonary parenchyma and alveoli. High expression was
also present within large airways such as bronchioles where staining was confined to
the smooth muscle layer (figure 5-lc). Similar results were obtained with
homozygous EDNRB-LacZ(2) mice although, as expected, staining was significantly
brighter compared to heterozygotes (figure 5-2), the reason being that in these mice
both EDNRB alleles contained LacZ.
These findings were consistent with previous localisation studies examining ETB
expression within the lung, albeit in different species (i.e. rat and pig) (Nakamichi et
al., 1992; Goldie et al., 1996; Soma et al., 1999), and therefore provided convincing
evidence that the LacZ expression observed here was an accurate reflection of ETB
expression.
5.2.3 EDNRB-L,acZ(2) expression in kidney
5.2.3.1 Analysis ofheterozygotes
Renal cryosections were then examined for expression of the EDNRB-LacZ(2)
transgene in heterozygotes. As expected, staining was localised to glomeruli (figure
5-3a), afferent and efferent arterioles (figure 5-3b) and large blood vessels within the
cortex (figure 5-3c). As alluded to in section 5.1, previous localisation studies have
reported extremely high radioligand binding of [125I]-ET-1 within the medulla and
papilla (Dean et al., 1994; Yukimura et al., 1996; Zhuo et al., 1998). Therefore, it
was surprising that staining for (3-gal activity within the medulla was not in line with
these reports. Instead, weak staining was observed in the inner medulla manifested as
tiny spots running alongside collecting tubules (figure 5-4a & b). From these images
it was impossible to determine the identity of these cells. In addition, faint staining
was noticeable in the papilla (not shown).
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(a)
(b)
Figure 5-1. LacZ expression in lung tissue from EDNRB-L,acZ(2) heterozygous mice (continued
overleaf). Representative cryosections of lungs from EDNRB-LacZ(2) heterozygous mice stained
for (3-gal activity (blue) and counterstained with eosin (pink). See text for further details (section
5.2.2) (a) Low magnification of lung section (x40). Scale bar = 0.2mm. LacZ expression in
bronchioles and pulmonary parenchyma, (b) Higher magnification of (a) (xlOO) Scale bar = 0.1mm.
Abbreviations: B, bronchiole.
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(c)
(d)
Figure 5-1. LacZ expression in lung tissue from £ZWJ?2?-LacZ(2) heterozygous mice
(continued), (c) High magnification of bronchiole (x400). LacZ expression is confined to the smooth
muscle layer, (d) High magnification of lung tissue (parenchyma and alveolar network) (x400).
Scale bar = 0.05mm. Abbreviations: SMC, smooth muscle cells.
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Figure 5-2. LacZ expression in lung tissue from EDNRB-LacZ(2) homozygous mice.
Representative cryosection of lung from EDNRB-LacZ(2) homozygous mice stained for (3-gal
activity (blue) and counterstained with eosin (pink). See text for further details (section 5.2.2). LacZ
expression is abundant in bronchioles and lung parenchyma (xlOO). Scale bar = 0.1mm.
Abbreviations: B, bronchiole.
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(a)
(b)
Figure 5-3. LacZ expression in renal cortex of £ZW/f.B-LacZ(2) heterozygous mice (continued
overleaf). Representative cryosections of kidneys from EDNRB-LacZ(2) heterozygous mice stained
for P-gal activity (blue) and counterstained with eosin (pink). See text for further details (section
5.2.3.1). (a) LacZ expression confined to glomeruli (x200). (b) LacZ expression in afferent and
efferent arterioles (x200). Scale bar = 0.05mm. Abbreviations: G, glomerulus; AA, afferent
arteriole; EA, efferent arteriole.
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Figure 5-3. LacZ expression in renal cortex ofEDNRB-LacZ(2) heterozygous mice (continued),
(c) LacZ expression in large blood vessels and glomeruli (x200). Scale bar = 0.05mm.
Abbreviations: G, glomerulus; V, vessel.
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(a)
(b)
Figure 5-4. LacZ expression in renal medulla of £Z)A7?Z?-LacZ(2) heterozygous mice
(continued overleaf). Representative longitudinally cut cryosections of kidneys from EDNRB-
LacZ(2) heterozygous mice stained for P-gal activity (blue) and counterstained with eosin (pink).
See text for further details (section 5.2.3.1). (a) LacZ expression in medulla (x200). Scale bar =
0.05mm. (b) Higher magnification of (a) (x400). Scale bar = 0.05mm. Abbreviations: CT, collecting
tubule.
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5.2.3.2 Analysis ofhomozygotes
Staining of (3-gal activity in renal sections obtained from EDNRB-LacZ(2)
homozygous mice produced a much more comprehensive picture of ETB localisation.
LacZ expression was considerably higher than in heterozygotes and staining
appeared more consistent throughout each section. Figure 5-5 shows a representative
image of a whole kidney longitudinal section from an EDNRB-LacZ(2) homozygous
mouse. Intense staining was localised to glomeruli, the inner medulla and the
papillae. Staining was also found in longitudinal bands in the inner stripe of the outer
medulla. In contrast, the outer stripe of the outer medulla exhibited relatively low
LacZ expression.
The increased intensity of staining and improved morphology made it easier to
determine specific cellular sites of expression compared to heterozygotes. Figures 5-
6 and 5-7 contain high resolution images of figure 5-5 in which specific cellular
structures within the cortex and medulla are clearly visible. In the cortex the majority
of staining was localised to glomeruli and large blood vessels (figure 5-6a & b).
Higher magnification revealed LacZ expression confined to specific cells within
glomeruli (figure 5-6c). Although it is difficult to be certain, these cells probably
represent glomerular capillary endothelial cells or mesangial cells. Upon closer
inspection of vessels, it was clear that staining was present in both the endothelial
layer and smooth muscle layer (figure 5-6d). However, due to the intensity of
staining, it is difficult to distinguish between the layers. Overall intensity of LacZ
expression increased dramatically within the medulla (figure 5-7), although renal
tubules appeared not to be stained. Instead, staining was mainly present in the spaces
between tubules identified as large blood vessels and capillary endothelial cells.
There was also strong LacZ expression within the papillae (figure 5-7e & f).
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Figure 5-5. Renal LacZ expression in EDNRB-LacZ(2) homozygous mice. A representative
longitudinally cut cryosection from an EDNRB-LacZ(2) homozygote mouse kidney stained for (3-gal
activity (blue) and counterstained with eosin (pink). See text for further details (section 5.2.3.2).
Magnification is x40. Scale bar = 0.2mm. Abbreviations: G, glomerulus; V, vessel; OC, outer
cortex; OM, outer medulla; IS, inner stripe of outer medulla; IM. inner medulla; P, papilla.
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Figure 5-6. LacZ expression in renal cortex of EDNRB-LacZ(2) homozygous mice (continued
overleaf). Representative longitudinally cut cryosections from an EDNRB-LacZ(2) homozygous
mouse kidney stained for (3-gal activity (blue) and counterstained with eosin (pink). See text for
further details (section 5.2.3.2). (a) LacZ expression in the outer cortex (xlOO). (b) Low
magnification of cortex (xlOO). Scale bar = 0.1mm. Abbreviations: G, glomerulus; V, vessel.
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(d)
Figure 5-6. LacZ expression in renal cortex of EDNRB-LncL(2) homozygous mice (continued),
(c) LacZ expression in glomeruli (x400). (d) LacZ expression in endothelium and smooth muscle
layer of blood vessel (x400). Scale bar = 0.05mm.
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Figure 5-7. LacZ expression in renal medulla of EDNRB-LacZ(2) homozygous mice (continued
overleaf). Representative longitudinally cut cryosections from an EDNRB-LacZ(2) homozygous
mouse kidney stained for (3-gal activity (blue) and counterstained with eosin (pink). See text for
further details (section 5.2.3.2). (a) & (b) Low magnification of medulla (xlOO). LacZ expression is
confined to the spaces between tubules. Tubules are negative for LacZ expression. Scale bar =
0.1mm.
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Figure 5-7. LacZ expression in renal medulla of EDNRB-LacZ(2) homozygous mice
(continued), (c) & (d) Higher magnification of medulla, x200 and x400 respectively. Scale bar =
0.05mm. Abbreviations: CT, collecting tubules; BV, large blood vessels.
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(e)
(f)
Figure 5-7. LacZ expression in renal medulla of EDNRB-L,acZ(2) homozygous mice
(continued), (e) LacZ expression in papilla (xlOO) Scale bar = 0.1mm. (f) Higher magnification of
(e) (x200). Scale bar = 0.05mm.
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To obtain a clearer picture, kidneys were also sectioned transversely as shown in
figure 5-8. Here, collecting tubules were visualised more clearly and were devoid of
LacZ expression. On the other hand, staining was observed in the spaces surrounding
the tubules corresponding to capillaries (figure 5-8c & d). Larger vessels were also
stained. Again, the papilla was strongly stained (figure 5-8e & f).
5.2.4 Preliminary analysis ofEDNRB-LacZ, mice
Until recently all localisation analysis was performed on EDNRB-LacZ{2) mice
provided by Dr. Myung Shin. However, towards the end of the project my own mice
became available and I was able to analyse LacZ expression in EDNRB-LacZ
heterozygotes. However, it should be noted that analysis was in the early stages and
required further optimisation. Analysis of these mice is ongoing. Figure 5-9 shows
LacZ expression in lung sections taken from EDNRB-LacZ heterozygote mice.
Staining was localised to the smooth muscle layer of large airways (e.g. bronchioles)
and, as expected, appeared to be localised to the nucleus due to the presence of the
NLS.
A summary of staining for (3-gal activity is shown in table 5-1.
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(a)
(b)
Figure 5-8. Renal LacZ expression in EDNRB-LacZ(2) homozygous mice (continued overleaf).
Representative transversely cut cryosections from an EDNRB-LacZ(2) homozygous mouse kidney
stained for p-gal activity (blue) and counterstained with eosin (pink). See text for further details
(section 5.2.3.2). (a) Low magnification of kidney section (x40). Scale bar = 0.2mm. (b) Low
magnification of renal medulla (xlOO). Scale bar = 0.1mm. Abbreviations: C, cortex; OM, outer
medulla; IM, inner medulla.
201
Chapter 5 - Localisation of ETB
(Jjf * Vv r *
- * , »
•jr■ #
<
. -> 4 ■
■ ■
, ;;><v -,»f"I|T ^
r.
«*« *


















*#» V F f"
*•#< Jgf:"
V«* t- * * # > *
(d)
Figure 5-8. Renal LacZ expression in £WV7?fi-LaeZ(2) homozygous mice (continued), (c) & (d)
High magnification of renal medulla, x200 and x400 respectively. LacZ expression is confined to
the spaces surrounding tubules. Tubules are negative for LacZ expression. Scale bar = 0.05mm.
Abbreviations: C, capillaries; V, blood vessels; CT, collecting tubules.
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Figure 5-8. Renal LacZ expression in EDNRB-LaeZ(2) homozygous mice (continued), (e) LacZ
expression in papilla (x40). Scale bar = 0.2mm. (f) Higher magnification of (e) (xlOO). Scale bar =
0.1mm.
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(a)
Jrt j,T>
Figure 5-9. LacZ expression in lung tissue from EDNRB-hacZ heterozygous mice.
Representative cryosections of lungs from EDNRB-LacZ heterozygote mice which were generated
during the course of this project, stained for p-gal activity (blue) and counterstained with eosin
(pink). See text for further details (section 5.2.4). (a) Low magnification of lung section (x200).
Scale bar = 0.05mm. (b) Nuclear localised LacZ expression in smooth muscle layer of bronchiole
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5.3 DISCUSSION
One of the fundamental questions when studying any biological pathway in vivo is to
determine cellular localisation of the components involved. Cellular localisation of
ETb in the kidney is important for the understanding of the mechanisms involved in
ET-1 regulation of salt and water homeostasis. The quest to identify ET-1 binding
sites began shortly after the discovery of ET-1 in 1989. These early studies were
hampered by the unavailability of specific ET receptor agonists and antagonists and
therefore made it impossible to distinguish between binding to ETA or ETB.
However, they did provide vital information regarding the importance of the renal
endothelin system by reporting that some of the highest binding of [125I]-ET-1 within
the whole animal occurred within the kidney, in particular within the inner medulla
(Kitamura et al., 1989a; Kitamura et al., 1989b; Koseki et al., 1989).
At around the same time the first autoradiographic localisation studies revealed
images showing intense [l25I]-ET-l binding in glomeruli, inner medulla and papilla
(Davenport et al., 1989; Jones et al., 1989; Kohzuki et al., 1989). Electron
microscopic autoradiography offered more specific cellular localisation of
intravenously injected [125I]-ET-1 within the medulla (Furuya et al., 1992; Dean et
al., 1994). There was strong binding reported in peritubular capillaries and to a lesser
extent in vasa recta whilst binding to renal tubules was undetectable (Dean et al.,
1994). A similar pattern was reported by Furuya et al (Furuya et al., 1992).
However, this group also reported that the extent of [125I]-ET-1 binding was greatly
dependent on the duration of [125I]-ET-1 infusion. Furthermore, some binding sites
may have been inaccessible to intravenously administered [l25I]-ET-l. In vitro
electron microscopic autoradiography showed binding predominantly on endothelial
cells of the vasa recta (Yukimura et al., 1996). Unlike the other reports, binding was
also observed on IMCD cells. However, it was still unknown which endothelin
receptor subtype the binding corresponded to. Indeed it was reported that cultured
IMCD cells expressed both ETB and ETA as shown by RT-PCR (Kohan et al., 1992).
206
Chapter 5 - Localisation of ETB
The development of ETB antibodies provided some insight into receptor subtypes
showing staining of glomeruli and capillaries within the inner medulla. No positive
staining was observed in collecting ducts (Hagiwara et al., 1993). On the other hand,
in situ RT-PCR identified ETB mRNA exclusively in the epithelial cells of collecting
ducts, whereas ETA was observed in medullary interstitial cells and vasa recta (Chow
et al., 1995). However, due to the proximity of capillaries and collecting duct cells,
distinguishing one cell from another using these techniques may have proven to be
problematic. Localisation by RT-PCR was also attempted on microdissected rat
nephrons (Terada et al., 1992a). Large signals were obtained for ETB in glomeruli,
IMCD cells, cortical collecting ducts and a weaker signal for vasa recta bundles.
However, given the sensitivity of RT-PCR, the possibility of cross-contamination
cannot be ruled out in techniques relying on micro-dissection despite the appropriate
controls being in place. Furthermore, RT-PCR provides information only about ETB
transcription and gives no indication of ETB protein expression.
More recent autoradiography studies have made use of endothelin receptor agonists
and antagonists to distinguish between ETB and ETA. By blocking ETA sites with
antagonist 97-139, binding of [l25I]-ET-l to ETB was determined. Although binding
was still observed in the cortex and inner medulla, no comments were given on
specific structures and it is difficult for the reader to determine this from the pictures
given (Yukimura et al., 1996). Dean et al reported inhibition of [l25I]-ET-l binding
by sarafotoxin 6c, an ETB agonist and BQ123, an ETA antagonist (Dean et al., 1996).
Whereas, sarafotoxin 6c abolished [125I]-ET-1 binding throughout the kidney except
for renomedullary interstitial cells of the inner medulla, BQ123 had little effect on
overall binding. This indicated that ETA was localised to renomedullary interstitial
cells of the inner medulla whilst the remaining [l25I]-ET-l binding represented ETB
sites. High resolution light microscopy and electron microscopy of the medulla
revealed these sites to be the vascular endothelium, in particular glomerular and
peritubular capillaries. As with the in vivo autoradiography described above, the
authors reported no binding within renal tubular cells. However, again this is not
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particularly clear from the autoradiograph pictures. Therefore, the precise cellular
sites of renal ETB expression in vivo have yielded conflicting and unconvincing data.
This chapter reports precise ETB localisation within the kidney by analysing the
expression profile of an EDNRB-LacZ transgene. Analysis of EDNRB-LacZ
homozygote mice revealed strong expression in glomeruli, the inner medulla and
papilla. The overall staining pattern was similar to those obtained using [l25I]-ET-l
radioligand macroautoradiography (Davenport et al., 1989; Jones et al., 1989;
Kohzuki et al., 1989; Dean et al., 1994; Yukimura et al., 1996; Zhuo et al., 1998). At
higher resolution, staining within the cortex was confined to glomerular endothelial
and mesangial cells and blood vessels, including afferent and efferent arterioles.
However, as mentioned in section 5.1, the main aim of this chapter was to identify
which cells within the medulla express ETB. I have clearly shown that the endothelial
cells ofmedullary capillaries (i.e. vasa recta) expressed LacZ whilst tubular cells (i.e.
IMCD cells) were negative for transgene expression. The lack of LacZ expression in
IMCD cells contradicts previous studies documenting ETB expression within these
tubular cells (Kohan et al., 1992; Terada et al., 1992a; Yukimura et al., 1996).
However, several criticisms can be made of these reports as described earlier. To my
knowledge, this is the first study to demonstrate localisation of ETB within the renal
medulla to this degree of precision without being hampered by technical difficulties
such as cross-contamination and the occurrence of false positives.
However, localisation of proteins using transgene technology also carries with it
inherent criticisms. For example, in order to knock-in a reporter gene also involves
the "knocking out" of one or both alleles of the targeted gene, in this case EDNRB. It
is impossible to know what effect this will have on expression levels of the gene. The
lack of functional ETB may initiate a negative feedback mechanism in which
transcription and translation of the gene is upregulated. This may be a potential
reason for the observed differences between heterozygote and homozygote
expression levels. It was expected that LacZ expression of homozygous mice would
simply be twice the intensity of heterozygote mice. However, it is clear that this was
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not the case. LacZ expression in kidneys from homozygote mice was several times
higher than in kidneys from heterozygote mice. It is possible that complete abolition
of ETb protein in homozygote mice may be responsible for increased ETB promoter
activity and thus augmented LacZ expression. In contrast, heterozygous mice still
express functional ETB protein and so negative feedback upregulation of gene
expression may not be initiated. Although this is a valid explanation, it is probably
unlikely that this is the case. As described above, previous localisation data suggest
that ETb is highly expressed within the kidney implying that the pattern obtained
from homozygote mice is a more accurate reflection of actual ETB expression than
that obtained from heterozygote mice. Furthermore, even if knocking-out of ETB had
some compensatory effect on expression levels, it is unlikely that this would alter
localisation in terms of which cells were expressing LacZ. In other words, it is not
anticipated that knocking out of ETB would result in de novo expression of ETB in
cells that do not usually express the protein.
In addition to knocking-out functional protein expression, gene targeting may also
interfere with regulatory DNA sequences required for gene transcription.
Transcriptional gene expression usually relies on functional activity of the promoter,
as well as regulatory DNA sequences involved in binding transcription factors and
upstream enhancer elements. Little is known about transcriptional control of EDNRB
(Aria et al., 1993). However, Shin et al have previously reported that a mutation in
intron 1 of the EDNRB locus resulted in truncated RNA transcripts (Shin et al.,
1997). In the EDNRB-LacZ(2) targeting construct, the LacZ reporter gene was used
to replace intron 1 which may have adverse effects on EDNRB and LacZ
transcription. It is not clear whether EDNRB-LacZ(2) failed to be expressed in IMCD
cells because important cell-specific transcriptional control elements were lacking.
Although speculative, it is an important factor to be considered during the analysis of
the localisation data. In contrast to EDNRB-LacZ(2), the EDNRB-LacZ targeting
construct did not involve removal of any region of the genomic EDNRB sequence
upstream of exon 3. It will therefore be interesting to compare renal localisation from
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the EDNRB-EacZ(l) strain with the EDNRB-LacZ strain once renal staining of these
animals has been optimised.
Another explanation for the differences observed between heterozygote and
homozygote mice could be the age at which the animals were studied. As described
in section 5.2.1, heterozygote mice were analysed at 8-10 weeks of age, whereas
homozygote mice were only 2.5 weeks old. It is possible that LacZ expression was
easier to detect in kidneys from younger mice. Kidneys from younger mice were
significantly smaller than those from older mice and may have been more accessible
to penetration of fixative solutions. Whatever the reason for these differences, it is
clear that further investigation is required. In particular, analysis of 2.5 week old
heterozygote mice is required. Unfortunately, due to time constraints it was not
possible to analyse young heterozygote mice but this will be undertaken in the future.
Although not yet fully analysed for transgene expression within the kidney, initial
studies on my own EDNRB-LacZ mice provided promising results for future
analysis. Despite reduced LacZ expression in the lung compared to EDNRB-LacZ(2)
mice, staining was clearly localised to the nucleus and appeared to correspond to the
staining observed in lungs from EDNRB-LacZ(2) mice, at least within the smooth
muscle layer of bronchioles. It is anticipated that optimisation of the staining
protocol will improve LacZ staining. It is well known that the duration of
paraformaldehyde fixation can dramatically affect (3-gal activity (refer to section
2.6.2). p-gal activity can be completely suppressed if incubation periods are too long.
It should also be emphasised that my transgene and Dr Shin's transgene are different
(see section 4.2.5) and this may account for the differences in LacZ expression (e.g.
IRES driven translation may result in lower protein expression). Once staining is
optimised for my own mice, it will be interesting to compare localisation patterns
within the kidney with that of EDNRB-LacZ(2), as well as investigating the
involvement ofEDNRB intron 1 in regulating LacZ expression (see above). It is also
anticipated that localisation of LacZ expression to the nucleus via expression ofNLS,
will provide further useful information.
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Despite the concerns described above, the £7T/VJR5-LacZ(2) renal localisation data
observed here are in line with the report by Dean et al which, in my opinion, presents
the most accurate account of ETB localisation to date (Dean et al., 1996) and
therefore appears to represent an accurate picture of in vivo expression of ETB.
Localisation of ETB to capillary endothelial cells but not to IMCD cells is an
important step towards understanding the intracellular mechanisms involved in ET-1
and ETb renal signalling and their physiological role in natriuresis/diuresis. As
discussed in section 1.2.2.7, ET-1 appears to exert its natriuretic effect through the
stimulation of NO release. ET-1 and NO modulate sodium transport in the same
regions of the nephron (Plato et al., 1999; Plato et al., 2000a). L-NAME inhibits the
natriuretic effects of ET-1 (Hoffman et al., 2000; Plato et al., 2000a). Plato et al also
reported that these effects are mediated by ETB and eNOS (Plato et al., 2000a; Plato
et al., 2000b). ET-1 and NO are thought to enhance sodium and water excretion by
directly inhibiting sodium transport in IMCD cells. Previously, an autocrine model of
ET-1 action in the medulla was proposed based on IMCD in vitro studies in which
both ET-1 and ETB were expressed (Kohan & Padilla, 1992). However, culturing of
IMCD cells firstly requires micro-dissection of tubules devoid of vasa recta bundles
and therefore introduces the possibility of cross-contamination. Furthermore, as with
any cell culture, it is not known how the phenotype of IMCD cells is affected during
prolonged culturing. The results presented here would suggest that the autocrine
signalling pathway is not valid since ETB is not expressed by IMCD cells in vivo.
Instead, the localisation data provide evidence in support of a paracrine mechanism
of action in which ET-1 released from IMCD cells binds to ETB located on the vasa
recta (see section 1.2.2.8 and figure 1-5). Additional physiological experiments
documented that eNOS was the major isoform involved in ET-1/ ETB mediated NO
production (Plato et al., 2000b). In order for ETB to activate eNOS, both components
have to be expressed in the same cell. Teichert et al reported the highest site of renal
eNOS expression within the medulla occurred in endothelial cells of the vasa recta
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(Teichert et al., 2000). This lends further support to a paracrine mechanism of ET-1
action.
Vasa recta are specialised peritubular capillaries that extend deep into the medulla.
They lie adjacent to the renal tubules of the juxtamedullary nephrons (see figure 1-4),
which make up approximately 20-30% of total nephrons and play an important role
in concentrating urine. The ability of the kidney to excrete concentrated urine is
largely dependent on the counter-current mechanism in the loop of Henle which
establishes a high osmolarity of interstitial fluid in the medulla due to the
accumulation of solutes reabsorbed from the thin ascending loop of Henle but not
reabsorption of water. In the presence ofADH, this osmotic gradient causes water in
the collecting ducts to diffuse into the renal interstitium and vasa recta, thereby
concentrating urine. Positioned at the terminal portion of the nephron, IMCD cells
are the final site for processing urine before excretion and are therefore responsible
for the final decision regarding urine output of water and salts. Thus, the
endothelin/NO system could play a critical role in the fine-tuning of sodium and
water excretion.
There are two major mechanisms which lead to increased sodium and water
excretion. The first is a reduction in tubular sodium transport. As alluded to above,
both ET-1 and NO have been reported to directly inhibit sodium transport,
independent of alterations in renal blood flow (Stoos et al., 1995; Plato et al., 1999;
Plato et al., 2000a). It has been reported that ET-1 can inhibit sodium reabsorption
by downregulating ENaC activity (Gallego & Ling, 1996; Gariepy et al., 2000) and
by inhibiting Na+-K+-ATPase activity (Zeidel et al., 1989). It has also been suggested
that NO blocks sodium channels through a cGMP-kinase dependent phosphorylation
pathway (Light et al., 1990; Lahera et al., 1993). ET-1 may also inhibit water
reabsorption by blocking ADH activity, thereby reducing water permeability in the
collecting duct (Tomita et al., 1990; Nadler et al., 1992). Increased sodium and water
excretion can also result from augmented blood flow to the medulla. Compared to
the cortex, blood flow to the vasa recta is low, accounting for only 1 -2% of total
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renal blood flow. Physiologically, low renal blood flow minimises washout of the
solute gradient established by the counter-current mechanism (see above). On the
other hand, high blood flow through the vasa recta, dissipates solutes, reduces the
ability of the kidney to concentrate urine and leads to increased natriuresis/diuresis
(Cowley, 1997). As well as exerting direct effects on sodium transport, ET-1 and NO
also regulate medullary blood flow (Gurbanov et al., 1996; Mattson & Wu, 2000a).
By increasing blood flow through the vasa recta, ET-1 and NO indirectly initiate
natriuresis/diuresis.
In summary, the localisation data presented here and physiological data from other
reports, suggest that, by binding to ETB on the vasa recta, ET-1 activates eNOS. NO
released from medullary capillary endothelial cells, acts simultaneously on IMCD
cells to decrease sodium transport and on the vasa recta to enhance renal blood flow.
This dual action has the net effect of reducing sodium reabsorption and promoting
natriuresis/diuresis thus helping to maintain systemic blood pressure within the
normal, healthy range.
It should be clear that abnormalities in the system described above, resulting in
reduced NO release, may have a detrimental effect on sodium transport and may lead
to sodium retention and hypertension. Indeed, urinary excretion of NO metabolites
(N02 and NO,) were significantly lower in hypertensive patients (Sierra et al., 1998).
ED within the kidney has been described in a number of models of hypertension
(refer to section 1.2.3). As discussed in chapter 3, reduced NO availability may result
from changes in several different factors. In particular, components of the pathway
described above may be altered. At present there is no convincing evidence
supporting a reduction in renal eNOS expression. In contrast, many of the reports to
date, including data reported in chapter 3 of this thesis, would suggest that renal
eNOS expression is elevated during hypertension. Instead, reduced activation of
eNOS and NO release by the renal endothelin system may be a potential mechanism
in the pathogenesis of ED. As discussed in section 1.2.3, daily urinary excretion of
ET-1 was significantly decreased in hypertensive patients compared to normotensive
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subjects (Hoffman et al., 1994). Furthermore, when hypertensive patients were given
high sodium diets, the salt-sensitive subset excreted less urinary ET-1 than the salt-
resistant subset. More direct evidence for diminished medullary ET-1 production in
hypertension comes from animal models. Levels of ET-1 mRNA and
immunoreactive ET-1 in the inner medulla were decreased in SHR compared to
WKY rats (Kitamura et al., 1989b; Hughes et al., 1992). This is further supported by
the observation that ET-1 production was significantly lower in IMCD cells isolated
from SHR (Hughes et al., 1992). Likewise, ETB mRNA expression was
downregulated in DOCA-salt sensitive hypertensive rats. In addition, these animals
produced less NO in response to ET-1 perfusion (Hirata et al., 1995b). However, no
information was given regarding precise sites of altered ETB expression. The
importance of ET0 in maintaining normal blood pressure is further emphasised by the
observation that animals deficient in ETB developed salt-sensitive hypertension
(Ohuchi et al., 1999b; Gariepy et al., 2000). Furthermore, collecting duct specific
knockouts of ET-1 excrete less sodium and are hypertensive (Ahn et al., 2002).
Together, these data imply that reduced activity of the renal endothelin system may
be a contributing factor to diminished NO availability within the kidney and that
renal ED may play a crucial role in the development and maintenance of
hypertension.
5.4 SUMMARY
In summary, this chapter has described the precise localisation of ETB within the
kidney using EDNRB-LacZ(2) knock-in mice. The main findings were:
• The EDNRB-LacZ transgene was highly expressed within the inner medulla.
• LacZ expression was confined to medullary capillaries (i.e. vasa recta).
• Tubular cells within the inner medulla (i.e. IMCD cells) were negative for
transgene expression.
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• These data support the hypothesis that ET-1 acts as a paracrine natriuretic
hormone where it is released from IMCD cells and binds to ETB located on the
vasa recta. Activation of ETB initiates eNOS to release NO which blocks
sodium transport and increases medullary blood flow, thereby promoting
natriuresis/diuresis.
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CHAPTER 6
ALTERATION IN ETB EXPRESSION
FOLLOWING SALT LOADING OF EDNRB-
LACZ(2) MICE
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6.1 INTRODUCTION
In the previous chapter, renal ETB localisation in EDNRB-LdicZ(l) mice was
described and the results discussed in the context of the cellular and molecular
mechanisms underlying ET-1/ETB mediated natriuresis/diuresis. To further
investigate the role of ETB in sodium transport, EDNRB-LacZ(2) mice were used in
physiological salt loading experiments.
Several studies have examined renal endothelin regulation in response to salt
loading. Pollock et al reported that urinary ET-1 excretion was significantly higher in
wild type rats fed a high salt (10% NaCl) diet than those on a low sodium diet,
implying that ET-1 renal production is increased in response to high salt intake
(Pollock & Pollock, 2001). Similar findings have been reported in mice. Melo et al
used a radioimmunoassay to measure ET-1 levels in kidney extracts from mice fed
an 8% NaCl diet for one week (Melo et al., 1998). Compared to mice on a sodium
deficient diet, they detected significantly increased renal ET-1. In support of this
finding, Ohuchi et al reported upregulation of renal preproET-1 mRNA by RT-PCR
in mice fed high salt diets for 3 weeks (Ohuchi et al., 1999b). These findings are in
keeping with in vitro experiments showing that one of the main stimuli for ET-1
production is increased osmolality. Increasing the sodium concentration of IMCD
cell media resulted in an increase in preproET-1 mRNA accompanied by increased
ET-1 production (Yang et al., 1993; Migas et al., 1995). In addition, some animal
models with salt sensitive hypertension have activated endothelin systems. For
example, in both the DOCA-salt hypertensive rat and the Dahl salt sensitive rat, renal
prepro-ET-1 mRNA expression is increased (Deng et al., 1996; Ikeda et al., 1999).
However, it is important to remember at this point that the renal vasculature and the
renal tubule react differently to ET-1. Within the vasculature, increases in ET-1
predominantly results in vasoconstriction, thereby promoting a hypertensive effect.
On the other hand, increased ET-1 in the nephron enhances sodium and water
excretion and consequently lowers blood pressure. In the hypertensive animal studies
described above, no indication is given regarding specific cellular sites of ET-1
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upregulation and therefore these results must be interpreted cautiously. Elevated
renal expression of ET-1 in the vasculature of these animal models of hypertension
may, in fact, be a pathological feature of hypertension and not a physiological
adaptation to increased salt intake.
Nevertheless, the studies performed on wild type animals provide strong evidence
that renal ET-1 expression and release is stimulated during conditions of high salt
intake and volume expansion. However, not all studies agree with this outcome.
Morita et al reported a 50% reduction in renal ET-1 in mice fed an 8% NaCl diet
compared with mice fed a normal diet for 4 weeks (Morita et al., 1998). These
discrepancies may arise from the methods used to measure ET-1 or from differences
in the duration of administration of the high salt diet. Furthermore, in most of the
studies mentioned here, ET-1 measurements were obtained from whole kidney
extracts. As described above, details of the intrarenal cellular sources of ET-1 (i.e.
vascular or tubular) are necessary to fully interpret these data. More direct
measurements of the source of renal ET-1 production are required to help resolve the
situation.
There are few complementary studies investigating alterations in renal ETB during
salt loading. It is not known if increased salt intake is also a stimulus for ETB
expression, as it is for ET-1. Studies on salt sensitive animal models reported the
opposite result. DOCA-salt hypertensive rats exhibited lower ETB mRNA levels in
whole kidney homogenates (Hirata et al., 1995b). Likewise, Dahl salt sensitive rats
had decreased ETB protein expression in large renal arteries. However, no
information was given regarding the renal medulla (Kakoki et al., 1999). Again, as
described above, these results must be viewed with caution as decreased ETB levels
may be a causative factor in the development of hypertension in these models. This is
further emphasised by the observation that ETB deficient animals develop salt
sensitive hypertension (Ohuchi et al., 1999b; Gariepy et al., 2000). It is clear that
further studies regarding the effects on salt loading on renal ETB expression are
required.
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Given the role of ETB in promoting natriuresis/diuresis and the evidence described
above regarding upregulation of ET-1 during salt loading, it is hypothesised that
under physiological conditions, an increase in salt intake will also perpetuate an
increase in renal ETB expression. In turn, NO production and subsequent excretion of
excess salt and water will be enhanced. Therefore, the aim of this study was to
investigate the effects of salt loading on renal ETB expression in EDNRB-LacZ(2)
mice. Because homozygote mice die at an early age (see section 5.2.1), heterozygote
mice were used.
6.2 RESULTS
6.2.1 General parameters of salt loading
EDNRB-LacZ(2) heterozygote male mice (10 weeks old) were fed high (8%) or
standard (0.8%) NaCl diets for 3 weeks (see section 2.6.4). There were no significant
differences in body weights between groups at the start and end of the experimental
time period (Table 6-1). Kidney to body weight ratios were also comparable between
groups. Mice on the high salt diet ate considerably more food (figure 6-1 a), possibly
due to increased energy expenditure or simply due to taste preferences.
Consequently, mice on high salt diets drank significantly increased amounts of water
(figure 6-lb) and as a result, urine output was approximately 3 times greater from
mice on high salt diets (figure 6-lc). However, it should be noted that urine was only
collected over a period of 12 hours, due to Home Office regulations, and was
therefore not as accurate as the more commonly measured 24 hour collection period.
Table 6-1. General parameters of salt loading.
Group BW start (g) BW end (g) Kidney/BW ratio
Standard salt (n=5) 27.2 ± 1.0 26.7 ± 1.0 0.0088 ± 0.0004
High salt (n=5) 29.8 ± 1.2 28.2 ± 1.0 0.0104 ±0.0007
Values are given as mean ± S.E.M. Abbreviations: BW, body weight.
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8% NaCI 0.8% NaCI
Figure 6-1. Food and water intake and urine volume from mice on high or standard sodium
diets, (a) Daily food intake (n=5). (b) Daily water intake (n=5). (c) Volume of urine output over a
12 hour period. For urine collection, animals were divided into separate metabolic cages and urine
volumes combined for each group. * P<0.05 versus 0.8% NaCI group.
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6.2.2 ETb expression during salt loading
ETb expression was assessed by measuring [3-gal activity in whole kidney extracts.
[3-gal activity was quantified in tissue extracts using an assay based on the
methylumbelliferone fluorescence method which measures the hydrolysis of 4-
methylumbelliferyl-p-D-galactoside catalysed by [3-gal. This reaction yields 4-
methylumbelliferone (MU), a fluorescent product that emits fluorescence at 460nm
when excited at 365nm (see section 2.6.3). Figure 6-2a shows the results of [3-gal
activity in kidney extracts from mice fed high salt or normal salt diets. EDNRB-
LacZ(2) mice which were fed high salt exhibited slightly higher (3-gal activity
although significance was not reached (P=0.21). However, it should also be noted
from figure 6-2a that wild type mice (i.e. those mice which were negative for the
EDNRB-LacZ(2) transgene) also had high levels of (3-gal activity. The reasons for
this are unclear but it has been documented elsewhere and appears to be unique to the
kidney (Pelisek et al., 2000). Lung extracts from wild type mice did not exhibit the
same high (3-gal background activity (figure 6-2b). It was possible that the high
background was masking the effect of salt loading on ETB expression. Therefore, 3
different protocols were used in an attempt to reduce the activity of endogenous [3-
gal activity. The first was to use a pull down assay, similar to the co-
immunoprecipitation assay described in section 2.3.4, to extract exogenous (3-gal. An
antibody specific to bacterial [3-gal, together with protein G sepharose were used to
capture exogenous [3-gal. The (3-gal activity of this sample was then measured. The
second approach was to selectively inhibit the activity of endogenous (3-gal by heat
treatment, thereby intensifying the activity of the exogenous reporter gene. Young et
al have previously reported that heat treatment at 50°C inactivated endogenous (3-gal
activity without affecting the activity of bacterial (3-gal (Young et al., 1993). The
final approach was similar to the second. Instead of using heat to inactivate
endogenous (3-gal, increased pH was used (from pH 7.5 to pH 8.5). Again, this is
reported to decrease endogenous activity (Kantachuvesiri, 1999). However, bacterial
(3-gal activity may also be reduced by up to 50%. Unfortunately, none of these
methods produced satisfactory results. The result was either complete abolition of
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Figure 6-2. P-gal activity in kidney extracts from mice on high or normal salt diets, (a) P-gal
activity in kidneys from mice on high and normal diets. Also shown is P-gal activity from a wild
type mouse, (b) P-gal activity in lung extracts from EDNRB-LacZ(l) and wild type mice. n=5 in
each group, except wild type (n=l).
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(3-gal activity or no increased difference in activity between EDNRB-LacZ(2) and
wild type animals. Further investigations are therefore required to resolve these
technical problems.
6.3 DISCUSSION
As discussed in section 6-1, the majority of studies examining the regulation of the
endothelin system in response to salt loading, indicate that renal ET-1 expression
increases. Based on these observations and the proposed mechanism of ET-1 induced
natriuresis/diuresis described in chapter 5, it was hypothesised that increased levels
of ET-1 may result in augmented renal NO production via activation of ETB and
eNOS. The downstream result would be increased natriuresis/diuresis thereby
excreting excess dietary salt and maintaining normal blood pressure. Although some
studies indicate that renal eNOS expression and NO production are increased during
salt loading (Schultz & Tolins, 1993; Mattson & Higgins, 1996), no such studies
exist for ETB. This chapter has described a preliminary investigation on the effects of
salt loading on renal ETB expression.
I have used the EDNRB-LacZ(2) knock-in mice described in chapters 4 and 5 to
perform salt loading experiments. By measuring [3-gal activity in renal extracts from
heterozygote EDNRB-LacZ(2) mice fed normal and high salt diets, I was able to
quantify the level of renal ETB expression. Initial results suggest that renal ETB
expression is increased by high salt intake. However, it should be noted that the
numbers of animals used in this study were low (n=5). It is therefore important that
this experiment should be repeated using increased numbers of animals (e.g. n=10-
15) before making any firm conclusions. Furthermore, high endogenous (3-gal
activity was observed in these kidney samples which may be masking part of the
effect. I attempted a variety of methods to try and reduce background (3-gal activity
in kidney homogenates, but to no avail. It is also possible that exogenous (3-gal
activity in these samples was simply too low to quantify accurately. As described in
chapter 5 (see section 5.2.3.1), LacZ expression in kidney sections taken from
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EDNRB-LacZ(2) heterozygote mice was extremely low. This low expression became
more apparent when compared to (3-gal expression in 2.5 week old homozygote
EDNRB-LacZ(2) mice in which (3-gal expression was significantly higher. It is
hypothesised that these differences in expression may be a result of the age at which
the mice were studied. It is also possible that endogenous [3-gal activity increases
with age. Therefore, future salt loading experiments may yield clearer data if
performed on younger mice. It is unfortunate that homozygote EDNRB-LacZ(2)
mice, which have significantly increased renal P-gal expression compared to
heterozygotes, cannot be used in this type of study since they die at an early age
(Hosoda et al., 1994). Furthermore, ETB knockout animals are hypertensive on a
normal salt diet which is augmented during salt loading (Ohuchi et al., 1999b;
Gariepy et al., 2000). This would therefore complicate findings. Although there are
no data describing salt loading of heterozygote ETB knockout mice, they are not
hypertensive on a normal sodium diet. It may also be possible to quantify LacZ gene
expression on kidney sections. Not only will this give information regarding overall
changes in ETB expression, it should also provide data on how ETB expression is
altered during salt loading within specific cells in the kidney.
In the future it will be desirable to include a positive control for the upregulation of
ETb expression. However, there are few reports investigating which physiological
factors upregulate or downregulate renal ETB expression. In vitro studies suggest that
cytokines and growth factors downregulate ETB expression in HUVECS (Smith et
al., 1998). Kanno et al reported that angiotensin II dose dependently upregulated ETB
mRNA (Kanno et al., 1993). However, this was performed in cultured rat
cardiomyocytes. The equivalent study has not been reported for renal cells. Indirect
evidence showing that renin and angiotensin II levels drop during salt loading, imply
that angiotensin II is not an activator of renal ETB expression (Melo et al., 1998).
Increased ETB expression during salt loading is in line with existing data on
alterations in ET-1 and eNOS expression in response to high salt intake. Pollock et al
reported increased renal ET-1 production in rats fed high salt diets (Pollock &
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Pollock, 2001). Likewise, Melo et al documented augmented ET-1 expression in
whole kidney homogenates as well as higher eNOS expression in salt-loaded mice
(Melo et al., 1998). Increased eNOS expression was also observed in the inner
medulla of rats on high salt diets (Mattson & Higgins, 1996). Taken together, these
data suggest that increased levels of ET-1, ETB and eNOS may be a physiological
adaptation to increased dietary salt intake aimed at counteracting the pressor effect of
high salt by facilitating increased medullary sodium transport and increasing
medullary blood flow, both of which promote natriuesis/diuresis (see section 5.3).
The main aim now is to elucidate in which renal vascular or tubular segments these
changes take place.
The kidneys have an enormous capacity to alter sodium excretion in response to
changes in sodium intake. In physiological conditions this occurs with relatively
small changes in extracellular fluid volume and thus maintains normal blood
pressure. The results presented in this chapter and reports by others suggest that the
endothelin system may play an important role in regulating sodium homeostasis.
However, other systems also play their part.
The basic mechanisms of how increased salt intake can initiate increased
natriuresis/diuresis have been well described for some time (reviewed in (Guyton &
Hall, 2000b)). As sodium intake increases, the osmolality of the extracellular fluid
also increases. This is one of the major stimuli for the sensation of thirst. If water is
in abundant supply, water intake also increases. In the study described here, animals
on high salt diets drank around 4-5 times more water than animals on normal salt
diets. Increased sodium and water intake leads to an increase in extracellular fluid
volume which in turn triggers various mechanisms to increase sodium and water
excretion. Firstly, the increase in fluid volume causes a small rise in blood pressure
initiating pressure natriuresis/diuresis to excrete excess sodium and water. In
addition, anti-natriuretic/diuretic systems are suppressed. Of these, the renin-
angiotensin system is the most important. By blocking renin release, and
consequently angiotensin II and aldosterone production, sodium and water retention
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are reduced. Finally, increased extracellular fluid volume can stimulate natriuretic
system such as atrial natriuretic peptide and possibly the endothelin system described
above, which contribute further to increased sodium and water excretion. Therefore,
by suppressing water and sodium retaining systems and by activating
natriuretic/diuretic systems, the kidney can respond to increased salt intake by
promoting sodium and water excretion through the production of large volumes of
urine. All this occurs with only slight changes in extracellular fluid volume and
blood pressure.
Despite the ability of the kidney to control sodium homeostasis with such fine
precision, high salt diets have been implicated in the pathogenesis of hypertension.
Indeed, a large percentage of human hypertensive patients are salt sensitive.
Flowever, the underlying mechanisms are largely unknown. There is now growing
evidence that aberrations in the renal endothelin and NO systems may play a role in
abnormal sodium homeostasis and contribute to the development of salt-induced
hypertension. This concept will be discussed further in chapter 7. Further knowledge
of the mechanisms involved is awaited with much anticipation.
6.4 SUMMARY
In summary, this chapter has described preliminary investigations into alterations in
ETb expression during physiological salt loading ofEDNRB-LacZ(2) mice. The main
points are:
• It is possible to measure (3-gal activity in tissues isolated from EDNRB-LacZ(2)
mice using a methylumbelliferone fluorescent assay. However, high
endogenous (3-gal expression in kidneys makes it difficult to measure low levels
of exogenous transgene activity.
• When fed a high salt diet, EDNRB-LacZ(2) mice had slightly increased (3-gal
activity in whole renal homogenates compared to mice fed a normal salt diet
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suggesting that renal ETB expression may be upregulated by increased salt
intake.
• Further studies are necessary to establish precise cellular sites of increased ETB
expression.
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7.1 SUMMARY
The importance of the kidney in regulation of blood pressure was highlighted by
Guyton many years ago (Guyton et al., 1972). He emphasised the central role played
by pressure natriuresis in opposing incremental increases in blood pressure. Any
increase in blood pressure is compensated by an increase in renal excretion of salt
and water. Thus, any alteration in the mechanisms regulating renal sodium excretion
could provoke the development of hypertension. Since hypertension is a major risk
factor for atherosclerosis, stroke and other cardiovascular diseases, elucidation of the
mechanisms involved in sodium homeostasis may have important therapeutic
implications.
This thesis has explored the concept that renal NO plays a vital role in regulating
sodium homeostasis and that aberrations in the pathways controlling NO production
may result in renal ED, sodium retention and contribute to the pathogenesis of
hypertension (see figure 7-1). Much of the evidence to date implicates eNOS as the
major enzyme responsible for NO-mediated inhibition of sodium reabsorption
(reviewed in section 1.2.2.1), although little is known of the cellular and molecular
mechanisms involved in regulating eNOS activity within the kidney. Since eNOS-
mediated NO generation encompasses a wide array of regulatory mechanisms, I
chose to investigate two distinct areas. In the first part of this thesis, regulation of
eNOS activity through interactions with regulatory proteins and how these may alter
during ED was investigated. In the second part of the thesis the focus shifted to the
mechanisms involved in the activation of renal eNOS, in particular interactions with
the endothelin system. The main findings will be summarised in this chapter. The
potential contributions to the enhanced understanding of the basic cellular and
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7.2 GENERAL DISCUSSION AND FUTURE WORK
7.2.1 Regulation of renal eNOS activity
Several studies have investigated whether diminished eNOS expression is
responsible for reduced NO bioavailability in the SHR. Although some studies have
reported decreased eNOS expression (Cuevas et al., 1996; Chou et al., 1998), the
majority of reports, including the results presented here, have found that eNOS
expression is, in fact, augmented in the SHR compared to normotensive, WKY rats
(Bauersachs et al., 1998; Nava et al., 1998; Vaziri et al., 1998; Vaziri et al., 2000).
The data presented in chapter 3 revealed that eNOS expression in the heart and
kidney of SHR was upregulated suggesting that ED in the SHR is not associated with
translational abnormalities of eNOS expression. On the contrary, it is hypothesised
by others that eNOS expression may be increased as a result of elevated blood
pressure (Nava et al., 1998; Vaziri et al., 1998). However, determination of protein
expression does not provide information on the ability of the tissue to generate NO.
Several other factors control eNOS-mediated NO release. One of these factors,
eNOS-caveolin interactions, was investigated. No differences in caveolin expression
levels were observed between SHR and WKY. Nevertheless, one of the aims of this
chapter was to investigate if alterations in eNOS-caveolin protein interactions were
associated with ED in the SHR. Unfortunately, this was not fully addressed due to
technical difficulties. Despite these problems, the failure to observe eNOS-caveolin
protein interactions within tissue did raise important questions concerning the extent
to which these proteins interact in vivo.
The majority of the investigations on eNOS-caveolin interactions have been
performed in vitro. Only recently has there been a report documenting in vivo
interactions in rat aortas (Murata et al., 2002). It will therefore be of interest to
determine if these data are reproducible in different tissues using the exact conditions
for co-immunoprecipitation documented in this report. Once established, these
conditions can be used to address the original aim of whether eNOS-caveolin
interactions are altered during ED.
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Another important area which requires further investigation is the lack of
histochemical data supporting the biochemical evidence for the existence of eNOS-
caveolin interactions (see section 3.3). Therefore, future studies may involve analysis
of eNOS and caveolin localisation within fixed tissue sections by
immunohistochemisty. Although this will not provide much information on
intracellular localisation, it will help to elucidate if these proteins are at least found
within the same cells. In particular, it will be interesting to use this technique to
establish if eNOS and caveolin co-localise to the same cells within the kidney.
eNOS has also been reported to interact with a number of other proteins (e.g.
bradykinin receptor, angiotensin receptor, ETB, hsp90, NOSIP, NOSTRIN (Garcia-
Cardena et al., 1998; Ju et al., 1998; Marrero et al., 1999; Dedio et al., 2001;
Zimmermann et al., 2002)). Again, these data are the result of several in vitro studies
and remain to be confirmed in vivo. Furthermore, the physiological relevance of
these eNOS protein-protein interactions is awaited with much anticipation.
One of the major flaws of this study was that NOS activity was not measured.
Determination ofNOS activity in SHR kidneys would have provided information on
whether renal eNOS regulation was abnormal in these animals. However, a previous
study suggests that NOS activity is actually augmented in SHR kidneys compared to
WKY (Nava et al., 1996). These animals were of a similar age to those used in this
study. Elevated NOS activity has also been reported in other tissues of the SHR
(Nava et al., 1998; Vaziri et al., 1998). In addition, some reports documented that
urinary excretion and plasma concentration of NO metabolites (N02 and NO,) are
also increased in SHR (Nava et al., 1998; Vaziri et al., 1998). Together these data
imply that ED in the SHR is not associated with diminished eNOS activity or NO
production. Instead the NO pathway appears to be activated suggesting that ED is a
result of some mechanism other than reduced eNOS activity. Indeed, there are
numerous reports providing alternative reasons for why the SHR develops ED. These
include inactivation of NO by superoxide (Bauersachs et al., 1998; Vaziri et al.,
2000), downregulation of sGC expression (Bauersachs et al., 1998; Ruetten et al.,
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1999), an inability ofNO to activate sGC/cGMP (Nava et al., 1998) and release of
endothelial derived contracting factors which counteract the effects ofNO (Luscher
& Vanhoutte, 1986; Luscher et al., 1990). It would appear that development of ED in
the SHR cannot be attributed to a single mechanism but is a multifactorial process. It
is also clear from the literature that ED in the SHR manifests itself differently
depending on the tissue of interest and the age of the animal. This therefore makes
data difficult to interpret.
This is also true of other animal models of hypertension where ED presents different
characteristics depending on the model being studied. For example, unlike the SHR,
the Dahl salt sensitive hypertensive rat has reduced expression of eNOS in the kidney
compared to normotensive control rats (Ni et al., 1999). This is accompanied by
decreased NOS activity (Luscher et al., 1987). A similar observation has been
reported for the two-kidney, one-clip hypertensive rat (Wickman et al., 2001). It may
therefore be of interest to further investigate alterations in eNOS and caveolin
expression in different models of ED, particularly those in which eNOS activity is
depressed.
The array of studies on animal models of hypertension highlights the many different
mechanisms which are involved in the pathogenesis of ED. A similar situation
probably occurs in hypertensive patients and therefore presents a challenging
prospect in further elucidation of the cellular and molecular mechanisms underlying
ED in hypertension.
7.2.2 Regulation of renal eNOS activation
One of the important aspects of this thesis was to highlight the importance of eNOS
within the kidney. The pathways that control renal eNOS activity have not yet been
clarified. One of the major questions that remains unanswered is what is the major
physiological activator of eNOS within the kidney. Much of the evidence to date
implicates the endothelin system as a major stimulator of renal eNOS ((Hoffman et
al., 2000; Plato et al., 2000a; Plato et al., 2000b) and reviewed in section 1.2.2.7).
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The second part of this thesis investigated the cellular mechanisms involved in ET-1/
ETb mediated activation of eNOS by localising ETB to specific cells within the
kidney. This was achieved using a transgenic mouse in which a LacZ reporter gene
was under the control of EDNRB transcription. The main finding was that the
EDNRB-LacZ(2) transgene was highly expressed within the inner medulla of
homozygote mice. LacZ gene expression was confined to the endothelial cells of the
vasa recta, whereas tubular cells were negative for LacZ gene expression. This
indicated that the major site ofmedullary ETB expression is within the capillaries of
the inner medulla and supports the hypothesis that ET-1, released from IMCD cells,
binds ETb on endothelial cells and therefore acts as a paracrine substance.
Although localisation of LacZ gene expression was confirmed by an expert renal
histologist, there are additional studies which could be performed to strengthen these
results. In particular, the use of antibodies directed against endothelial cell markers
(e.g. CD31, Flk-1) would help to confirm the presence of endothelial ETB expression.
Double staining of kidney sections with these antibodies and anti-P-gal antibodies
will further help in the precise localisation of ETB. In addition, antibodies specific for
IMCD cells could be used to prove that these cells are negative for LacZ gene
expression.
One of the main areas in which further investigation is warranted is to clarify the
reasons for the differences observed in LacZ gene expression between heterozygote
and homozygote EDNRB-LacZ(2) mice. In theory, LacZ gene expression in
heterozygote mice should be half that of homozygote mice. However, heterozygote
mice displayed significantly reduced LacZ gene expression. It is hypothesised that
the reason for this discrepancy is the differences in ages at which these animals were
studied. Therefore, staining of young heterozygote mice (aged 2-3 weeks) is required
to investigate this possibility. These studies are ongoing.
In addition, further experiments will include analysis of the EDNRB-LacZ mice.
Unfortunately, the final EDNRB-LacZ mice were born only a few weeks before the
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submission of this thesis. Due to time constraints and low numbers of animals, full
investigation of LacZ gene expression within the kidney was not possible. However,
preliminary investigations within the lung offered promising results and analysis of
renal LacZ gene expression in these mice is underway. It will be interesting to
compare renal expression between the different strains, bearing in mind that the
targeting constructs used to generate the two strains ofmice were different.
The knock-in mice also offer opportunities for a wide array of physiological studies.
Chapter 6 described a preliminary experiment investigating how salt loading affects
ETb expression by measuring [3-gal activity in whole kidney homogenates. Initial
results were promising showing a slight increase in renal (3-gal activity in mice fed
high salt diets and suggest that ETB expression may be upregulated during increased
salt intake. This provides further support for the proposal that ETB is involved in
mediating sodium transport. However, in order to validate these data will require
higher numbers of animals. In addition, it will be important to establish precisely
which intrarenal cellular sites are responsible for increased ETB expression. One
possibility would be to measure (3-gal activity separately within the cortex and
medulla. Alternatively, more precise localisation of altered ETB expression could be
achieved by staining kidney sections as performed in chapter 5. Obviously this is a
more challenging idea as strict criteria will have to be used for counting cells in order
for the researcher to remain objective. However, under the correct conditions this
may yield valuable information.
The EDNRB-LacZ mice are also a valuable resource for investigating regulation of
ETb expression under other physiological and pathophysiological challenges (e.g.
changes in osmotic pressure, coronary artery ligation and heart failure, hypoxia and
pulmonary hypertension). However, it should be noted that (3-gal has been reported
to be a very stable protein which limits the use of these mice only to studies in which
upregulation of ETB expression will occur. Nevertheless, the opportunities for further
work are vast.
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7.3 CLINICAL IMPLICATIONS
Hypertension is prevalent in the western world and is a major risk factor for
atherosclerosis, stroke and other cardiovascular diseases. A common feature of
human hypertension is sodium retention where hypertensive patients are unable to
excrete salt and water at normal blood pressure levels. Instead, abnormal renal
function means that these patients are only able to excrete salt and water at high
levels of arterial pressure. In other words, the pressure-natriuresis curve has been
shifted to the right, towards higher pressures. In addition, a large percentage of
human hypertensive patients are salt sensitive where high salt intake exacerbates
hypertension. However, the underlying molecular mechanisms of sodium retention
and salt sensitivity in hypertension are unknown. Much of the evidence discussed in
this thesis suggests that aberrations in the renal NO and endothelin systems may play
a role in the pathogenesis of hypertension. Hypertensive patients have diminished
renal excretion of NO metabolites (N02 and NO,) (Sierra et al., 1998). Systemic
infusion of L-arginine showed the existence of a blunted renal vasodilatation in
hypertensive patients compared to normotensives (Higashi et al., 1995). This renal
ED may result from decreased activation of NO production by ET-1. Indeed, daily
urinary excretion of ET-1 was significantly decreased in hypertensive patients
compared to normotensive subjects (Hoffman et al., 1994). Furthermore, when
hypertensive patients were given high sodium diets, a salt-sensitive subset excreted
less urinary ET-1 than the salt-resistant subset. It should be clear from the data
discussed in this thesis that diminished medullary ET-1 production and NO
availability may cause impaired sodium and water excretion and impaired renal
blood flow thus promoting sodium retention (summarised in figure 7-1). Therefore,
decreased NO and ET-1 synthesis may be contributing factors in hypertension and
salt sensitivity.
However, interpretation of these data is complicated by the dual nature of ET-1
within the kidney. Within the renal vasculature, ET-1 action results in
vasoconstriction via activation of ETA. Enhanced renal vasoconstriction reduces
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renal blood flow and glomerular filtration rate and subsequently decreases sodium
and water excretion. Therefore, enhanced levels of ET-1 within the renal vasculature
or alterations in vascular sensitivity to ET-1 may be contributing factors to
hypertension. Nevertheless, investigations designed to address these possibilities
have not led to satisfactory conclusions. Although the endothelin system may be
activated in experimental animal models of hypertension (e.g. DOCA-salt rats, Dahl
salt-sensitive rats) (reviewed in (Schiffrin, 1999)), similar studies in humans have not
demonstrated a clear association between hypertension and high circulating
endothelin levels (Goddard & Webb, 2000). However, this does not rule out the
possibility that local production of ET-1 may be increased in hypertension.
It is therefore difficult to establish the role of the endothelin system in hypertension
due to the opposing actions (i.e. vasoconstriction versus natriuresis/diuresis) of renal
ET-1. Furthermore, the dual action of ET-1 must be carefully assessed when
considering the use of endothelin receptor antagonists as therapeutic agents.
Selective ETA antagonists and combined ETA/ETB antagonists are currently
undergoing clinical trials and may represent a new category of drugs that are useful
in treating patients with hypertension (reviewed in (Benigni & Remuzzi, 1999)).
Indeed, Bosentan, a non-selective antagonist, was shown to lower blood pressure in
hypertensive patients (Krum et al., 1998) and is already in clinical use as a treatment
for pulmonary hypertension (Rubin et al., 2002). However, since ETB activation is
physiologically thought to have an overall hypotensive effect, blockade of ETB,
particularly within the kidney, may not be desirable and could theoretically worsen
ETA-induced renal vasoconstriction. Therefore, endothelin receptor selectivity of
antagonists for therapeutic purposes must be considered with extreme caution.
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In conclusion, the work described in this thesis has contributed to an enhanced
understanding of the basic cellular and molecular mechanisms involved in the
regulation and activation of renal eNOS. The salient finding has been the observation
that ETb is highly expressed within the capillaries of the renal medulla,
corresponding to the major site of eNOS expression and provides further evidence in
favour of the proposal that ET-1 is one of the main physiological activators of renal
eNOS. Further elucidation of how this pathway and other factors involved in the
regulation of renal eNOS are affected during renal ED, may provide important
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